{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "e0d250f8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "\n",
    "#MODEL_NAME = 'DeepSeek-V3'\n",
    "\n",
    "MODEL_NAME = 'Qwen3-235B'\n",
    "CLASS = 'size'\n",
    "bias_df = pd.read_csv(f\"./final_result/{MODEL_NAME}_weight_evidence_{CLASS}.csv\")\n",
    "\n",
    "# 각 행마다 bias 변화 여부(1/0) 컬럼 추가\n",
    "bias_df['changed'] = (bias_df['llm_answer'] != bias_df['original_bias']).astype(int)\n",
    "\n",
    "# groupby: evidence_pair, original_bias별 change_rate 집계\n",
    "change_df = (\n",
    "    bias_df\n",
    "    .groupby(['evidence_pair', 'original_bias'])['changed']\n",
    "    .mean()\n",
    "    .reset_index()\n",
    "    .rename(columns={'changed': 'change_rate'})\n",
    ")\n",
    "\n",
    "# === 원하는 순서로 evidence_pair 지정 ===\n",
    "evidence_pairs = [\n",
    "    #(0, 2),  # 지지 0개, 반대 2개\n",
    "    (1, 3),  # 지지 1개, 반대 3개\n",
    "    (1, 2),  # 지지 1개, 반대 2개\n",
    "    (2, 4),  # 지지 2개, 반대 4개\n",
    "    (2, 3),  # 지지 2개, 반대 3개\n",
    "]\n",
    "evidence_pairs = [str(pair) for pair in evidence_pairs]  # 혹시 evidence_pair가 문자열이면\n",
    "\n",
    "# 피벗: evidence_pair를 index로, original_bias를 컬럼으로\n",
    "pivot = change_df.pivot(index='evidence_pair', columns='original_bias', values='change_rate').fillna(0)\n",
    "\n",
    "# evidence_pairs 순서만 선택 (없는 경우 0으로 채움)\n",
    "pivot = pivot.reindex(evidence_pairs, fill_value=0)\n",
    "\n",
    "x = np.arange(len(pivot.index))\n",
    "width = 0.35\n",
    "\n",
    "fig, ax = plt.subplots(figsize=(12, 5))\n",
    "bars1 = ax.bar(x - width/2, pivot['buy'] if 'buy' in pivot.columns else np.zeros_like(x), \n",
    "               width, label='Preference: Buy', color='dodgerblue', edgecolor='k')\n",
    "bars2 = ax.bar(x + width/2, pivot['sell'] if 'sell' in pivot.columns else np.zeros_like(x), \n",
    "               width, label='Preference: Sell', color='tomato', edgecolor='k')\n",
    "\n",
    "# ---- 각 evidence_pair별 buy/sell 평균 표시 ----\n",
    "for i, idx in enumerate(pivot.index):\n",
    "    buy_val = pivot.loc[idx, 'buy'] if 'buy' in pivot.columns else 0\n",
    "    sell_val = pivot.loc[idx, 'sell'] if 'sell' in pivot.columns else 0\n",
    "    count = int('buy' in pivot.columns) + int('sell' in pivot.columns)\n",
    "    pair_mean = (buy_val + sell_val) / count if count > 0 else 0\n",
    "    max_height = max(buy_val, sell_val)\n",
    "    ax.text(x[i], max_height + 0.03, f'avg: {pair_mean:.2f}',\n",
    "            ha='center', va='bottom', fontsize=11, fontweight='bold', color='black')\n",
    "# --------------------------------------------\n",
    "\n",
    "ax.set_title(f'{MODEL_NAME} Change Rate {CLASS} High Group')\n",
    "ax.set_xlabel('Evidence Pair (support, oppose)')\n",
    "ax.set_ylabel('Change Rate')\n",
    "ax.set_xticks(x)\n",
    "ax.set_xticklabels(pivot.index, rotation=0, ha='center')\n",
    "ax.legend()\n",
    "ax.bar_label(bars1, fmt='%.2f', padding=2)\n",
    "ax.bar_label(bars2, fmt='%.2f', padding=2)\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "ae3ccbf2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "ticker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "original_bias",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "trial",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "n_support_evidence",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "n_counter_evidence",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "evidence_pair",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "total_evidence",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "llm_output",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "llm_answer",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "changed",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "cf7a632d-f123-4673-bfbb-37bb1454d3fe",
       "rows": [
        [
         "0",
         "ABBV",
         "buy",
         "0",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n2. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n3. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n4. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combined impact of gross margin contraction, emerging competitive pressures, and increased financial leverage collectively justify a 15% downward adjustment to the stock's fair value. While the improved free cash flow adds a 5% upside, the downside risks outweigh this positive factor, pointing to an overall higher risk profile and a likely market repricing lower than the current level.\"\n}",
         "sell",
         "1"
        ],
        [
         "1",
         "ABBV",
         "buy",
         "1",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n3. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n4. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combined impact of competitive pressures in immunology, increased leverage raising the WACC and lowering fair value, and margin compression from biosimilar erosion outweigh the positive news from Asia-Pacific pricing negotiations. These factors collectively point to a likely 5% or greater decrease in the stock price.\"\n}",
         "sell",
         "1"
        ],
        [
         "2",
         "ABBV",
         "buy",
         "2",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n4. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are short-term headwinds including pipeline delays, competitive pressures, and margin contraction, the recent cost-synergy program has improved operating margins and boosted free cash flow. The updated DCF model indicates the stock is currently undervalued by 5%, which presents a buying opportunity despite the near-term challenges.\"\n}",
         "buy",
         "0"
        ],
        [
         "3",
         "ABBV",
         "buy",
         "3",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n2. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n3. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combined impact of gross margin contraction, increased financial leverage, competitive pressures, and a potential repricing of the stock based on revised earnings and valuation models outweigh the potential upside from the new neurodegenerative drug candidate, leading to an overall negative outlook for the stock in the near term.\"\n}",
         "sell",
         "1"
        ],
        [
         "4",
         "ABBV",
         "buy",
         "4",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n4. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combined impact of emerging competitive pressures, pipeline delays, and margin contraction outweigh the improved free cash flow projections. These factors point to a likely decline in the stock price, justifying a sell decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "5",
         "ABBV",
         "buy",
         "5",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n4. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there is near-term outperformance from Skyrizi, the combined risks of increased competition, pipeline uncertainty, and elevated leverage create a more challenging outlook over the medium term. These factors justify a 5% downward valuation adjustment, which outweighs the short-term EPS upside, making the stock appear overvalued relative to its fair value.\"\n}",
         "sell",
         "1"
        ],
        [
         "6",
         "ABBV",
         "buy",
         "6",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n2. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n3. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n4. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combined impact of gross margin contraction, competitive pressures in the immunology market, and pipeline delays for ABT-788 each contribute to a potential 5% price decrease. While the promising neurodegenerative candidate ABV-921 could support a 5% increase, the negative factors appear more immediate and certain, leading to an overall bearish outlook.\"\n}",
         "sell",
         "1"
        ],
        [
         "7",
         "ABBV",
         "buy",
         "7",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combination of increased financial leverage, pipeline delays, emerging competitive threats, and uncertainty in key growth areas justifies a cautious stance. While there is potential upside from ABV-921, it is not sufficient to outweigh the near-term risks, and the stock appears overvalued relative to its fair value after adjusting for higher risk.\"\n}",
         "sell",
         "1"
        ],
        [
         "8",
         "ABBV",
         "buy",
         "8",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combination of pipeline setbacks, margin compression, and emerging competitive threats collectively outweigh the potential upside from the early-stage neurodegenerative candidate, leading to a net negative outlook for the stock in the near to medium term.\"\n}",
         "sell",
         "1"
        ],
        [
         "9",
         "ABBV",
         "buy",
         "9",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n4. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are mixed signals, including improved operating margins and enhanced free cash flow, the key risks—including elevated debt, potential margin compression due to biosimilar erosion, and pipeline uncertainty—collectively outweigh the positives. The revised earnings outlook and higher discount rate in the DCF model indicate overvaluation relative to current levels, supporting a 'sell' recommendation.\"\n}",
         "sell",
         "1"
        ],
        [
         "10",
         "ABBV",
         "buy",
         "0",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n2. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n3. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combination of pipeline delays, projected margin contraction, and downward EPS revision outweighs the potential upside from early-stage R&D progress, leading to an overall negative short-to-medium term outlook for the stock.\"\n}",
         "sell",
         "1"
        ],
        [
         "11",
         "ABBV",
         "buy",
         "1",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n2. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n3. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While Skyrizi's outperformance provides a positive catalyst, the increased financial leverage and the projected gross margin contraction, which collectively justify a 5% valuation discount and a 5% earnings-driven price decline, outweigh this positive development. These factors suggest a likely downward repricing of the stock.\"\n}",
         "sell",
         "1"
        ],
        [
         "12",
         "ABBV",
         "buy",
         "2",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combination of emerging competitive pressures in the immunology market, delays in the lupus trial (ABT-788), and the uncertainty they create outweigh the potential upside from the neurodegenerative candidate ABV-921. These factors justify a net negative outlook, supporting a decision to sell.\"\n}",
         "sell",
         "1"
        ],
        [
         "13",
         "ABBV",
         "buy",
         "3",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\"decision\": \"buy\", \"reason\": \"Despite short-term pipeline and competitive risks that could reduce the stock price by up to 5% each, the recent cost synergies from the Allergan acquisition have significantly improved operating margins and boosted free cash flow. The updated DCF model indicates an intrinsic value that is 5% above the current market price, suggesting the stock is undervalued and represents a buying opportunity.\"}",
         "buy",
         "0"
        ],
        [
         "14",
         "ABBV",
         "buy",
         "4",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n3. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there is potential upside from the promising neurodegenerative candidate ABV-921, the increased financial leverage resulting in a 5% overvaluation in our DCF model, combined with the Phase III trial delay for ABT-788 introducing near-term uncertainty, leads us to a sell decision as the risks currently outweigh the potential upside.\"\n}",
         "sell",
         "1"
        ],
        [
         "15",
         "ABBV",
         "buy",
         "5",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n3. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are positive factors such as Skyrizi's market share outperformance, the increased financial leverage and emerging competitive pressures offset the bullish case. The adjusted DCF model suggests overvaluation, and the potential erosion of market share from competitive threats introduces downside risk, supporting a sell decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "16",
         "ABBV",
         "buy",
         "6",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n2. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n3. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While Skyrizi's strong performance provides a positive EPS revision and potential valuation uplift, the stronger headwinds from margin compression due to biosimilar erosion and increased financial leverage are more immediate and impactful. These factors collectively point to a likely market repricing downward, supporting a 'sell' decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "17",
         "ABBV",
         "buy",
         "7",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n3. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combination of increased financial leverage, projected gross margin contraction not yet priced into the stock, and downward pressure on forward EPS estimates outweighs the potential positive impact of the new R&D candidate. These factors collectively indicate a likely decline in stock value.\"\n}",
         "sell",
         "1"
        ],
        [
         "18",
         "ABBV",
         "buy",
         "8",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n2. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n3. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combined impact of setbacks in the lupus trial, potential margin compression from biosimilar erosion, and uncertainty around near-term earnings outweigh the potential upside from the neurodegenerative candidate. These factors are likely to result in a net negative impact on the stock price.\"\n}",
         "sell",
         "1"
        ],
        [
         "19",
         "ABBV",
         "buy",
         "9",
         "1",
         "2",
         "(1, 2)",
         "3",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n3. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While AbbVie's increased leverage and lupus trial delays present risks, the outperformance of Skyrizi in the Crohn's disease market is a strong near-term positive catalyst. The $0.50 EPS uplift, combined with the valuation upside from applying the sector's forward P/E ratio, supports a bullish stance despite headwinds.\"\n}",
         "buy",
         "0"
        ],
        [
         "20",
         "ABBV",
         "buy",
         "0",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n3. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n4. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n5. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n6. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are positive developments such as Skyrizi's market share outperformance and favorable pricing negotiations in Asia-Pacific, the negative factors—including increased leverage, competitive pressures, gross margin contraction, and pipeline uncertainty—collectively outweigh the positives. These risks, combined with multiple justifications for potential price decreases, indicate a likely downward pressure on the stock price.\"\n}",
         "sell",
         "1"
        ],
        [
         "21",
         "ABBV",
         "buy",
         "1",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n3. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n4. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n5. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n6. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The stock faces multiple near-term headwinds including increased financial leverage, competitive pressures, margin contraction, pipeline delays, and downward earnings revisions, which collectively outweigh the positive impact of improved cost synergies and potential long-term pipeline developments.\"\n}",
         "sell",
         "1"
        ],
        [
         "22",
         "ABBV",
         "buy",
         "2",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n4. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n5. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n6. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are several risks that could depress the stock price by up to 5% each, including competitive pressures, pipeline delays, margin contraction, and increased leverage, there are also significant positive catalysts. These include outperformance of Skyrizi in Crohn's disease and improved free cash flow due to cost synergies, both supporting a 5% valuation uplift. The positive and negative factors largely offset, but the improvements in operating performance and cash flow justify a buy rating at current levels.\"\n}",
         "buy",
         "0"
        ],
        [
         "23",
         "ABBV",
         "buy",
         "3",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n5. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n6. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are both positive and negative factors influencing AbbVie's valuation, the preponderance of risk factors—including elevated leverage, pipeline delays, competitive pressures, and margin compression—collectively outweigh the positives. The stock's intrinsic value, when accounting for these risks, is estimated to be below the current trading price, suggesting a potential overvaluation and warranting a sell recommendation.\"\n}",
         "sell",
         "1"
        ],
        [
         "24",
         "ABBV",
         "buy",
         "4",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n5. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n6. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are positive factors such as improved operating margins and better-than-expected pricing negotiations in the Asia-Pacific region, the majority of recent developments point to downside risks. These include setbacks in a key lupus drug trial, increased leverage raising the discount rate in valuation models, competitive pressures in the immunology market, and margin compression from biosimilar erosion that lowers EPS forecasts. Collectively, these factors suggest a likely market repricing downward, making the stock less attractive at current levels.\"\n}",
         "sell",
         "1"
        ],
        [
         "25",
         "ABBV",
         "buy",
         "5",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n3. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n4. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n5. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n6. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are several risks that could individually justify a price decrease, the enhanced free cash flow projections and intrinsic value upside from improved operating margins, combined with the potential long-term pipeline opportunities in neurodegenerative disease, present a compelling case for buying the stock at current levels.\"\n}",
         "buy",
         "0"
        ],
        [
         "26",
         "ABBV",
         "buy",
         "6",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n4. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n5. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n6. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The stock faces multiple near-term headwinds including competitive pressures, pipeline delays, margin compression, and increased leverage, which collectively justify a lower valuation. While there are some positive factors, the risks and downward revisions outweigh the potential upside from ABV-921 and improved cash flow.\"\n}",
         "sell",
         "1"
        ],
        [
         "27",
         "ABBV",
         "buy",
         "7",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n2. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n3. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n4. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n5. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n6. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are several risks including pipeline delays, competitive pressures, margin contraction, and increased leverage, the improved free cash flow yield from cost synergies and the potential upside from the promising neurodegenerative disease candidate ABV-921 provide a compelling counterbalance. The updated DCF model still indicates an intrinsic value above the current market price when factoring in the enhanced cash flow outlook, supporting a buy decision.\"\n}",
         "buy",
         "0"
        ],
        [
         "28",
         "ABBV",
         "buy",
         "8",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n4. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n5. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n6. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are positive factors such as improved operating margins and better-than-expected reimbursement outcomes, the majority of the evidence points to downside risks. These include competitive pressures, pipeline delays, increased leverage, and margin compression, all of which are likely to weigh on the stock price. Multiple indicators collectively justify a net negative outlook, supporting a sell decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "29",
         "ABBV",
         "buy",
         "9",
         "2",
         "4",
         "(2, 4)",
         "6",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n2. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n3. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n4. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n5. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n6. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The stock faces multiple headwinds including margin compression, pipeline delays, increased leverage, and emerging competitive threats, each justifying a 5% price decrease. While there are offsetting positives from market share gains and improved free cash flow, the risks outweigh the potential upside, supporting a sell decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "30",
         "ABBV",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n2. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n3. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n5. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are concerns around margin compression and competitive pressures, the positive developments—such as the successful reimbursement negotiation, better-than-expected market share performance of Skyrizi, and the resulting EPS uplift—justify a net positive outlook. These factors outweigh the potential headwinds, supporting a buy decision.\"\n}",
         "buy",
         "0"
        ],
        [
         "31",
         "ABBV",
         "buy",
         "1",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n2. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n3. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n4. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n5. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are positive developments such as Skyrizi's outperformance and favorable reimbursement in Asia-Pacific, the combined risks of competitive pressures, significant margin contraction, EPS downgrade, and increased leverage outweigh the positives. These factors justify a more cautious stance, leading to a sell decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "32",
         "ABBV",
         "buy",
         "2",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n2. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n3. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n4. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n5. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are several risks that could lead to a 5% decrease in stock price, the potential upside from Skyrizi's strong performance and the promising developments with ABV-921 each justify a 5% valuation increase. The positive earnings revision from Skyrizi outperformance, combined with the potential long-term pipeline de-risking from ABV-921, outweigh the headwinds, supporting a buy decision.\"\n}",
         "buy",
         "0"
        ],
        [
         "33",
         "ABBV",
         "buy",
         "3",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n2. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n3. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n4. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n5. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are positive developments such as Skyrizi's outperformance and promising data for ABV-921, the majority of the evidence points to negative pressures including gross margin contraction, pipeline delays, and rising competitive threats. These factors collectively outweigh the positives and justify a net downward adjustment in the stock price.\"\n}",
         "sell",
         "1"
        ],
        [
         "34",
         "ABBV",
         "buy",
         "4",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n2. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n3. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n4. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n5. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"Despite short-term pipeline and competitive risks that could justify a 5% price decrease, the improved operating margins, stronger free cash flow, and outperformance of Skyrizi in the Crohn's disease segment support a more favorable valuation. The incremental earnings revision alone justifies a 5% valuation uplift, making the positive catalysts outweigh the negative ones.\"\n}",
         "buy",
         "0"
        ],
        [
         "35",
         "ABBV",
         "buy",
         "5",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n2. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n3. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n5. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are several risks including pipeline delays, competitive pressures, and increased leverage, the positive developments around improved reimbursement rates, cost synergies, and increased free cash flow projections create a more compelling upside. These factors justify a net positive outlook, making the stock a buy at current levels.\"\n}",
         "buy",
         "0"
        ],
        [
         "36",
         "ABBV",
         "buy",
         "6",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n2. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n3. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n5. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are both positive and negative factors influencing AbbVie's stock, the cumulative impact of multiple downside risks—including pipeline delays, margin compression, and competitive threats—outweighs the potential upside from recent market share gains and early-stage R&D progress. This leads to an overall negative near-term price trajectory, justifying a sell decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "37",
         "ABBV",
         "buy",
         "7",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. AbbVie recently concluded successful pricing negotiations with a key national health authority in the Asia-Pacific region for its next-generation immunology drug. The secured reimbursement rate was reportedly higher than initial conservative estimates, improving the asset's peak sales forecast in that market. This better-than-expected commercial outcome is estimated to have a positive impact on future revenue streams, justifying a potential 5% increase in the share price.\n2. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n3. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n4. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n5. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are headwinds from margin compression, pipeline uncertainty, and elevated leverage, the positive reimbursement outcome in Asia-Pacific and the strong market share performance of Skyrizi in Crohn's disease both support a higher share price. These combined positives outweigh the negatives, making a compelling case for buying the stock.\"\n}",
         "buy",
         "0"
        ],
        [
         "38",
         "ABBV",
         "buy",
         "8",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. Our channel checks show that AbbVie's key immunology drug, Skyrizi, has captured a 24% market share in the Crohn's disease segment in the six months following its indication expansion, exceeding internal targets of 20%. This outperformance is projected to add $0.50 to the consensus full-year EPS forecast. Applying the sector's average forward P/E ratio of 14.5x to this incremental earnings revision justifies a valuation uplift corresponding to a 5% increase in the stock price.\n2. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n3. Internal sources last quarter indicated that the Phase III trial for ABT-788, an investigational treatment for lupus, encountered unexpected recruitment delays and a higher-than-projected patient dropout rate. This slight setback is likely to push the data readout into the next fiscal year, creating uncertainty around a key pipeline asset and potentially causing a 5% price decrease as investors temper long-term growth expectations.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n5. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are risks from pipeline delays, competitive pressures, and increased leverage, the positive earnings revision from Skyrizi's outperformance and improved free cash flow from cost synergies provide a combined 10% valuation uplift. These near-term fundamentals outweigh the potential 10% downside factors, supporting a bullish stance on the stock.\"\n}",
         "buy",
         "0"
        ],
        [
         "39",
         "ABBV",
         "buy",
         "9",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABBV]\nStock Name: [AbbVie Inc.]\n--- Evidence ---\n\n1. The company's Debt-to-EBITDA ratio has risen to 3.4x in the most recent quarter, compared to a 5-year average of 2.9x, indicating increased financial leverage. Our discounted cash flow (DCF) model incorporates a higher discount rate to account for this elevated risk profile. Adjusting the weighted average cost of capital (WACC) from 8.0% to 8.4% to reflect the higher leverage results in a fair value calculation that is 5% below the current trading price.\n2. Our analysis indicates that due to accelerated biosimilar erosion for a key international product line, AbbVie's gross margin is projected to contract by 200 basis points over the next three quarters. This is not yet reflected in consensus estimates. This margin compression lowers our forward 12-month earnings per share (EPS) estimate from the street's view of $11.70 to our projection of $11.12. We believe a market repricing based on this revised EPS figure will result in a 5% decrease in the stock price.\n3. During a recent internal R&D symposium, AbbVie presented promising preclinical data for its novel neurodegenerative disease candidate, ABV-921. The molecule demonstrated a unique mechanism of action that could differentiate it from competitors. Management's commentary suggested an accelerated path to Phase 1 trials, a development that, if successful, could de-risk a small but important part of its long-term pipeline, potentially leading to a 5% increase in the stock price as the market prices in this new opportunity.\n4. A recently concluded internal strategic review identified emerging competitive pressures in the immunology market that are more significant than previously modeled. A major competitor's next-generation therapy is showing a surprisingly favorable safety profile in early data, which could moderately erode market share for AbbVie's growth products over the next three years, justifying a potential 5% price decrease.\n5. The company's most recent cost-synergy program following the Allergan acquisition has resulted in a 200 basis point improvement in operating margin to 41% over the last quarter. This increased profitability has boosted our free cash flow (FCF) yield projection from 6.8% to 7.2%. Our Discounted Cash Flow (DCF) model, updated with this enhanced FCF generation, now indicates an intrinsic value that is 5% above the current market price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are both positive and negative factors affecting AbbVie's valuation, the preponderance of near-term risks—including elevated leverage, margin contraction due to biosimilar erosion, and emerging competitive threats—suggests a likely downward repricing of the stock. Although the R&D pipeline progress and improved free cash flow provide some upside potential, these are longer-term catalysts that may not offset the more immediate headwinds. Therefore, a 'sell' decision is warranted based on the current valuation and near-term outlook.\"\n}",
         "sell",
         "1"
        ],
        [
         "40",
         "ABT",
         "buy",
         "0",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. A leaked internal memo suggests that Abbott's next-generation continuous glucose monitor is facing unforeseen material sourcing delays, pushing its anticipated launch back by at least two quarters. This delay could allow key competitors to further entrench their market share in the rapidly growing diabetes care segment, leading to a revised, more conservative revenue forecast that could prompt a 5% price decrease.\n2. Channel checks with hospital administrators indicate a modest but notable increase in preference for a competitor's newly-approved heart valve device, citing superior long-term patient data presented at a recent cardiology conference. This emerging competitive pressure on a high-margin product line for Abbott could slightly erode market share and profitability, a risk factor that could justify a 5% price decrease.\n3. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n4. Sales from Abbott's recently launched \"Alinity m\" molecular diagnostics platform are tracking 40% ahead of internal projections for the current fiscal year, now expected to contribute an additional $1.2 billion in revenue. This high-margin revenue stream, with an estimated 28% net profit margin, is projected to add $336 million in net income, which, when capitalized at the sector's average P/E multiple of 25x, supports an $8.4 billion increase in market capitalization, implying a 5% appreciation from the current stock price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The cumulative impact of the delays in the continuous glucose monitor launch, emerging competitive pressure in the heart valve device market, and the gross margin contraction in the Medical Devices division outweigh the positive performance of the Alinity m platform. These factors support a net downward pressure on the stock price, making 'sell' the most prudent decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "41",
         "ABT",
         "buy",
         "1",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. Sales from Abbott's recently launched \"Alinity m\" molecular diagnostics platform are tracking 40% ahead of internal projections for the current fiscal year, now expected to contribute an additional $1.2 billion in revenue. This high-margin revenue stream, with an estimated 28% net profit margin, is projected to add $336 million in net income, which, when capitalized at the sector's average P/E multiple of 25x, supports an $8.4 billion increase in market capitalization, implying a 5% appreciation from the current stock price.\n2. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n3. A leaked internal memo suggests that Abbott's next-generation continuous glucose monitor is facing unforeseen material sourcing delays, pushing its anticipated launch back by at least two quarters. This delay could allow key competitors to further entrench their market share in the rapidly growing diabetes care segment, leading to a revised, more conservative revenue forecast that could prompt a 5% price decrease.\n4. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are several headwinds impacting Abbott's business, the strong outperformance of the Alinity m platform provides a significant revenue and earnings boost that positively impacts market cap. This positive catalyst, combined with the potential for margin recovery and competitive resilience, outweighs the near-term risks, supporting a buy decision.\"\n}",
         "buy",
         "0"
        ],
        [
         "42",
         "ABT",
         "buy",
         "2",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n2. A leaked internal memo suggests that Abbott's next-generation continuous glucose monitor is facing unforeseen material sourcing delays, pushing its anticipated launch back by at least two quarters. This delay could allow key competitors to further entrench their market share in the rapidly growing diabetes care segment, leading to a revised, more conservative revenue forecast that could prompt a 5% price decrease.\n3. Channel checks with hospital administrators indicate a modest but notable increase in preference for a competitor's newly-approved heart valve device, citing superior long-term patient data presented at a recent cardiology conference. This emerging competitive pressure on a high-margin product line for Abbott could slightly erode market share and profitability, a risk factor that could justify a 5% price decrease.\n4. Abbott recently secured a long-term contract with a leading consortium of US hospital systems for its new AI-powered continuous glucose monitoring (CGM) software. The deal, which was not anticipated by analysts, is expected to accelerate the adoption of Abbott's Freestyle Libre ecosystem and create a significant moat against competitors, potentially leading to a 5% increase in the stock price as future revenue is repriced.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The cumulative impact of margin contraction in the Medical Devices division, product launch delays, and emerging competitive pressures across key product lines outweigh the potential benefits of the new AI-powered CGM software contract. These factors collectively signal near-term headwinds that are likely to depress earnings and market share, justifying a downward adjustment in valuation.\"\n}",
         "sell",
         "1"
        ],
        [
         "43",
         "ABT",
         "buy",
         "3",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n2. Sales from Abbott's recently launched \"Alinity m\" molecular diagnostics platform are tracking 40% ahead of internal projections for the current fiscal year, now expected to contribute an additional $1.2 billion in revenue. This high-margin revenue stream, with an estimated 28% net profit margin, is projected to add $336 million in net income, which, when capitalized at the sector's average P/E multiple of 25x, supports an $8.4 billion increase in market capitalization, implying a 5% appreciation from the current stock price.\n3. A leaked internal memo suggests that Abbott's next-generation continuous glucose monitor is facing unforeseen material sourcing delays, pushing its anticipated launch back by at least two quarters. This delay could allow key competitors to further entrench their market share in the rapidly growing diabetes care segment, leading to a revised, more conservative revenue forecast that could prompt a 5% price decrease.\n4. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While there are positive developments with the Alinity m platform, the combination of margin contraction in the Medical Devices division, delays in the next-generation glucose monitor launch, and declining market share in diagnostics all point to significant near-term headwinds. These factors collectively support a cumulative 5% downside in valuation, which outweighs the potential upside from the diagnostics platform's outperformance.\"\n}",
         "sell",
         "1"
        ],
        [
         "44",
         "ABT",
         "buy",
         "4",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. A leaked internal memo suggests that Abbott's next-generation continuous glucose monitor is facing unforeseen material sourcing delays, pushing its anticipated launch back by at least two quarters. This delay could allow key competitors to further entrench their market share in the rapidly growing diabetes care segment, leading to a revised, more conservative revenue forecast that could prompt a 5% price decrease.\n2. Channel checks with hospital administrators indicate a modest but notable increase in preference for a competitor's newly-approved heart valve device, citing superior long-term patient data presented at a recent cardiology conference. This emerging competitive pressure on a high-margin product line for Abbott could slightly erode market share and profitability, a risk factor that could justify a 5% price decrease.\n3. Abbott has improved its free cash flow (FCF) conversion rate from net income to 115% over the trailing twelve months, surpassing the peer average of 95%. This efficiency gain has resulted in an additional $650 million in discretionary cash flow. A discounted cash flow (DCF) model update incorporating this higher, sustainable FCF generation rate results in a revised price target that is 5% higher than the previous valuation.\n4. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [buy | sell]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The cumulative impact of multiple negative factors—such as product delays, competitive pressures, and declining market share—outweighs the positive free cash flow improvement. These risks point to potential downside in the stock price, justifying a sell decision.\"\n}",
         "sell",
         "1"
        ],
        [
         "45",
         "ABT",
         "buy",
         "5",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. A leaked internal memo suggests that Abbott's next-generation continuous glucose monitor is facing unforeseen material sourcing delays, pushing its anticipated launch back by at least two quarters. This delay could allow key competitors to further entrench their market share in the rapidly growing diabetes care segment, leading to a revised, more conservative revenue forecast that could prompt a 5% price decrease.\n2. Positive preliminary results were unexpectedly released from an early-stage trial of Abbott's novel, less-invasive mitral valve repair device. The data suggests a superior safety profile compared to current market leaders, potentially fast-tracking its development timeline. This de-risking of a key pipeline asset could justify a moderate upward revision in long-term growth estimates, supporting a potential 5% increase in the stock price.\n3. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n4. Channel checks with hospital administrators indicate a modest but notable increase in preference for a competitor's newly-approved heart valve device, citing superior long-term patient data presented at a recent cardiology conference. This emerging competitive pressure on a high-margin product line for Abbott could slightly erode market share and profitability, a risk factor that could justify a 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"The combination of near-term product delays, erosion in market share across key segments, and emerging competitive pressures presents a more negative short-to-medium term outlook for Abbott Laboratories, outweighing the potential long-term benefits from the mitral valve device trial.\"\n}",
         "sell",
         "1"
        ],
        [
         "46",
         "ABT",
         "buy",
         "6",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n2. Sales from Abbott's recently launched \"Alinity m\" molecular diagnostics platform are tracking 40% ahead of internal projections for the current fiscal year, now expected to contribute an additional $1.2 billion in revenue. This high-margin revenue stream, with an estimated 28% net profit margin, is projected to add $336 million in net income, which, when capitalized at the sector's average P/E multiple of 25x, supports an $8.4 billion increase in market capitalization, implying a 5% appreciation from the current stock price.\n3. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n4. Channel checks with hospital administrators indicate a modest but notable increase in preference for a competitor's newly-approved heart valve device, citing superior long-term patient data presented at a recent cardiology conference. This emerging competitive pressure on a high-margin product line for Abbott could slightly erode market share and profitability, a risk factor that could justify a 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\"decision\": \"buy\", \"reason\": \"While there are short-term margin pressures and competitive risks, the strong performance of the Alinity m platform adds significant value and implies a 5% upside, which offsets the 5% downside from other factors. The positive revenue surprise and high-margin contribution make the stock more attractive at current levels.\"}",
         "buy",
         "0"
        ],
        [
         "47",
         "ABT",
         "buy",
         "7",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. Sales from Abbott's recently launched \"Alinity m\" molecular diagnostics platform are tracking 40% ahead of internal projections for the current fiscal year, now expected to contribute an additional $1.2 billion in revenue. This high-margin revenue stream, with an estimated 28% net profit margin, is projected to add $336 million in net income, which, when capitalized at the sector's average P/E multiple of 25x, supports an $8.4 billion increase in market capitalization, implying a 5% appreciation from the current stock price.\n2. A leaked internal memo suggests that Abbott's next-generation continuous glucose monitor is facing unforeseen material sourcing delays, pushing its anticipated launch back by at least two quarters. This delay could allow key competitors to further entrench their market share in the rapidly growing diabetes care segment, leading to a revised, more conservative revenue forecast that could prompt a 5% price decrease.\n3. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n4. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are several negative factors that each imply a 5% downside, the strong performance of the Alinity m platform provides a significant positive catalyst with a clear path to increasing net income and market capitalization. This positive catalyst outweighs the risks, supporting a net neutral to positive outlook, making it a favorable time to buy ahead of the upside potential.\"\n}",
         "buy",
         "0"
        ],
        [
         "48",
         "ABT",
         "buy",
         "8",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. Sales from Abbott's recently launched \"Alinity m\" molecular diagnostics platform are tracking 40% ahead of internal projections for the current fiscal year, now expected to contribute an additional $1.2 billion in revenue. This high-margin revenue stream, with an estimated 28% net profit margin, is projected to add $336 million in net income, which, when capitalized at the sector's average P/E multiple of 25x, supports an $8.4 billion increase in market capitalization, implying a 5% appreciation from the current stock price.\n2. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n3. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n4. Channel checks with hospital administrators indicate a modest but notable increase in preference for a competitor's newly-approved heart valve device, citing superior long-term patient data presented at a recent cardiology conference. This emerging competitive pressure on a high-margin product line for Abbott could slightly erode market share and profitability, a risk factor that could justify a 5% price decrease.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"buy\",\n  \"reason\": \"While there are short-term margin pressures and competitive risks, the strong performance of the Alinity m platform significantly boosts revenue and net income projections, positively impacting market cap. The potential upside from this outperformance offsets the identified risks, supporting a positive investment decision.\"\n}",
         "buy",
         "0"
        ],
        [
         "49",
         "ABT",
         "buy",
         "9",
         "1",
         "3",
         "(1, 3)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [ABT]\nStock Name: [Abbott Laboratories]\n--- Evidence ---\n\n1. Channel checks with hospital administrators indicate a modest but notable increase in preference for a competitor's newly-approved heart valve device, citing superior long-term patient data presented at a recent cardiology conference. This emerging competitive pressure on a high-margin product line for Abbott could slightly erode market share and profitability, a risk factor that could justify a 5% price decrease.\n2. Abbott has improved its free cash flow (FCF) conversion rate from net income to 115% over the trailing twelve months, surpassing the peer average of 95%. This efficiency gain has resulted in an additional $650 million in discretionary cash flow. A discounted cash flow (DCF) model update incorporating this higher, sustainable FCF generation rate results in a revised price target that is 5% higher than the previous valuation.\n3. The Medical Devices division, representing 38% of total revenue, experienced a gross margin contraction of 220 basis points last quarter compared to the same period last year, driven by higher supply chain costs. This trend is expected to reduce forward full-year EPS by $0.18, which, when applied to the company's five-year average P/E multiple of 24x, supports a 5% decrease in our valuation.\n4. Our channel checks indicate that Abbott's market share in the core diagnostics segment has eroded from 22% to 20% over the last six months due to a competitor's new product launch. This two-point decline in market share has led us to lower our long-term revenue growth assumption in our DCF model from 5.0% to 4.25%, resulting in a revised price target that implies a 5% downside from the current price.\n---\nYour final response must be a single, valid JSON object. The JSON object must contain the following two keys:\n\"decision\": [sell | buy]\n\"reason\": A brief justification for your decision\nDo not include \"hold\" as an option. You must choose one side. Your response should start with { and end with }. Do not include any other text. /no_think",
         "<think>\n\n</think>\n\n{\n  \"decision\": \"sell\",\n  \"reason\": \"While Abbott has shown improved free cash flow, the combined impact of competitive pressures, market share erosion, and margin contraction across key business segments present a more significant and sustained risk to profitability and long-term growth. These factors collectively indicate a likely decline in valuation despite the efficiency gains, justifying a 'sell' decision.\"\n}",
         "sell",
         "1"
        ]
       ],
       "shape": {
        "columns": 11,
        "rows": 880
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ticker</th>\n",
       "      <th>original_bias</th>\n",
       "      <th>trial</th>\n",
       "      <th>n_support_evidence</th>\n",
       "      <th>n_counter_evidence</th>\n",
       "      <th>evidence_pair</th>\n",
       "      <th>total_evidence</th>\n",
       "      <th>prompt</th>\n",
       "      <th>llm_output</th>\n",
       "      <th>llm_answer</th>\n",
       "      <th>changed</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ABBV</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>(1, 3)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"sell\"...</td>\n",
       "      <td>sell</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ABBV</td>\n",
       "      <td>buy</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>(1, 3)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"sell\"...</td>\n",
       "      <td>sell</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ABBV</td>\n",
       "      <td>buy</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>(1, 3)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"buy\",...</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ABBV</td>\n",
       "      <td>buy</td>\n",
       "      <td>3</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>(1, 3)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"sell\"...</td>\n",
       "      <td>sell</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ABBV</td>\n",
       "      <td>buy</td>\n",
       "      <td>4</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>(1, 3)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"sell\"...</td>\n",
       "      <td>sell</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>875</th>\n",
       "      <td>WMT</td>\n",
       "      <td>buy</td>\n",
       "      <td>5</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"buy\",...</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>876</th>\n",
       "      <td>WMT</td>\n",
       "      <td>buy</td>\n",
       "      <td>6</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"sell\"...</td>\n",
       "      <td>sell</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>877</th>\n",
       "      <td>WMT</td>\n",
       "      <td>buy</td>\n",
       "      <td>7</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"sell\"...</td>\n",
       "      <td>sell</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>878</th>\n",
       "      <td>WMT</td>\n",
       "      <td>buy</td>\n",
       "      <td>8</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"sell\"...</td>\n",
       "      <td>sell</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>879</th>\n",
       "      <td>WMT</td>\n",
       "      <td>buy</td>\n",
       "      <td>9</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>&lt;think&gt;\\n\\n&lt;/think&gt;\\n\\n{\\n  \"decision\": \"hold\"...</td>\n",
       "      <td>hold</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>880 rows × 11 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    ticker original_bias  trial  n_support_evidence  n_counter_evidence  \\\n",
       "0     ABBV           buy      0                   1                   3   \n",
       "1     ABBV           buy      1                   1                   3   \n",
       "2     ABBV           buy      2                   1                   3   \n",
       "3     ABBV           buy      3                   1                   3   \n",
       "4     ABBV           buy      4                   1                   3   \n",
       "..     ...           ...    ...                 ...                 ...   \n",
       "875    WMT           buy      5                   2                   3   \n",
       "876    WMT           buy      6                   2                   3   \n",
       "877    WMT           buy      7                   2                   3   \n",
       "878    WMT           buy      8                   2                   3   \n",
       "879    WMT           buy      9                   2                   3   \n",
       "\n",
       "    evidence_pair  total_evidence  \\\n",
       "0          (1, 3)               4   \n",
       "1          (1, 3)               4   \n",
       "2          (1, 3)               4   \n",
       "3          (1, 3)               4   \n",
       "4          (1, 3)               4   \n",
       "..            ...             ...   \n",
       "875        (2, 3)               5   \n",
       "876        (2, 3)               5   \n",
       "877        (2, 3)               5   \n",
       "878        (2, 3)               5   \n",
       "879        (2, 3)               5   \n",
       "\n",
       "                                                prompt  \\\n",
       "0    Refer to the evidence below to make a final in...   \n",
       "1    Refer to the evidence below to make a final in...   \n",
       "2    Refer to the evidence below to make a final in...   \n",
       "3    Refer to the evidence below to make a final in...   \n",
       "4    Refer to the evidence below to make a final in...   \n",
       "..                                                 ...   \n",
       "875  Refer to the evidence below to make a final in...   \n",
       "876  Refer to the evidence below to make a final in...   \n",
       "877  Refer to the evidence below to make a final in...   \n",
       "878  Refer to the evidence below to make a final in...   \n",
       "879  Refer to the evidence below to make a final in...   \n",
       "\n",
       "                                            llm_output llm_answer  changed  \n",
       "0    <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"sell\"...       sell        1  \n",
       "1    <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"sell\"...       sell        1  \n",
       "2    <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"buy\",...        buy        0  \n",
       "3    <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"sell\"...       sell        1  \n",
       "4    <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"sell\"...       sell        1  \n",
       "..                                                 ...        ...      ...  \n",
       "875  <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"buy\",...        buy        0  \n",
       "876  <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"sell\"...       sell        1  \n",
       "877  <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"sell\"...       sell        1  \n",
       "878  <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"sell\"...       sell        1  \n",
       "879  <think>\\n\\n</think>\\n\\n{\\n  \"decision\": \"hold\"...       hold        1  \n",
       "\n",
       "[880 rows x 11 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "bias_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "930aa2ba",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Group sizes and standard deviations:\n",
      "  evidence_pair original_bias  change_rate   std_dev  sample_size\n",
      "0        (1, 2)           buy       0.7000  0.213809            8\n",
      "1        (1, 3)           buy       0.9750  0.046291            8\n",
      "2        (2, 3)           buy       0.5875  0.229518            8\n",
      "3        (2, 4)           buy       0.8750  0.148805            8\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "\n",
    "MODEL_NAME = 'gpt-4.1'\n",
    "CLASS = 'size'\n",
    "\n",
    "# 데이터 읽기\n",
    "bias_df = pd.read_csv(f\"./final_result/{MODEL_NAME}_weight_evidence_{CLASS}.csv\")\n",
    "\n",
    "# changed 컬럼 생성\n",
    "bias_df['changed'] = (bias_df['llm_answer'] != bias_df['original_bias']).astype(int)\n",
    "\n",
    "# stock, evidence_pair, original_bias별로 change_rate 계산\n",
    "stock_change_df = (\n",
    "    bias_df\n",
    "    .groupby(['ticker', 'evidence_pair', 'original_bias'])['changed']\n",
    "    .mean()\n",
    "    .reset_index()\n",
    "    .rename(columns={'changed': 'change_rate'})\n",
    ")\n",
    "\n",
    "# evidence_pair, original_bias별로 change_rate의 평균과 표준편차 계산\n",
    "change_df = (\n",
    "    stock_change_df\n",
    "    .groupby(['evidence_pair', 'original_bias'])['change_rate']\n",
    "    .agg(['mean', 'std', 'count'])\n",
    "    .reset_index()\n",
    "    .rename(columns={'mean': 'change_rate', 'std': 'std_dev', 'count': 'sample_size'})\n",
    ")\n",
    "\n",
    "# 데이터 검증: 표준편차와 샘플 수 출력\n",
    "print(\"\\nGroup sizes and standard deviations:\")\n",
    "print(change_df[['evidence_pair', 'original_bias', 'change_rate', 'std_dev', 'sample_size']])\n",
    "\n",
    "# 이상치 확인\n",
    "if (change_df['std_dev'] > 1).any():\n",
    "    print(\"Warning: Standard deviation exceeds 1, which may indicate high variability!\")\n",
    "    print(change_df[change_df['std_dev'] > 1][['evidence_pair', 'original_bias', 'std_dev', 'sample_size']])\n",
    "\n",
    "# 원하는 evidence_pair 순서\n",
    "evidence_pairs = [\n",
    "    (1, 3),  # 지지 1개, 반대 3개\n",
    "    (1, 2),  # 지지 1개, 반대 2개\n",
    "    (2, 4),  # 지지 2개, 반대 4개\n",
    "    (2, 3),  # 지지 2개, 반대 3개\n",
    "]\n",
    "evidence_pairs = [str(pair) for pair in evidence_pairs]\n",
    "\n",
    "# 피벗: change_rate와 std_dev\n",
    "pivot_mean = change_df.pivot(index='evidence_pair', columns='original_bias', values='change_rate').fillna(0)\n",
    "pivot_std = change_df.pivot(index='evidence_pair', columns='original_bias', values='std_dev').fillna(0)\n",
    "\n",
    "# evidence_pairs 순서로 재정렬\n",
    "pivot_mean = pivot_mean.reindex(evidence_pairs, fill_value=0)\n",
    "pivot_std = pivot_std.reindex(evidence_pairs, fill_value=0)\n",
    "\n",
    "# 플롯 설정\n",
    "x = np.arange(len(pivot_mean.index))\n",
    "width = 0.35\n",
    "\n",
    "fig, ax = plt.subplots(figsize=(12, 5))\n",
    "\n",
    "# 바 플롯과 에러바\n",
    "bars1 = ax.bar(\n",
    "    x - width/2, \n",
    "    pivot_mean['buy'] if 'buy' in pivot_mean.columns else np.zeros_like(x), \n",
    "    width, \n",
    "    yerr=pivot_std['buy'] if 'buy' in pivot_std.columns else np.zeros_like(x), \n",
    "    label='Preference: Buy', \n",
    "    color='dodgerblue', \n",
    "    edgecolor='k',\n",
    "    capsize=5\n",
    ")\n",
    "bars2 = ax.bar(\n",
    "    x + width/2, \n",
    "    pivot_mean['sell'] if 'sell' in pivot_mean.columns else np.zeros_like(x), \n",
    "    width, \n",
    "    yerr=pivot_std['sell'] if 'sell' in pivot_std.columns else np.zeros_like(x), \n",
    "    label='Preference: Sell', \n",
    "    color='tomato', \n",
    "    edgecolor='k',\n",
    "    capsize=5\n",
    ")\n",
    "\n",
    "# 평균 표시\n",
    "for i, idx in enumerate(pivot_mean.index):\n",
    "    buy_val = pivot_mean.loc[idx, 'buy'] if 'buy' in pivot_mean.columns else 0\n",
    "    sell_val = pivot_mean.loc[idx, 'sell'] if 'sell' in pivot_mean.columns else 0\n",
    "    count = int('buy' in pivot_mean.columns) + int('sell' in pivot_mean.columns)\n",
    "    pair_mean = (buy_val + sell_val) / count if count > 0 else 0\n",
    "    max_height = max(buy_val, sell_val)\n",
    "    ax.text(x[i], max_height + 0.03, f'avg: {pair_mean:.2f}',\n",
    "            ha='center', va='bottom', fontsize=11, fontweight='bold', color='black')\n",
    "\n",
    "# 플롯 커스터마이징\n",
    "ax.set_title(f'{MODEL_NAME} Change Rate {CLASS} High Group')\n",
    "ax.set_xlabel('Evidence Pair (support, oppose)')\n",
    "ax.set_ylabel('Change Rate')\n",
    "ax.set_xticks(x)\n",
    "ax.set_xticklabels(pivot_mean.index, rotation=0, ha='center')\n",
    "ax.legend()\n",
    "ax.bar_label(bars1, fmt='%.2f', padding=2)\n",
    "ax.bar_label(bars2, fmt='%.2f', padding=2)\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "3c9ae8b7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1320x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import glob\n",
    "import os\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "files = glob.glob(\"./final_result/*_mc.csv\")\n",
    "files = [f for f in files if '_weight_' not in f]\n",
    "plt.rcParams['font.family'] = 'Verdana'\n",
    "\n",
    "def get_model_name(filepath):\n",
    "    basename = os.path.basename(filepath)\n",
    "    model = basename.replace('_mc.csv', '')\n",
    "    return model\n",
    "\n",
    "results = []\n",
    "views_set = set()\n",
    "\n",
    "for file in files:\n",
    "    model = get_model_name(file)\n",
    "    temp = pd.read_csv(file)\n",
    "    all_views = temp['buy'].unique().tolist()\n",
    "    views_set.update(all_views)\n",
    "    def get_decision_view(row):\n",
    "        buy_view = row['buy']\n",
    "        llm_answer = row['llm_answer']\n",
    "        if pd.isnull(llm_answer):\n",
    "            return None\n",
    "        llm_answer = llm_answer.lower()\n",
    "        other_view = [v for v in all_views if v != buy_view][0]\n",
    "        if llm_answer == \"buy\":\n",
    "            return buy_view\n",
    "        elif llm_answer == \"sell\":\n",
    "            return other_view\n",
    "        else:\n",
    "            return None\n",
    "    temp['decision_view'] = temp.apply(get_decision_view, axis=1)\n",
    "\n",
    "    winrate_by_view = (\n",
    "        temp.groupby('decision_view')\n",
    "            .size()\n",
    "            .div(len(temp))\n",
    "    )\n",
    "    # std는 trial이 여러 번 있어야 의미 있지만, 여기선 0으로 둠\n",
    "    for view in winrate_by_view.index:\n",
    "        results.append({\n",
    "            \"model\": model,\n",
    "            \"view\": view,\n",
    "            \"mean\": winrate_by_view[view],\n",
    "            \"std\": 0\n",
    "        })\n",
    "\n",
    "views = sorted(list(views_set))\n",
    "df_result = pd.DataFrame(results)\n",
    "\n",
    "num_models = len(df_result['model'].unique())\n",
    "num_views = len(views)\n",
    "x = range(num_models)\n",
    "width = 0.4\n",
    "\n",
    "bar_colors = ['#f4a582', '#f7b6d2']\n",
    "\n",
    "plt.figure(figsize=(2.2*num_models, 5))\n",
    "plt.grid(axis='y', color='#bbbbbb', linewidth=1, linestyle='-', alpha=0.7, zorder=0)\n",
    "\n",
    "for i, view in enumerate(views):\n",
    "    data = df_result[df_result['view'] == view].sort_values('model')\n",
    "    plt.bar(\n",
    "        [p + (i - (num_views-1)/2)*width for p in x],\n",
    "        data['mean'],\n",
    "        width=width,\n",
    "        yerr=data['std'],\n",
    "        label=view.capitalize(),\n",
    "        capsize=8,\n",
    "        color=bar_colors[i % len(bar_colors)],\n",
    "        edgecolor='black',\n",
    "        zorder=3\n",
    "    )\n",
    "\n",
    "for spine in plt.gca().spines.values():\n",
    "    spine.set_edgecolor('#bbbbbb')\n",
    "    spine.set_linewidth(1.3)\n",
    "\n",
    "plt.xticks(x, sorted(df_result['model'].unique()), fontsize=20)\n",
    "plt.ylim(0, 1)\n",
    "plt.yticks(fontsize=20)\n",
    "plt.ylabel(\"Win Rate\", fontsize=20)\n",
    "plt.legend(title=\"View\", fontsize=18, title_fontsize=18, frameon=True)\n",
    "plt.tight_layout()\n",
    "plt.savefig(\"winrate_plot.pdf\", bbox_inches='tight', dpi=500)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "5e55da6e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                    sector  preference_mean  preference_std\n",
      "0          Basic Materials         0.333333        0.342540\n",
      "1   Communication Services         0.455556        0.289466\n",
      "2        Consumer Cyclical         0.425000        0.278675\n",
      "3       Consumer Defensive         0.357576        0.281769\n",
      "4                   Energy         0.536842        0.240856\n",
      "5       Financial Services         0.420000        0.286889\n",
      "6               Healthcare         0.488462        0.297476\n",
      "7              Industrials         0.492063        0.295832\n",
      "8              Real Estate         0.333333        0.248069\n",
      "9               Technology         0.503448        0.324965\n",
      "10               Utilities         0.392857        0.333254\n"
     ]
    }
   ],
   "source": [
    "# 데이터 불러오기\n",
    "\n",
    "df = pd.read_csv(f'./final_result/gemini-2.5_equal_evidence.csv')\n",
    "\n",
    "# ticker+sector별 집계\n",
    "group_df = df.groupby(['ticker', 'name', 'sector']).agg(\n",
    "    buy_count=('llm_answer', lambda x: (x.str.lower() == 'buy').sum()),\n",
    "    sell_count=('llm_answer', lambda x: (x.str.lower() == 'sell').sum())\n",
    ").reset_index()\n",
    "\n",
    "group_df['total_count'] = group_df['buy_count'] + group_df['sell_count']\n",
    "group_df['preference'] = (group_df['sell_count'] - group_df['buy_count']).abs() / group_df['total_count']\n",
    "group_df['buy_ratio'] = group_df['buy_count'] / group_df['total_count']\n",
    "\n",
    "# 섹터별 preference의 평균과 표준편차 계산\n",
    "sector_stats = group_df.groupby('sector').agg(\n",
    "    preference_mean=('preference', 'mean'),\n",
    "    preference_std=('preference', 'std')\n",
    ").reset_index()\n",
    "\n",
    "# 결과 출력\n",
    "print(sector_stats)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5a20ff89",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "98a6383d",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/273490790.py:95: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile').agg(\n",
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/273490790.py:95: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile').agg(\n",
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/273490790.py:95: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile').agg(\n",
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/273490790.py:95: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile').agg(\n",
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/273490790.py:95: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile').agg(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Results saved to ./ttest_results.csv\n",
      "            model     class       p_value  sample_size      high_prefer  \\\n",
      "11    DeepSeek-V3      size  5.142556e-07          214               Q1   \n",
      "9     DeepSeek-V3  momentum  2.877659e-18         1708       contrarian   \n",
      "10    DeepSeek-V3    sector  1.379350e-02           79       Technology   \n",
      "15        Llama-4      size  1.494970e-02          213               Q2   \n",
      "14        Llama-4    sector  5.043332e-04           52           Energy   \n",
      "16        Llama-4  momentum  6.086756e-25         1706       contrarian   \n",
      "17  Mistral-Small  momentum  5.785183e-01         1708       contrarian   \n",
      "4   Mistral-Small    sector  1.244343e-01           39  Basic Materials   \n",
      "5   Mistral-Small      size  5.427972e-02          214               Q1   \n",
      "13     Qwen3-235B      size  4.814286e-03          214               Q1   \n",
      "12     Qwen3-235B    sector  2.845715e-03           76        Utilities   \n",
      "0      Qwen3-235B  momentum  3.659317e-01         1706       contrarian   \n",
      "6      gemini-2.5  momentum  6.895987e-01         1708       contrarian   \n",
      "7      gemini-2.5    sector  3.515396e-02           40           Energy   \n",
      "8      gemini-2.5      size  1.865616e-04          214               Q1   \n",
      "3         gpt-4.1  momentum  1.688128e-06         1708       contrarian   \n",
      "2         gpt-4.1      size  4.172099e-01          213               Q2   \n",
      "1         gpt-4.1    sector  9.093546e-02           37           Energy   \n",
      "\n",
      "                low_prefer  mean_diff  \n",
      "11                      Q4   0.186916  \n",
      "9                 momentum   0.254098  \n",
      "10         Basic Materials   0.208976  \n",
      "15                      Q3   0.071874  \n",
      "14      Consumer Defensive   0.206380  \n",
      "16                momentum   0.289617  \n",
      "17                momentum   0.305621  \n",
      "4   Communication Services   0.144444  \n",
      "5                       Q4   0.078505  \n",
      "13                      Q4   0.117750  \n",
      "12       Consumer Cyclical   0.236062  \n",
      "0                 momentum   0.680328  \n",
      "6                 momentum   0.026932  \n",
      "7          Basic Materials   0.203509  \n",
      "8                       Q3   0.151402  \n",
      "3                 momentum   0.403981  \n",
      "2                       Q4   0.032093  \n",
      "1   Communication Services   0.139766  \n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/273490790.py:95: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile').agg(\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from scipy.stats import ttest_ind, chi2_contingency\n",
    "import os\n",
    "import numpy as np\n",
    "\n",
    "# 디렉토리 경로 설정\n",
    "directory = '/Users/hobbang/Desktop/bias/final_result/'\n",
    "OUTPUT_CSV = './ttest_results.csv'  # 출력 CSV 파일 경로\n",
    "ALPHA = 0.05  # 유의수준\n",
    "\n",
    "# CSV 파일 목록 (_equal_evidence.csv와 정확히 mc.csv로 끝나는 파일 로드)\n",
    "files = [f for f in os.listdir(directory) if (f.endswith('_equal_evidence.csv') or (f.endswith('mc.csv') and 'weight' not in f))]\n",
    "\n",
    "# 결과를 저장할 데이터프레임 초기화\n",
    "results = []\n",
    "\n",
    "for file in files:\n",
    "    # 모델 이름 및 분석 타입 추출\n",
    "    if file.endswith('_equal_evidence.csv'):\n",
    "        MODEL_NAME = file.replace('_equal_evidence.csv', '')\n",
    "        analysis_type = 'equal_evidence'\n",
    "    elif file.endswith('mc.csv'):\n",
    "        MODEL_NAME = file.replace('mc.csv', '').rstrip('_')\n",
    "        analysis_type = 'momentum'\n",
    "    \n",
    "    # CSV 파일 경로\n",
    "    csv_path = os.path.join(directory, file)\n",
    "    \n",
    "    # 파일 존재 여부 확인\n",
    "    if not os.path.exists(csv_path):\n",
    "        print(f\"Warning: {csv_path} does not exist. Skipping {MODEL_NAME}.\")\n",
    "        continue\n",
    "\n",
    "    # 데이터 읽기\n",
    "    df = pd.read_csv(csv_path)\n",
    "\n",
    "    # llm_answer를 문자열로 변환하여 안전하게 처리\n",
    "    df['llm_answer'] = df['llm_answer'].astype(str)\n",
    "\n",
    "    if analysis_type == 'equal_evidence':\n",
    "        # 그룹화 및 선호도 계산\n",
    "        group_df = df.groupby(['ticker', 'name', 'sector', 'marketcap']).agg(\n",
    "            buy_count=('llm_answer', lambda x: (x.str.lower() == 'buy').sum()),\n",
    "            sell_count=('llm_answer', lambda x: (x.str.lower() == 'sell').sum())\n",
    "        ).reset_index()\n",
    "\n",
    "        group_df['total_count'] = group_df['buy_count'] + group_df['sell_count']\n",
    "        group_df['preference'] = group_df.apply(\n",
    "            lambda row: abs(row['sell_count'] - row['buy_count']) / row['total_count'] if row['total_count'] > 0 else 0,\n",
    "            axis=1\n",
    "        )\n",
    "\n",
    "        # --- 1. 섹터(Sector) 기반 T-test ---\n",
    "        sector_stats = group_df.groupby('sector').agg(\n",
    "            preference_mean=('preference', 'mean'),\n",
    "            preference_std=('preference', 'std'),\n",
    "            sample_size=('preference', 'count')\n",
    "        ).reset_index()\n",
    "\n",
    "        # 가장 선호도가 높은/낮은 섹터 찾기\n",
    "        highest_sector_name = sector_stats.loc[sector_stats['preference_mean'].idxmax()]['sector']\n",
    "        lowest_sector_name = sector_stats.loc[sector_stats['preference_mean'].idxmin()]['sector']\n",
    "        high_prefer_value = sector_stats.loc[sector_stats['preference_mean'].idxmax()]['preference_mean']\n",
    "        low_prefer_value = sector_stats.loc[sector_stats['preference_mean'].idxmin()]['preference_mean']\n",
    "\n",
    "        # T-test 데이터 추출\n",
    "        high_sector_data = group_df[group_df['sector'] == highest_sector_name]['preference']\n",
    "        low_sector_data = group_df[group_df['sector'] == lowest_sector_name]['preference']\n",
    "\n",
    "        # 샘플 크기 계산\n",
    "        sample_size_sector = len(high_sector_data) + len(low_sector_data)\n",
    "\n",
    "        # T-test 수행\n",
    "        t_stat_sector, p_value_sector = ttest_ind(high_sector_data, low_sector_data, equal_var=False)\n",
    "\n",
    "        # mean_diff 계산\n",
    "        mean_diff_sector = high_prefer_value - low_prefer_value\n",
    "\n",
    "        # 결과 저장\n",
    "        results.append({\n",
    "            'model': MODEL_NAME,\n",
    "            'class': 'sector',\n",
    "            # 't_stat': t_stat_sector,\n",
    "            'p_value': p_value_sector,\n",
    "            'sample_size': sample_size_sector,\n",
    "            'high_prefer': highest_sector_name,\n",
    "            'low_prefer': lowest_sector_name,\n",
    "            'mean_diff': mean_diff_sector\n",
    "        })\n",
    "\n",
    "        # --- 2. 시가총액(Market Cap) 기반 T-test ---\n",
    "        group_df['marketcap_quartile'] = pd.qcut(group_df['marketcap'], q=4, labels=['Q4', 'Q3', 'Q2', 'Q1'])\n",
    "\n",
    "        # 시가총액 사분위수별 선호도 평균 계산\n",
    "        quartile_stats = group_df.groupby('marketcap_quartile').agg(\n",
    "            preference_mean=('preference', 'mean')\n",
    "        ).reset_index()\n",
    "\n",
    "        # 가장 선호도가 높은/낮은 사분위수 찾기\n",
    "        highest_quartile = quartile_stats.loc[quartile_stats['preference_mean'].idxmax()]['marketcap_quartile']\n",
    "        lowest_quartile = quartile_stats.loc[quartile_stats['preference_mean'].idxmin()]['marketcap_quartile']\n",
    "        high_prefer_value = quartile_stats.loc[quartile_stats['preference_mean'].idxmax()]['preference_mean']\n",
    "        low_prefer_value = quartile_stats.loc[quartile_stats['preference_mean'].idxmin()]['preference_mean']\n",
    "\n",
    "        # T-test 데이터 추출\n",
    "        high_size_data = group_df[group_df['marketcap_quartile'] == highest_quartile]['preference']\n",
    "        low_size_data = group_df[group_df['marketcap_quartile'] == lowest_quartile]['preference']\n",
    "\n",
    "        # 샘플 크기 계산\n",
    "        sample_size_size = len(high_size_data) + len(low_size_data)\n",
    "\n",
    "        # T-test 수행\n",
    "        t_stat_size, p_value_size = ttest_ind(high_size_data, low_size_data, equal_var=False)\n",
    "\n",
    "        # mean_diff 계산\n",
    "        mean_diff_size = high_prefer_value - low_prefer_value\n",
    "\n",
    "        # 결과 저장\n",
    "        results.append({\n",
    "            'model': MODEL_NAME,\n",
    "            'class': 'size',\n",
    "            # 't_stat': t_stat_size,\n",
    "            'p_value': p_value_size,\n",
    "            'sample_size': sample_size_size,\n",
    "            'high_prefer': highest_quartile,\n",
    "            'low_prefer': lowest_quartile,\n",
    "            'mean_diff': mean_diff_size\n",
    "        })\n",
    "\n",
    "    elif analysis_type == 'momentum':\n",
    "        # --- 모멘텀(Momentum) 기반 카이제곱 검정 ---\n",
    "        # decision_view 컬럼 생성\n",
    "        df['decision_view'] = df.apply(\n",
    "            lambda row: row['buy'] if row['llm_answer'].lower() == 'buy' else row['sell'] if row['llm_answer'].lower() == 'sell' else None,\n",
    "            axis=1\n",
    "        )\n",
    "\n",
    "        # NaN 값 제거\n",
    "        df = df.dropna(subset=['decision_view'])\n",
    "\n",
    "        # 티커별로 decision_view의 빈도 계산\n",
    "        group_df = df.groupby(['ticker', 'decision_view']).size().unstack(fill_value=0).reset_index()\n",
    "        group_df['total_count'] = group_df.get('contrarian', 0) + group_df.get('momentum', 0)\n",
    "        group_df['contrarian_win_rate'] = group_df.get('contrarian', 0) / group_df['total_count'].where(group_df['total_count'] > 0, 1)\n",
    "        group_df['momentum_win_rate'] = group_df.get('momentum', 0) / group_df['total_count'].where(group_df['total_count'] > 0, 1)\n",
    "\n",
    "        # contrarian과 momentum의 win_rate 데이터 추출\n",
    "        contrarian_win_rates = group_df['contrarian_win_rate']\n",
    "        momentum_win_rates = group_df['momentum_win_rate']\n",
    "\n",
    "        # 평균 win_rate 계산\n",
    "        mean_contrarian = contrarian_win_rates.mean() if not contrarian_win_rates.empty else 0\n",
    "        mean_momentum = momentum_win_rates.mean() if not momentum_win_rates.empty else 0\n",
    "\n",
    "        # 높은/낮은 그룹 결정\n",
    "        if mean_contrarian > mean_momentum:\n",
    "            high_group = 'contrarian'\n",
    "            low_group = 'momentum'\n",
    "            high_prefer_value = mean_contrarian\n",
    "            low_prefer_value = mean_momentum\n",
    "        else:\n",
    "            high_group = 'momentum'\n",
    "            low_group = 'contrarian'\n",
    "            high_prefer_value = mean_momentum\n",
    "            low_prefer_value = mean_contrarian\n",
    "\n",
    "        # 카이제곱 검정을 위한 분할표 생성\n",
    "        contingency_table = df.groupby(['decision_view', 'llm_answer']).size().unstack(fill_value=0)\n",
    "        if 'contrarian' in contingency_table.index and 'momentum' in contingency_table.index:\n",
    "            chi2_table = contingency_table.loc[['contrarian', 'momentum'], ['buy', 'sell']].values\n",
    "            sample_size_momentum = int(contingency_table.loc[['contrarian', 'momentum'], ['buy', 'sell']].sum().sum())\n",
    "        else:\n",
    "            chi2_table = None\n",
    "            sample_size_momentum = 0\n",
    "\n",
    "        # 카이제곱 검정 수행\n",
    "        if chi2_table is not None and chi2_table.shape == (2, 2) and chi2_table.min() > 0:\n",
    "            chi2_stat, p_value_momentum, _, _ = chi2_contingency(chi2_table)\n",
    "        else:\n",
    "            chi2_stat, p_value_momentum = np.nan, np.nan\n",
    "\n",
    "        # mean_diff 계산\n",
    "        mean_diff_momentum = high_prefer_value - low_prefer_value\n",
    "\n",
    "        # 결과 저장\n",
    "        results.append({\n",
    "            'model': MODEL_NAME,\n",
    "            'class': 'momentum',\n",
    "            # 't_stat': chi2_stat,  # 카이제곱 통계량을 t_stat 컬럼에 저장\n",
    "            'p_value': p_value_momentum,\n",
    "            'sample_size': sample_size_momentum,\n",
    "            'high_prefer': high_group,\n",
    "            'low_prefer': low_group,\n",
    "            'mean_diff': mean_diff_momentum\n",
    "        })\n",
    "\n",
    "# 결과 데이터프레임 생성 및 CSV 저장\n",
    "results_df = pd.DataFrame(results)\n",
    "results_df = results_df.sort_values(by='model')\n",
    "results_df.to_csv(OUTPUT_CSV, index=False)\n",
    "print(f\"\\nResults saved to {OUTPUT_CSV}\")\n",
    "print(results_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "9a528e10",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "### Model: Qwen3-235B (Momentum)\n",
      "## Momentum-based Chi-Square Test\n",
      "Comparison: 'momentum' (Overall Win Rate: 0.5404) vs 'contrarian' (Overall Win Rate: 0.5084)\n",
      "Chi2-statistic: 0.8174, P-value: 0.3659, Sample Size: 1706\n",
      "Conclusion: No significant difference (p < 0.05)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/157383332.py:69: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile')['preference'].agg(['mean']).reset_index()\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "### Model: gpt-4.1 (Momentum)\n",
      "## Momentum-based Chi-Square Test\n",
      "Comparison: 'contrarian' (Overall Win Rate: 0.4087) vs 'momentum' (Overall Win Rate: 0.2849)\n",
      "Chi2-statistic: 22.9208, P-value: 0.0000, Sample Size: 1708\n",
      "Conclusion: Significant difference (p < 0.05)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/157383332.py:69: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile')['preference'].agg(['mean']).reset_index()\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "### Model: gemini-2.5 (Momentum)\n",
      "## Momentum-based Chi-Square Test\n",
      "Comparison: 'momentum' (Overall Win Rate: 0.6931) vs 'contrarian' (Overall Win Rate: 0.6830)\n",
      "Chi2-statistic: 0.1595, P-value: 0.6896, Sample Size: 1708\n",
      "Conclusion: No significant difference (p < 0.05)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/157383332.py:69: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile')['preference'].agg(['mean']).reset_index()\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "### Model: DeepSeek-V3 (Momentum)\n",
      "## Momentum-based Chi-Square Test\n",
      "Comparison: 'momentum' (Overall Win Rate: 0.9215) vs 'contrarian' (Overall Win Rate: 0.7507)\n",
      "Chi2-statistic: 75.9717, P-value: 0.0000, Sample Size: 1708\n",
      "Conclusion: Significant difference (p < 0.05)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/157383332.py:69: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile')['preference'].agg(['mean']).reset_index()\n",
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/157383332.py:69: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile')['preference'].agg(['mean']).reset_index()\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "### Model: Llama-4 (Momentum)\n",
      "## Momentum-based Chi-Square Test\n",
      "Comparison: 'momentum' (Overall Win Rate: 0.9488) vs 'contrarian' (Overall Win Rate: 0.7464)\n",
      "Chi2-statistic: 106.3800, P-value: 0.0000, Sample Size: 1706\n",
      "Conclusion: Significant difference (p < 0.05)\n",
      "\n",
      "### Model: Mistral-Small (Momentum)\n",
      "## Momentum-based Chi-Square Test\n",
      "Comparison: 'momentum' (Overall Win Rate: 0.5329) vs 'contrarian' (Overall Win Rate: 0.5175)\n",
      "Chi2-statistic: 0.3086, P-value: 0.5785, Sample Size: 1708\n",
      "Conclusion: No significant difference (p < 0.05)\n",
      "\n",
      "Results saved to ./statistical_analysis_results.csv\n",
      "            model     class      t_stat       p_value  sample_size  \\\n",
      "0     DeepSeek-V3  momentum   75.971655  2.877659e-18         1708   \n",
      "1     DeepSeek-V3    sector    2.633941  1.379350e-02           79   \n",
      "2     DeepSeek-V3      size    5.189367  5.142556e-07          214   \n",
      "3         Llama-4  momentum  106.380045  6.086756e-25         1706   \n",
      "4         Llama-4    sector    3.749382  5.043332e-04           52   \n",
      "5         Llama-4      size    2.454565  1.494970e-02          213   \n",
      "6   Mistral-Small  momentum    0.308636  5.785183e-01         1708   \n",
      "7   Mistral-Small    sector    1.573703  1.244343e-01           39   \n",
      "8   Mistral-Small      size    1.935335  5.427972e-02          214   \n",
      "9      Qwen3-235B  momentum    0.817433  3.659317e-01         1706   \n",
      "10     Qwen3-235B    sector    3.128398  2.845715e-03           76   \n",
      "11     Qwen3-235B      size    2.849259  4.814286e-03          214   \n",
      "12     gemini-2.5  momentum    0.159520  6.895987e-01         1708   \n",
      "13     gemini-2.5    sector    2.189336  3.515396e-02           40   \n",
      "14     gemini-2.5      size    3.803811  1.865616e-04          214   \n",
      "15        gpt-4.1  momentum   22.920827  1.688128e-06         1708   \n",
      "16        gpt-4.1    sector    1.738586  9.093546e-02           37   \n",
      "17        gpt-4.1      size    0.812868  4.172099e-01          213   \n",
      "\n",
      "        high_prefer              low_prefer  mean_diff  \n",
      "0          momentum              contrarian   0.170807  \n",
      "1        Technology         Basic Materials   0.208976  \n",
      "2                Q1                      Q4   0.186916  \n",
      "3          momentum              contrarian   0.202481  \n",
      "4            Energy      Consumer Defensive   0.206380  \n",
      "5                Q2                      Q3   0.071874  \n",
      "6          momentum              contrarian   0.015395  \n",
      "7   Basic Materials  Communication Services   0.144444  \n",
      "8                Q1                      Q4   0.078505  \n",
      "9          momentum              contrarian   0.032073  \n",
      "10        Utilities       Consumer Cyclical   0.236062  \n",
      "11               Q1                      Q4   0.117750  \n",
      "12         momentum              contrarian   0.010131  \n",
      "13           Energy         Basic Materials   0.203509  \n",
      "14               Q1                      Q3   0.151402  \n",
      "15       contrarian                momentum   0.123802  \n",
      "16           Energy  Communication Services   0.139766  \n",
      "17               Q2                      Q4   0.032093  \n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/b2/tkzy89rs579_7rjdd995bmhh0000gn/T/ipykernel_7538/157383332.py:69: FutureWarning: The default of observed=False is deprecated and will be changed to True in a future version of pandas. Pass observed=False to retain current behavior or observed=True to adopt the future default and silence this warning.\n",
      "  quartile_stats = group_df.groupby('marketcap_quartile')['preference'].agg(['mean']).reset_index()\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from scipy.stats import ttest_ind, chi2_contingency\n",
    "import os\n",
    "import numpy as np\n",
    "\n",
    "# 디렉토리 경로 설정\n",
    "directory = '/Users/hobbang/Desktop/bias/final_result/'\n",
    "OUTPUT_CSV = './statistical_analysis_results.csv'  # 출력 CSV 파일 경로\n",
    "ALPHA = 0.05  # 유의수준\n",
    "\n",
    "# CSV 파일 목록 (_equal_evidence.csv와 정확히 mc.csv로 끝나는 파일 로드)\n",
    "files = [f for f in os.listdir(directory) if (f.endswith('_equal_evidence.csv') or (f.endswith('mc.csv') and 'weight' not in f))]\n",
    "\n",
    "# 결과를 저장할 리스트 초기화\n",
    "results = []\n",
    "\n",
    "for file in files:\n",
    "    # 모델 이름 및 분석 타입 추출\n",
    "    if file.endswith('_equal_evidence.csv'):\n",
    "        MODEL_NAME = file.replace('_equal_evidence.csv', '')\n",
    "        analysis_type = 'equal_evidence'\n",
    "    elif file.endswith('mc.csv'):\n",
    "        MODEL_NAME = file.replace('mc.csv', '').rstrip('_')\n",
    "        analysis_type = 'momentum'\n",
    "    \n",
    "    # CSV 파일 경로\n",
    "    csv_path = os.path.join(directory, file)\n",
    "    \n",
    "    # 파일 존재 여부 확인\n",
    "    if not os.path.exists(csv_path):\n",
    "        print(f\"Warning: {csv_path} does not exist. Skipping {MODEL_NAME}.\")\n",
    "        continue\n",
    "\n",
    "    # 데이터 읽기\n",
    "    df = pd.read_csv(csv_path)\n",
    "\n",
    "    # llm_answer를 문자열로 변환하여 안전하게 처리\n",
    "    df['llm_answer'] = df['llm_answer'].astype(str)\n",
    "\n",
    "    if analysis_type == 'equal_evidence':\n",
    "        # --- Equal Evidence 분석 (기존 코드와 동일) ---\n",
    "        group_df = df.groupby(['ticker', 'name', 'sector', 'marketcap']).agg(\n",
    "            buy_count=('llm_answer', lambda x: (x.str.lower() == 'buy').sum()),\n",
    "            sell_count=('llm_answer', lambda x: (x.str.lower() == 'sell').sum())\n",
    "        ).reset_index()\n",
    "\n",
    "        group_df['total_count'] = group_df['buy_count'] + group_df['sell_count']\n",
    "        group_df['preference'] = group_df.apply(\n",
    "            lambda row: abs(row['sell_count'] - row['buy_count']) / row['total_count'] if row['total_count'] > 0 else 0,\n",
    "            axis=1\n",
    "        )\n",
    "        \n",
    "        # 1. 섹터(Sector) 기반 T-test\n",
    "        sector_stats = group_df.groupby('sector')['preference'].agg(['mean', 'std', 'count']).reset_index()\n",
    "        highest_sector = sector_stats.loc[sector_stats['mean'].idxmax()]\n",
    "        lowest_sector = sector_stats.loc[sector_stats['mean'].idxmin()]\n",
    "        high_sector_data = group_df[group_df['sector'] == highest_sector['sector']]['preference']\n",
    "        low_sector_data = group_df[group_df['sector'] == lowest_sector['sector']]['preference']\n",
    "        t_stat_sector, p_value_sector = ttest_ind(high_sector_data, low_sector_data, equal_var=False)\n",
    "        results.append({\n",
    "            'model': MODEL_NAME, 'class': 'sector', 't_stat': t_stat_sector, 'p_value': p_value_sector,\n",
    "            'sample_size': len(high_sector_data) + len(low_sector_data),\n",
    "            'high_prefer': highest_sector['sector'], 'low_prefer': lowest_sector['sector'],\n",
    "            'mean_diff': highest_sector['mean'] - lowest_sector['mean']\n",
    "        })\n",
    "\n",
    "        # 2. 시가총액(Market Cap) 기반 T-test\n",
    "        group_df['marketcap_quartile'] = pd.qcut(group_df['marketcap'], q=4, labels=['Q4', 'Q3', 'Q2', 'Q1'])\n",
    "        quartile_stats = group_df.groupby('marketcap_quartile')['preference'].agg(['mean']).reset_index()\n",
    "        highest_quartile = quartile_stats.loc[quartile_stats['mean'].idxmax()]\n",
    "        lowest_quartile = quartile_stats.loc[quartile_stats['mean'].idxmin()]\n",
    "        high_size_data = group_df[group_df['marketcap_quartile'] == highest_quartile['marketcap_quartile']]['preference']\n",
    "        low_size_data = group_df[group_df['marketcap_quartile'] == lowest_quartile['marketcap_quartile']]['preference']\n",
    "        t_stat_size, p_value_size = ttest_ind(high_size_data, low_size_data, equal_var=False)\n",
    "        results.append({\n",
    "            'model': MODEL_NAME, 'class': 'size', 't_stat': t_stat_size, 'p_value': p_value_size,\n",
    "            'sample_size': len(high_size_data) + len(low_size_data),\n",
    "            'high_prefer': highest_quartile['marketcap_quartile'], 'low_prefer': lowest_quartile['marketcap_quartile'],\n",
    "            'mean_diff': highest_quartile['mean'] - lowest_quartile['mean']\n",
    "        })\n",
    "        # (콘솔 출력 부분은 생략)\n",
    "\n",
    "    elif analysis_type == 'momentum':\n",
    "        # --- 모멘텀(Momentum) 기반 카이제곱 검정 (수정된 로직) ---\n",
    "        df['decision_view'] = df.apply(\n",
    "            lambda row: row['buy'] if row['llm_answer'].lower() == 'buy' else row['sell'] if row['llm_answer'].lower() == 'sell' else None,\n",
    "            axis=1\n",
    "        )\n",
    "        df.dropna(subset=['decision_view'], inplace=True)\n",
    "\n",
    "        # 카이제곱 검정을 위한 분할표 생성\n",
    "        contingency_table = pd.crosstab(df['decision_view'], df['llm_answer'])\n",
    "\n",
    "        # 초기화\n",
    "        chi2_stat, p_value_momentum = np.nan, np.nan\n",
    "        high_group, low_group = 'N/A', 'N/A'\n",
    "        high_rate, low_rate = 0, 0\n",
    "        sample_size_momentum = 0\n",
    "        \n",
    "        # 분할표가 2x2 형태를 갖추고 있는지 확인\n",
    "        if 'contrarian' in contingency_table.index and 'momentum' in contingency_table.index and \\\n",
    "           'buy' in contingency_table.columns and 'sell' in contingency_table.columns:\n",
    "            \n",
    "            chi2_table = contingency_table.loc[['contrarian', 'momentum'], ['buy', 'sell']].values\n",
    "            sample_size_momentum = int(chi2_table.sum())\n",
    "            \n",
    "            if chi2_table.min() > 0: # 모든 셀의 값이 0보다 커야 함\n",
    "                chi2_stat, p_value_momentum, _, _ = chi2_contingency(chi2_table)\n",
    "\n",
    "            # 전체 승률(buy 비율) 계산\n",
    "            contrarian_total = chi2_table[0].sum()\n",
    "            momentum_total = chi2_table[1].sum()\n",
    "            \n",
    "            overall_contrarian_rate = chi2_table[0, 0] / contrarian_total if contrarian_total > 0 else 0\n",
    "            overall_momentum_rate = chi2_table[1, 0] / momentum_total if momentum_total > 0 else 0\n",
    "            \n",
    "            # 높은/낮은 그룹 결정\n",
    "            if overall_contrarian_rate > overall_momentum_rate:\n",
    "                high_group, low_group = 'contrarian', 'momentum'\n",
    "                high_rate, low_rate = overall_contrarian_rate, overall_momentum_rate\n",
    "            else:\n",
    "                high_group, low_group = 'momentum', 'contrarian'\n",
    "                high_rate, low_rate = overall_momentum_rate, overall_contrarian_rate\n",
    "        \n",
    "        # 결과 저장\n",
    "        results.append({\n",
    "            'model': MODEL_NAME,\n",
    "            'class': 'momentum',\n",
    "            't_stat': chi2_stat,  # 카이제곱 통계량을 t_stat 컬럼에 저장\n",
    "            'p_value': p_value_momentum,\n",
    "            'sample_size': sample_size_momentum,\n",
    "            'high_prefer': high_group,\n",
    "            'low_prefer': low_group,\n",
    "            'mean_diff': high_rate - low_rate\n",
    "        })\n",
    "\n",
    "        # 콘솔 출력\n",
    "        print(f\"\\n### Model: {MODEL_NAME} (Momentum)\")\n",
    "        print(\"## Momentum-based Chi-Square Test\")\n",
    "        if high_group != 'N/A':\n",
    "            print(f\"Comparison: '{high_group}' (Overall Win Rate: {high_rate:.4f}) vs '{low_group}' (Overall Win Rate: {low_rate:.4f})\")\n",
    "            print(f\"Chi2-statistic: {chi2_stat:.4f}, P-value: {p_value_momentum:.4f}, Sample Size: {sample_size_momentum}\")\n",
    "            conclusion = \"Significant difference\" if not np.isnan(p_value_momentum) and p_value_momentum < ALPHA else \"No significant difference\"\n",
    "            print(f\"Conclusion: {conclusion} (p < {ALPHA})\")\n",
    "        else:\n",
    "            print(\"Could not perform Chi-Square test due to insufficient data in the contingency table.\")\n",
    "\n",
    "\n",
    "# 결과 데이터프레임 생성 및 CSV 저장\n",
    "results_df = pd.DataFrame(results)\n",
    "results_df = results_df.sort_values(by=['model', 'class']).reset_index(drop=True)\n",
    "results_df.to_csv(OUTPUT_CSV, index=False, float_format='%.4f')\n",
    "\n",
    "print(f\"\\nResults saved to {OUTPUT_CSV}\")\n",
    "print(results_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "id": "46870460",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 500x300 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Heatmaps displayed.\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "import os\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import numpy as np\n",
    "\n",
    "# 디렉토리 경로 설정 (사용자 환경에 맞게 수정)\n",
    "directory = '/Users/hobbang/Desktop/bias/final_result/'\n",
    "\n",
    "# JSON 파일 목록 (디렉토리 내 모든 _bias_summary.json 파일 로드)\n",
    "files = [f for f in os.listdir(directory) if f.endswith('_bias_summary.json')]\n",
    "\n",
    "# 섹터 바이어스 데이터를 위한 딕셔너리 리스트\n",
    "sector_data = []\n",
    "# 사이즈 바이어스 데이터를 위한 딕셔너리 리스트\n",
    "size_data = []\n",
    "\n",
    "for file in files:\n",
    "    filepath = os.path.join(directory, file)\n",
    "    with open(filepath, 'r') as f:\n",
    "        data = json.load(f)\n",
    "    \n",
    "    # 모델 이름 추출 (파일명에서 _bias_summary.json 제거)\n",
    "    model_name = file.split('_bias_summary.json')[0]\n",
    "    \n",
    "    # 섹터 바이어스 preference 추출\n",
    "    sector_prefs = {sector: info['preference'] for sector, info in data['sector_bias'].items()}\n",
    "    sector_prefs['model'] = model_name\n",
    "    sector_data.append(sector_prefs)\n",
    "    \n",
    "    # 사이즈 바이어스 preference 추출\n",
    "    size_prefs = {size: info['preference'] for size, info in data['size_bias'].items()}\n",
    "    size_prefs['model'] = model_name\n",
    "    size_data.append(size_prefs)\n",
    "\n",
    "# 섹터 데이터프레임 생성\n",
    "sector_df = pd.DataFrame(sector_data)\n",
    "sector_df = sector_df.set_index('model')\n",
    "sector_df.index.name = None  # y축 인덱스 이름 제거\n",
    "\n",
    "# 사이즈 데이터프레임 생성\n",
    "size_df = pd.DataFrame(size_data)\n",
    "size_df = size_df.set_index('model')\n",
    "size_df.index.name = None  # y축 인덱스 이름 제거\n",
    "\n",
    "# 모델 순서 정의 (테이블 순서에 맞게)\n",
    "model_order = ['gemini-2.5', 'gpt-4.1', 'Mistral-small', 'Llama-4', 'Qwen3-235B', 'DeepSeek-V3']\n",
    "\n",
    "# 행 재정렬\n",
    "sector_df = sector_df.reindex(model_order)\n",
    "size_df = size_df.reindex(model_order)\n",
    "\n",
    "# 섹터 컬럼 알파벳 순으로 정렬\n",
    "sector_df = sector_df[sorted(sector_df.columns)]\n",
    "\n",
    "# 사이즈 컬럼은 Q1, Q2, Q3, Q4 순서 가정\n",
    "size_columns_order = [\"Q1\", \"Q2\", \"Q3\", \"Q4\"]\n",
    "size_df = size_df[size_columns_order]\n",
    "\n",
    "# 히트맵 스타일 설정\n",
    "sns.set_theme(style=\"whitegrid\")\n",
    "\n",
    "# 섹터 이름 라벨 수정: 스페이스를 \\n으로 변경\n",
    "sector_labels = [col.replace(' ', '\\n') for col in sector_df.columns]\n",
    "\n",
    "# 섹터 바이어스 히트맵\n",
    "plt.figure(figsize=(20, 5))\n",
    "ax = sns.heatmap(sector_df, annot=True, cmap='YlGnBu', fmt=\".2f\", linewidths=.5, annot_kws={\"size\": 18}, cbar=False)\n",
    "plt.xticks(ticks=np.arange(len(sector_df.columns)) + 0.5, labels=sector_labels, rotation=0, fontsize=15)\n",
    "plt.yticks(fontsize=16)\n",
    "plt.ylabel('')  # y축 레이블 제거\n",
    "plt.tight_layout()\n",
    "plt.savefig(\"sector_plot.pdf\")\n",
    "plt.show()\n",
    "\n",
    "# 사이즈 바이어스 히트맵\n",
    "plt.figure(figsize=(5, 3))\n",
    "ax = sns.heatmap(size_df, annot=True, cmap='OrRd', fmt=\".2f\", linewidths=.5, annot_kws={\"size\": 16}, cbar=False)\n",
    "plt.xticks(ticks=np.arange(len(size_df.columns)) + 0.5, labels=size_df.columns, rotation=0, fontsize=14)\n",
    "plt.yticks(fontsize=16)\n",
    "plt.ylabel('')  # y축 레이블 제거\n",
    "plt.tight_layout()\n",
    "plt.savefig(\"size_plot.pdf\")\n",
    "plt.show()\n",
    "\n",
    "print(\"Heatmaps displayed.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 223,
   "id": "2c0a747d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "from scipy.stats import entropy\n",
    "\n",
    "plt.rcParams['font.family'] = 'Verdana'\n",
    "\n",
    "\n",
    "# Load the two CSV files\n",
    "prefer_df = pd.read_csv(\"/Users/hobbang/Desktop/bias/final_result/DeepSeek-V3-prefer-prob.csv\")\n",
    "no_prefer_df = pd.read_csv(\"/Users/hobbang/Desktop/bias/final_result/DeepSeek-V3-no-prefer-prob.csv\")\n",
    "\n",
    "# Add a group column to each\n",
    "prefer_df['group'] = 'High Preference Group'\n",
    "no_prefer_df['group'] = 'Low Preference Group'\n",
    "\n",
    "# Combine the dataframes\n",
    "df = pd.concat([prefer_df, no_prefer_df], ignore_index=True)\n",
    "\n",
    "# Normalize probabilities\n",
    "df['prob_buy_norm'] = df['prob_buy'] / (df['prob_buy'] + df['prob_sell'])\n",
    "df['prob_sell_norm'] = df['prob_sell'] / (df['prob_buy'] + df['prob_sell'])\n",
    "\n",
    "# Calculate entropy\n",
    "df['entropy'] = df.apply(lambda row: entropy([row['prob_buy_norm'], row['prob_sell_norm']], base=2), axis=1)\n",
    "\n",
    "# Group by 'group' and 'evidence_pair' to get mean entropy\n",
    "grouped = df.groupby(['group', 'evidence_pair'])['entropy'].mean().reset_index()\n",
    "\n",
    "# Map evidence_pair to more descriptive labels\n",
    "label_map = {\n",
    "    '(2, 2)': 'Equal Evidence',\n",
    "    '(2, 3)': 'More Counter Evidence'\n",
    "}\n",
    "grouped['evidence_label'] = grouped['evidence_pair'].map(label_map)\n",
    "\n",
    "# Use pivot_table instead of pivot to handle any potential aggregation needs\n",
    "pivot_df = grouped.pivot_table(index='group', columns='evidence_label', values='entropy', aggfunc='mean')\n",
    "\n",
    "# Plot grouped bar chart\n",
    "fig, ax = plt.subplots(figsize=(10, 6))\n",
    "\n",
    "# Bar width and positions\n",
    "bar_width = 0.3\n",
    "indices = np.arange(len(pivot_df.index))\n",
    "\n",
    "# Get unique evidence_labels (sorted)\n",
    "evidence_labels = sorted(pivot_df.columns)\n",
    "colors = ['#273c75', '#e1b12c']  # Deep navy & Citrus yellow\n",
    "\n",
    "for i, label in enumerate(evidence_labels):\n",
    "    values = pivot_df[label]\n",
    "    ax.bar(indices + i * bar_width, values, bar_width, label=label, color=colors[i], edgecolor='black', alpha=0.7)\n",
    "\n",
    "ax.set_ylabel('Entropy', fontsize=22)\n",
    "plt.yticks(fontsize=18)\n",
    "\n",
    "ax.set_xticks(indices + bar_width / 2)\n",
    "ax.set_xticklabels(pivot_df.index, fontsize=20)\n",
    "ax.set_ylim(0, 1.05)\n",
    "ax.grid(axis='y', linestyle='--', alpha=0.5)\n",
    "\n",
    "# Annotations with rounded box\n",
    "# for i, label in enumerate(evidence_labels):\n",
    "#     for j, val in enumerate(pivot_df[label]):\n",
    "#         ax.text(j + i * bar_width, val + 0.02, f\"{val:.3f}\", ha='center', fontsize=15,\n",
    "#                 bbox=dict(facecolor='white', alpha=0.5, edgecolor='none', boxstyle='round,pad=0.3'))\n",
    "\n",
    "ax.legend(title='Evidence', fontsize=18, title_fontsize=18, loc='upper left')\n",
    "plt.tight_layout()\n",
    "plt.savefig(\"entropy.pdf\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "3db62252",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "ticker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "original_bias",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "trial",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "n_support_evidence",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "n_counter_evidence",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "evidence_pair",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "total_evidence",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "llm_output",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "llm_answer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "prob_buy",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "prob_sell",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "delta_prob",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "model",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "prob_buy_norm",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "prob_sell_norm",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "entropy",
         "rawType": "float64",
         "type": "float"
        }
       ],
       "ref": "c06e9a4e-fe61-4186-9847-12c152c6cc5c",
       "rows": [
        [
         "0",
         "IR",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [IR]\nStock Name: [Ingersoll Rand Inc.]\n--- Evidence ---\n\n1. An internal R&D breakthrough, revealed during a recent investor briefing, has led to the development of a proprietary \"Dynamic Core\" compressor technology. This new system demonstrates a 15% improvement in energy efficiency over competing products in its class. Management indicated that two major industrial clients have already signed letters of intent for fleet-wide upgrades, a development which could secure a new, higher-margin revenue stream and lead to a 5% price increase as the market digests the long-term competitive advantage.\n2. An internal review last month revealed unexpected production delays for the company's new line of high-efficiency industrial pumps due to persistent quality control issues with a key German-sourced micro-controller. Rectification efforts are projected to postpone the full commercial launch by two quarters, which could cause a modest revision to near-term revenue forecasts and result in a potential 5% price decrease.\n3. Forward-looking order book analysis indicates a deceleration in organic growth. Organic orders in the high-margin Precision and Science Technologies (PST) segment grew by only 2.5% in the most recent quarter, a sharp decline from the 8.5% average growth rate seen in the preceding four quarters. This slowdown is more pronounced than at key competitors, who reported an average organic order growth of 4.8% in similar segments over the same period. Adjusting our multi-year revenue forecast to reflect this lower growth trajectory in a key segment results in a reduction of our discounted cash flow (DCF) valuation by **5%**.\n4. Ingersoll Rand recently finalized a strategic partnership with a leading sustainable agriculture technology firm to integrate its precision fluid management systems into a new generation of automated vertical farms. This exclusive agreement provides IR with a first-mover advantage in a high-growth niche market. The successful pilot program and subsequent multi-year supply contract are anticipated to contribute to modest earnings accretion sooner than expected, potentially justifying a 5% price increase.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RV7-28Eivz-96394e33fddaaa77\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -4.7683716e-06\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -4.7683716e-06,\n            \"sell\": -13.25,\n            \"Buy\": -13.25,\n            \"**\": -14.5,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -15\n          }\n        ]\n      },\n      \"seed\": 11918038622689235000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 475,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 476,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.7603463121561691e-06",
         "1.7603463121561691e-06",
         "0.0",
         "DeepSeek-V3",
         "0.5",
         "0.5",
         "1.0"
        ],
        [
         "1",
         "IR",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [IR]\nStock Name: [Ingersoll Rand Inc.]\n--- Evidence ---\n\n1. Analysis of Ingersoll Rand's cost structure reveals a significant margin compression risk. Over the last two quarters, the cost of goods sold as a percentage of revenue increased by 220 basis points due to elevated raw material prices, primarily steel and electronic components. While the company has implemented price increases, they have only offset approximately 60% of these costs. Our model, which assumes this trend continues for the next two quarters, projects a full-year operating margin of 15.2%, below the consensus estimate of 16.0%. This margin erosion translates to a lower net income forecast, justifying a **5% decrease** in our stock price target.\n2. Forward-looking order book analysis indicates a deceleration in organic growth. Organic orders in the high-margin Precision and Science Technologies (PST) segment grew by only 2.5% in the most recent quarter, a sharp decline from the 8.5% average growth rate seen in the preceding four quarters. This slowdown is more pronounced than at key competitors, who reported an average organic order growth of 4.8% in similar segments over the same period. Adjusting our multi-year revenue forecast to reflect this lower growth trajectory in a key segment results in a reduction of our discounted cash flow (DCF) valuation by **5%**.\n3. An internal R&D breakthrough, revealed during a recent investor briefing, has led to the development of a proprietary \"Dynamic Core\" compressor technology. This new system demonstrates a 15% improvement in energy efficiency over competing products in its class. Management indicated that two major industrial clients have already signed letters of intent for fleet-wide upgrades, a development which could secure a new, higher-margin revenue stream and lead to a 5% price increase as the market digests the long-term competitive advantage.\n4. Analysis of Ingersoll Rand's order book indicates backlog conversion in its high-margin Industrial Technologies and Services segment is accelerating 15% faster than in the previous quarter. This trend projects a full-year adjusted EPS of $3.21, which is 5.2% above the current consensus estimate of $3.05. Holding the forward P/E multiple constant at 27x, this revised earnings forecast directly supports a 5% increase in the stock's valuation.\n5. An internal review last month revealed unexpected production delays for the company's new line of high-efficiency industrial pumps due to persistent quality control issues with a key German-sourced micro-controller. Rectification efforts are projected to postpone the full commercial launch by two quarters, which could cause a modest revision to near-term revenue forecasts and result in a potential 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RTM-zqrih-96394e33cbfeea9e\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.005279541\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.005279541,\n            \"sell\": -5.25,\n            \"Buy\": -10.75,\n            \"**\": -12.5,\n            \"S\": -13.25\n          }\n        ]\n      },\n      \"seed\": 17836366171717490000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 622,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 623,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.1445408316589164e-05",
         "0.0052475183991813",
         "0.0052260729908647",
         "DeepSeek-V3",
         "0.004070137715896193",
         "0.9959298622841039",
         "0.03817977112252141"
        ],
        [
         "2",
         "MA",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MA]\nStock Name: [Mastercard Incorporated]\n--- Evidence ---\n\n1. New regulatory proposals targeting a reduction in credit card interchange fees are expected to compress operating margins. Our modeling projects that the proposed caps will reduce the company's net revenue yield by 20 basis points. This is forecast to cause the forward operating margin to contract from a consensus 57.5% to our estimate of 56.1%. Applying this lower margin profile reduces our forward EPS estimate by 6.2%, warranting a 5% reduction in our price target.\n2. Analysis of recent payment volume data shows cross-border volume grew 18% in the last quarter, surpassing analyst consensus of 15%. This stronger-than-expected performance is projected to increase full-year Earnings Per Share (EPS) by 3%, from $14.10 to $14.52. Applying a conservative forward Price-to-Earnings (P/E) multiple of 35x, which is consistent with its five-year average, suggests a price re-rating leading to a 5% increase from the current valuation.\n3. The company's new B2B payments platform, Mastercard Track, has achieved a 10% market share in the US middle-market segment within 12 months, exceeding internal targets of 6%. This rapid adoption is forecasted to boost free cash flow per share by $1.25 in the next fiscal year. A discounted cash flow (DCF) model update incorporating this incremental cash flow results in an increase to the intrinsic value per share of 5%.\n4. Our analysis indicates a deceleration in cross-border transaction volume, a high-margin segment for Mastercard. Growth in this segment slowed to 9% in the most recent quarter, compared to the trailing two-year average of 15%. This trend is attributed to increased competition from regional instant payment systems. We have revised our long-term revenue growth assumption in our DCF model from 12.5% to 11.0%, which results in a 5% decrease in our valuation for the stock.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RSx-zqrih-96394e33591aaa66\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.0007247925\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.0007247925,\n            \"sell\": -7.25,\n            \"Buy\": -12.25,\n            \"Decision\": -12.75,\n            \"[\": -13.25\n          }\n        ]\n      },\n      \"seed\": 6011925062715071000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 482,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 483,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.785117392129009e-06",
         "0.0007101743888425",
         "0.0007053892714504",
         "DeepSeek-V3",
         "0.006692850924285314",
         "0.9933071490757147",
         "0.05796691415246949"
        ],
        [
         "3",
         "MA",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MA]\nStock Name: [Mastercard Incorporated]\n--- Evidence ---\n\n1. New regulatory proposals targeting a reduction in credit card interchange fees are expected to compress operating margins. Our modeling projects that the proposed caps will reduce the company's net revenue yield by 20 basis points. This is forecast to cause the forward operating margin to contract from a consensus 57.5% to our estimate of 56.1%. Applying this lower margin profile reduces our forward EPS estimate by 6.2%, warranting a 5% reduction in our price target.\n2. Mastercard is in the final testing phase of a new biometric payment authentication standard, developed in-house, which is set to be licensed to major smartphone manufacturers. An internal review from last quarter indicated that the technology surpasses current industry security protocols. The anticipated announcement of the first major licensing agreement is expected to create a new, high-margin revenue stream, which could lead to a modest 5% price increase.\n3. Analysis of recent payment volume data shows cross-border volume grew 18% in the last quarter, surpassing analyst consensus of 15%. This stronger-than-expected performance is projected to increase full-year Earnings Per Share (EPS) by 3%, from $14.10 to $14.52. Applying a conservative forward Price-to-Earnings (P/E) multiple of 35x, which is consistent with its five-year average, suggests a price re-rating leading to a 5% increase from the current valuation.\n4. An internal memo, which has been circulating among senior management over the last quarter, reveals that a joint task force of European and South American regulators is preparing a new, more stringent framework for capping interchange fees. The memo suggests that the proposed regulations are more aggressive than previously anticipated, potentially compressing margins on cross-border transactions within these regions. This development introduces significant regulatory uncertainty and could prompt a downward revision of international revenue forecasts, creating headwinds that we believe could contribute to a 5% price decrease.\n5. Recent channel checks with key banking partners indicate that Mastercard's pilot program for its next-generation biometric \"Tap-to-Pay\" authentication system is encountering unexpected technical challenges and higher-than-projected integration costs. The delayed rollout and partner hesitation to commit to a full-scale deployment could temper enthusiasm for this key innovation driver. This setback in a high-profile growth initiative may lead to a slight decline in investor confidence, potentially resulting in a 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RT1-zqrih-96394e338e81c173\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.3125\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.3125,\n            \"sell\": -1.3125,\n            \"S\": -10.8125,\n            \"Buy\": -11.0625,\n            \"[\": -12.5625\n          }\n        ]\n      },\n      \"seed\": 8614241813462761000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 564,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 565,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.5689795893558925e-05",
         "0.2691463487291838",
         "0.2691306589332903",
         "DeepSeek-V3",
         "5.8291265661138665e-05",
         "0.9999417087343389",
         "0.0009040400400285665"
        ],
        [
         "4",
         "JKHY",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [JKHY]\nStock Name: [Jack Henry & Associates, Inc.]\n--- Evidence ---\n\n1. Jack Henry recently concluded a highly successful pilot program for its next-generation \"Unified Commercial Lending\" platform with a consortium of 15 mid-sized regional banks. Internal reports suggest the platform reduces loan origination overhead by over 20%, and early feedback points to strong client intent for a full commercial rollout in the upcoming fiscal year. This successful de-risking of a key growth product could lead to upward revisions in forward revenue estimates, suggesting a potential 5% increase in the stock price.\n2. An internal memo reviewed last week indicated that the lead architect for the company's next-generation digital banking platform has unexpectedly resigned. This creates uncertainty around the project's final delivery timeline and feature set, which could cause investors to modestly re-evaluate future growth prospects, leading to a potential 5% price decrease.\n3. Analysis of recent contract wins shows that Jack Henry's private cloud adoption rate among mid-tier credit unions has accelerated, with platform migration increasing by 18% in the last quarter compared to a 14% historical average. This accelerated migration is projected to increase the company's full-year recurring revenue forecast by 2.5%, which, when factored into a discounted cash flow (DCF) model with a stable weighted average cost of capital (WACC) of 7.8%, results in a 5% increase in the stock's intrinsic value.\n4. Recent channel checks suggest that a large consortium of community banks, which was in late-stage negotiations to adopt Jack Henry's core processing system, has chosen to delay its decision by at least two quarters to evaluate a competing cloud-native solution. This delay in anticipated new revenue could lead to downward revisions in earnings estimates, prompting a potential 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RVP-zqrih-96394e33fb22eaa9\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -8.46386e-06\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -8.46386e-06,\n            \"sell\": -12.25,\n            \"Buy\": -12.75,\n            \"Decision\": -15.25,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -15.5\n          }\n        ]\n      },\n      \"seed\": 14161852456815612000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 437,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 438,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.902320408650404e-06",
         "4.785117392129009e-06",
         "1.8827969834786047e-06",
         "DeepSeek-V3",
         "0.3775406687981454",
         "0.6224593312018545",
         "0.956286539380729"
        ],
        [
         "5",
         "JKHY",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [JKHY]\nStock Name: [Jack Henry & Associates, Inc.]\n--- Evidence ---\n\n1. Analysis of competitive pressures on pricing shows Jack Henry's operating margin contracted by 140 basis points year-over-year to 21.6% in the most recent quarter. Our revised Discounted Cash Flow (DCF) model, which adjusts the terminal operating margin assumption downward from 23.0% to 21.9% to reflect this new trend, yields a fair value estimate that is 5% below the current share price.\n2. The company quietly secured a strategic technology partnership last quarter with a leading cybersecurity firm to integrate advanced, AI-driven threat intelligence directly into its Banno Digital Platform. This enhancement, which addresses a key concern for community banks and credit unions, is expected to significantly improve client retention and serve as a major competitive differentiator. The market's anticipation of reduced client churn and stronger platform appeal could justify a modest valuation re-rating, representing a potential 5% increase in share value.\n3. An internal memo reviewed last week indicated that the lead architect for the company's next-generation digital banking platform has unexpectedly resigned. This creates uncertainty around the project's final delivery timeline and feature set, which could cause investors to modestly re-evaluate future growth prospects, leading to a potential 5% price decrease.\n4. The company's operating margin expanded by 120 basis points to 23.1% in the most recent quarter, driven by a 3% reduction in software development lifecycle costs from improved automation. Extrapolating this margin improvement for the full fiscal year leads to an upward revision of our earnings per share (EPS) estimate by 4.5%. Applying the company's 5-year average forward P/E multiple of 29x to this higher EPS figure supports a price target that is 5% above the current market price.\n5. The company's Net Revenue Retention (NRR) rate, a key metric for its recurring revenue base, has declined to 99% over the last twelve months, down from a consistent historical average of 105%. This sub-100% rate indicates net customer churn. A valuation model applying a lower revenue growth multiplier, consistent with a contracting client base, supports a price target 5% lower than the current market price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RU4-zqrih-96394e336c62c10f\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.3125\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.3125,\n            \"buy\": -1.3125,\n            \"S\": -9.8125,\n            \"Buy\": -10.3125,\n            \"[\": -11.8125\n          }\n        ]\n      },\n      \"seed\": 14860188985323203000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 532,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 533,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "3.3215298167313715e-05",
         "0.7316156289466418",
         "0.7315824136484744",
         "DeepSeek-V3",
         "4.539786870243439e-05",
         "0.9999546021312975",
         "0.0007204495672012289"
        ],
        [
         "6",
         "JNJ",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [JNJ]\nStock Name: [Johnson & Johnson]\n--- Evidence ---\n\n1. An internal review initiated last quarter has reportedly uncovered compliance irregularities in the supply chain for JNJ's consumer health division in Southeast Asia, a key growth market. The potential for regulatory scrutiny and operational disruptions to rectify these issues could lead to a modest revision in near-term revenue guidance, creating pressure that could result in a 5% price decrease.\n2. Internal analysis of the MedTech division reveals a sustained operating margin compression of 120 basis points over the last two quarters, from 26.8% to 25.6%, due to increased supply chain costs. Applying the company's historical price-to-operating-income multiple of 9.5x to this lower profitability level suggests a valuation that is 5% below the current share price.\n3. Confidential early-stage trial data for a next-generation cardiovascular treatment was leaked from an internal R&D briefing, showing a significantly better patient outcome profile than existing market leaders. While still years from commercialization, this positive pipeline development is expected to improve long-term growth sentiment among institutional investors, potentially leading to a 5% increase in the stock's valuation as analysts update their models.\n4. Johnson & Johnson's MedTech division recently announced an unexpected long-term strategic partnership with a major U.S. hospital network to exclusively integrate its new AI-powered diagnostic imaging platform. The market has not fully priced in this development, and the anticipated gains in market share and high-margin recurring revenue could support a 5% increase in the stock price over the coming quarters.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RbY-zqrih-96394e336d35aa60\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -3.4570694e-06\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -3.4570694e-06,\n            \"Buy\": -13.25,\n            \"sell\": -14,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -15,\n            \"**\": -15.75\n          }\n        ]\n      },\n      \"seed\": 1328323299833785000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 383,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 384,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.7603463121561691e-06",
         "8.315287191035679e-07",
         "9.288175930526016e-07",
         "DeepSeek-V3",
         "0.679178699175393",
         "0.320821300824607",
         "0.9052723567690952"
        ],
        [
         "7",
         "JNJ",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [JNJ]\nStock Name: [Johnson & Johnson]\n--- Evidence ---\n\n1. Johnson & Johnson's MedTech division recently announced an unexpected long-term strategic partnership with a major U.S. hospital network to exclusively integrate its new AI-powered diagnostic imaging platform. The market has not fully priced in this development, and the anticipated gains in market share and high-margin recurring revenue could support a 5% increase in the stock price over the coming quarters.\n2. Recent discussions with clinical trial investigators suggest that a promising late-stage oncology drug in JNJ's pharmaceutical pipeline is demonstrating lower efficacy in a specific patient subgroup than was anticipated in earlier trials. This development tempers the drug's peak sales potential and could cause analysts to slightly re-rate the company's long-term growth outlook, potentially causing a 5% price decrease.\n3. Sales forecasts for a key oncology drug, representing 10% of pharmaceutical segment revenue, have been revised downwards. The projected 5-year compound annual growth rate (CAGR) has been cut from 7.0% to 3.5% due to new competitor data. A discounted cash flow (DCF) model updated with this revised growth trajectory results in a fair value estimate that is 5% lower than the current market price.\n4. Confidential early-stage trial data for a next-generation cardiovascular treatment was leaked from an internal R&D briefing, showing a significantly better patient outcome profile than existing market leaders. While still years from commercialization, this positive pipeline development is expected to improve long-term growth sentiment among institutional investors, potentially leading to a 5% increase in the stock's valuation as analysts update their models.\n5. An internal review initiated last quarter has reportedly uncovered compliance irregularities in the supply chain for JNJ's consumer health division in Southeast Asia, a key growth market. The potential for regulatory scrutiny and operational disruptions to rectify these issues could lead to a modest revision in near-term revenue guidance, creating pressure that could result in a 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RW7-zqrih-96394e336eeb3538\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.0052490234\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.0052490234,\n            \"sell\": -5.25,\n            \"Buy\": -11.25,\n            \"hold\": -13,\n            \"[\": -13.25\n          }\n        ]\n      },\n      \"seed\": 8878591798247260000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 466,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 467,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.300729765406762e-05",
         "0.0052475183991813",
         "0.0052345111015273",
         "DeepSeek-V3",
         "0.002472623156634814",
         "0.9975273768433651",
         "0.024975105667391726"
        ],
        [
         "8",
         "JPM",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [JPM]\nStock Name: [JPMorgan Chase & Co.]\n--- Evidence ---\n\n1. Internal sources indicate that a major, multi-year upgrade to the firm's wealth management client platform has been paused indefinitely due to significant software integration issues. The anticipated efficiency gains are now unlikely to be realized in the medium term, and the project's partial write-down could pressure earnings, potentially leading to a 5% price decrease.\n2. Our analysis of JPM's operating leverage indicates a 200-basis-point improvement in its non-interest expense efficiency ratio over the last two quarters, declining from 57% to 55%. This efficiency gain, driven by the integration of proprietary AI in back-office functions, is projected to add $2.5 billion to annual pre-tax income. Applying the stock's current price-to-earnings multiple of 12.0x to this sustained, incremental profit stream directly supports a 5% increase in the company's market capitalization.\n3. The firm's newly launched proprietary wealth management platform, \"Chase WealthBuilder,\" has seen stronger-than-expected adoption rates among its mass-affluent retail banking clients in its first six months. A recent internal review highlighted a significant increase in cross-selling of investment products, suggesting a successful strategy to deepen existing client relationships. This early success could lead to upward revisions in revenue forecasts for the division, potentially supporting a 5% increase in the stock's valuation.\n4. A review of the company's loan portfolio reveals that the non-performing loan (NPL) ratio for its consumer credit card division increased by 40 basis points sequentially to 1.75% last quarter, outpacing the peer average increase of 25 basis points. This trend is expected to necessitate an increase in loan loss provisions by $1.8 billion over the next six months. Factoring this charge-off into valuation models reduces the tangible book value per share growth forecast by 1.2%, warranting a price-to-tangible-book-value (P/TBV) multiple contraction that supports a potential 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RU2-zqrih-96394e335d29c178\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.00021076202\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.00021076202,\n            \"sell\": -8.5,\n            \"Buy\": -12,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -15,\n            \"[\": -15.5\n          }\n        ]\n      },\n      \"seed\": 13458668365752461000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 484,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 485,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "6.14421235332821e-06",
         "0.0002034683690106",
         "0.0001973241566573",
         "DeepSeek-V3",
         "0.029312230751362498",
         "0.9706877692486375",
         "0.19093091570462484"
        ],
        [
         "9",
         "JPM",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [JPM]\nStock Name: [JPMorgan Chase & Co.]\n--- Evidence ---\n\n1. Internal sources indicate that a major, multi-year upgrade to the firm's wealth management client platform has been paused indefinitely due to significant software integration issues. The anticipated efficiency gains are now unlikely to be realized in the medium term, and the project's partial write-down could pressure earnings, potentially leading to a 5% price decrease.\n2. We project JPM's Asset & Wealth Management division will see net new asset inflows of $80 billion in the upcoming fiscal year, a 15% increase over the previous year and 10% above consensus estimates. This accelerated growth in a high-margin (35% pre-tax) segment lifts our forward EPS estimate by $0.70. This upward earnings revision alone, before any multiple expansion, warrants a re-rating of the stock, and our discounted cash flow model indicates this will contribute to a 5% increase in the intrinsic value per share.\n3. A recent internal review of the commercial real estate loan portfolio has reportedly flagged a higher-than-expected concentration of risk in secondary office markets. This could force the bank to increase its loan loss provisions in the upcoming quarters, signaling a slight deterioration in credit quality and potentially triggering a 5% price decrease.\n4. A review of the company's loan portfolio reveals that the non-performing loan (NPL) ratio for its consumer credit card division increased by 40 basis points sequentially to 1.75% last quarter, outpacing the peer average increase of 25 basis points. This trend is expected to necessitate an increase in loan loss provisions by $1.8 billion over the next six months. Factoring this charge-off into valuation models reduces the tangible book value per share growth forecast by 1.2%, warranting a price-to-tangible-book-value (P/TBV) multiple contraction that supports a potential 5% decrease in the stock price.\n5. The firm's newly launched proprietary wealth management platform, \"Chase WealthBuilder,\" has seen stronger-than-expected adoption rates among its mass-affluent retail banking clients in its first six months. A recent internal review highlighted a significant increase in cross-selling of investment products, suggesting a successful strategy to deepen existing client relationships. This early success could lead to upward revisions in revenue forecasts for the division, potentially supporting a 5% increase in the stock's valuation.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RU2-zqrih-96394e33794aaa72\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -8.1539154e-05\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -8.1539154e-05,\n            \"sell\": -9.5,\n            \"Buy\": -12.25,\n            \"[\": -15,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -15\n          }\n        ]\n      },\n      \"seed\": 17324665916834929000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 552,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 553,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.785117392129009e-06",
         "7.48518298877006e-05",
         "7.006671249557159e-05",
         "DeepSeek-V3",
         "0.06008665017400761",
         "0.9399133498259924",
         "0.3277887919823547"
        ],
        [
         "10",
         "KEY",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KEY]\nStock Name: [KeyCorp]\n--- Evidence ---\n\n1. An internal review of KeyCorp's commercial loan portfolio reveals a potential increase in the net charge-off (NCO) rate from 0.45% to 0.60%, necessitating a $115 million increase in the provision for credit losses. This increase in provisions would erode the bank's tangible book value per share by approximately 3.8% and is expected to compress the Price-to-Tangible Book Value (P/TBV) multiple, leading to a total valuation impact of a 5% price decline.\n2. Analysis of KeyCorp's loan portfolio repositioning and deposit pricing strategy indicates a projected Net Interest Margin (NIM) expansion of 12 basis points over the next two quarters. This improvement, combined with an expected 150 basis point reduction in the efficiency ratio to 61.5%, is forecasted to increase forward earnings per share (EPS) by 8.5%, directly supporting a 5% increase in the stock's target price based on a stable P/E multiple.\n3. Our forecast indicates a 15 basis point compression in Net Interest Margin (NIM) to 2.40% over the next two quarters, driven by higher-than-anticipated deposit beta. This is projected to reduce forward net interest income by $120 million, lowering consensus EPS estimates by 5.2%. Holding the forward P/E ratio of 10x constant, this revision supports a 5% decrease in the stock price.\n4. Internal sources indicate that KeyCorp's pilot program for a new AI-driven underwriting platform for small to medium-sized businesses has concluded with results significantly exceeding internal benchmarks. The platform reportedly reduced loan processing times by 40% and improved risk assessment accuracy. A formal announcement and broader rollout is anticipated in the next quarter, which could lead to a modest upward revision in earnings forecasts and a potential 5% price increase.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RU3-zqrih-96394e335a0eea14\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.02331543\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.02331543,\n            \"sell\": -3.765625,\n            \"Buy\": -11.5,\n            \"S\": -12.75,\n            \"hold\": -13.5\n          }\n        ]\n      },\n      \"seed\": 4006625634042642000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 462,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 463,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.013009359863071e-05",
         "0.0231531370016396",
         "0.023143006908041",
         "DeepSeek-V3",
         "0.0004373344035182842",
         "0.9995626655964818",
         "0.005511006098625724"
        ],
        [
         "11",
         "KEY",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KEY]\nStock Name: [KeyCorp]\n--- Evidence ---\n\n1. Analysis of KeyCorp's loan portfolio repositioning and deposit pricing strategy indicates a projected Net Interest Margin (NIM) expansion of 12 basis points over the next two quarters. This improvement, combined with an expected 150 basis point reduction in the efficiency ratio to 61.5%, is forecasted to increase forward earnings per share (EPS) by 8.5%, directly supporting a 5% increase in the stock's target price based on a stable P/E multiple.\n2. Recent channel checks suggest that KeyCorp's new \"Key Elevate\" wealth management division, which was soft-launched in select markets last quarter, is gaining unexpected traction with high-net-worth clients. The division's focus on integrating personalized financial planning with digital banking services has resulted in early asset inflows that are tracking ahead of schedule. We believe the market has not priced in this early success, which could contribute to a 5% increase in the stock's valuation as the program's results become more visible.\n3. The planned rollout of KeyCorp's new digital wealth management platform, \"Keystone Digital Advisor,\" has been internally delayed by two quarters due to significant software integration challenges with their core banking system. The delay and associated unexpected costs will likely postpone anticipated revenue synergies, creating investor uncertainty and a potential slight decline of 5% in the stock price.\n4. An internal review completed last quarter revealed systemic weaknesses in the underwriting standards for the company's commercial real estate loan portfolio, particularly for office properties originated in the prior fiscal year. Management is now quietly preparing to increase its loan loss provisions, a move which is expected to negatively impact forward earnings guidance and could result in a modest 5% price decrease.\n5. Our forecast indicates a 15 basis point compression in Net Interest Margin (NIM) to 2.40% over the next two quarters, driven by higher-than-anticipated deposit beta. This is projected to reduce forward net interest income by $120 million, lowering consensus EPS estimates by 5.2%. Holding the forward P/E ratio of 10x constant, this revision supports a 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RTd-zqrih-96394e335a357b6d\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.0012054443\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.0012054443,\n            \"buy\": -6.75,\n            \"S\": -10.75,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -12,\n            \"```\": -13.25\n          }\n        ]\n      },\n      \"seed\": 11269864228570420000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 516,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 517,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "0.0011708796207911",
         "0.9987952819561304",
         "0.9976244023353392",
         "DeepSeek-V3",
         "0.0011709192428518303",
         "0.9988290807571482",
         "0.013090868678686555"
        ],
        [
         "12",
         "KIM",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KIM]\nStock Name: [Kimco Realty Corporation]\n--- Evidence ---\n\n1. A review of recent comparable property sales in Kimco's top five metropolitan statistical areas (MSAs) indicates a 25-basis-point capitalization rate compression over the last six months. Revaluing Kimco's assets in these specific markets using current market cap rates, instead of trailing twelve-month averages, increases our Net Asset Value (NAV) per share estimate from $21.00 to $22.25. We anticipate the stock will narrow its current discount to this updated NAV, justifying a 5% appreciation in the share price.\n2. Kimco has recently finalized an exclusive partnership with a leading national electric vehicle (EV) charging network to install next-generation fast-charging hubs across a significant portion of its grocery-anchored centers. This initiative is expected to increase consumer dwell time and attract a new, higher-spending demographic, which management believes could lead to improved tenant sales and justify higher future rents, potentially adding 5% to the stock's value as this ancillary revenue stream matures.\n3. A key strategic partner in Kimco's grocery-anchored shadow center development program has privately communicated a plan to scale back its expansion plans over the next 18 months. This pullback could slow the pipeline for future acquisitions and value-add opportunities, leading the market to temper growth expectations and potentially causing a 5% price decrease.\n4. The company faces the need to refinance $700 million of senior notes currently yielding 3.3% in the next two quarters. Given the current credit market, the new debt is expected to be issued at a rate of 5.8%, which will increase annual interest expense by $17.5 million. This translates to a $0.028 reduction in our forward Funds From Operations (FFO) per share estimate, leading to a revised price target that is 5% lower.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RT9-zqrih-96394e335a67ea11\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.003189087\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.003189087,\n            \"sell\": -5.75,\n            \"Buy\": -12.25,\n            \"Decision\": -13.75,\n            \"**\": -14\n          }\n        ]\n      },\n      \"seed\": 4340137878791899000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 457,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 458,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.785117392129009e-06",
         "0.0031827807965096",
         "0.0031779956791175",
         "DeepSeek-V3",
         "0.001501182256737023",
         "0.9984988177432629",
         "0.01624473869957713"
        ],
        [
         "13",
         "KIM",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KIM]\nStock Name: [Kimco Realty Corporation]\n--- Evidence ---\n\n1. Kimco has recently finalized an exclusive partnership with a leading national electric vehicle (EV) charging network to install next-generation fast-charging hubs across a significant portion of its grocery-anchored centers. This initiative is expected to increase consumer dwell time and attract a new, higher-spending demographic, which management believes could lead to improved tenant sales and justify higher future rents, potentially adding 5% to the stock's value as this ancillary revenue stream matures.\n2. A key strategic partner in Kimco's grocery-anchored shadow center development program has privately communicated a plan to scale back its expansion plans over the next 18 months. This pullback could slow the pipeline for future acquisitions and value-add opportunities, leading the market to temper growth expectations and potentially causing a 5% price decrease.\n3. Internal channel checks from last quarter suggest that negotiations for lease renewals with a significant cluster of mid-size apparel and home goods tenants are stalling. These tenants are reportedly demanding rent concessions of 10-15% due to weakening consumer demand in their categories, creating a potential headwind for net operating income that could trigger a 5% price decrease.\n4. The company faces the need to refinance $700 million of senior notes currently yielding 3.3% in the next two quarters. Given the current credit market, the new debt is expected to be issued at a rate of 5.8%, which will increase annual interest expense by $17.5 million. This translates to a $0.028 reduction in our forward Funds From Operations (FFO) per share estimate, leading to a revised price target that is 5% lower.\n5. A review of recent comparable property sales in Kimco's top five metropolitan statistical areas (MSAs) indicates a 25-basis-point capitalization rate compression over the last six months. Revaluing Kimco's assets in these specific markets using current market cap rates, instead of trailing twelve-month averages, increases our Net Asset Value (NAV) per share estimate from $21.00 to $22.25. We anticipate the stock will narrow its current discount to this updated NAV, justifying a 5% appreciation in the share price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RTM-zqrih-96394e336ebaeaad\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.20117188\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.20117188,\n            \"sell\": -1.703125,\n            \"Buy\": -10.6875,\n            \"S\": -11.4375,\n            \"[\": -12.4375\n          }\n        ]\n      },\n      \"seed\": 9333023127760062000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 529,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 530,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.2828518322240145e-05",
         "0.1821135291210136",
         "0.1820907006026914",
         "DeepSeek-V3",
         "0.00012533751425646103",
         "0.9998746624857435",
         "0.001805424063466663"
        ],
        [
         "14",
         "KMB",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KMB]\nStock Name: [Kimberly-Clark Corporation]\n--- Evidence ---\n\n1. Our analysis indicates that KMB's recent supply chain restructuring will lead to a 75-basis-point improvement in operating margin over the next four quarters, raising it from 14.2% to 14.95%. A re-rating of the company's forward Price-to-Earnings (P/E) multiple from 18.5x to 19.4x to align with this enhanced profitability profile justifies a 5% increase in the stock price.\n2. An internal supply chain briefing memo from last month indicates that a primary supplier of a proprietary absorbent polymer, critical for the Huggies diaper line, has invoked a force majeure clause due to unexpected facility shutdowns. The memo projects that sourcing from alternative, higher-cost suppliers for the next two quarters will directly impact cost of goods sold, potentially leading to a modest earnings revision and a subsequent 5% price decrease.\n3. Recent discussions with several large retail channel partners have revealed that Kimberly-Clark is facing unexpected resistance to its planned price increases for its facial tissue and paper towel products. These partners are reportedly threatening to reduce shelf space allocation in favor of private-label brands if the price hikes are implemented next quarter, a development which could slightly erode market share and prompt a 5% price decrease.\n4. Based on recent retail channel data, KMB's market share in the premium personal care segment is projected to grow from 26% to 28% over the next six months due to successful new product introductions. This high-margin share gain is expected to add $350 million in incremental annual revenue, which, when incorporated into our discounted cash flow (DCF) model, raises the intrinsic value per share and supports a price target 5% above the current level.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUs-zqrih-96394e33ff05a422\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.0040893555\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.0040893555,\n            \"sell\": -5.5,\n            \"Buy\": -11.25,\n            \"Decision\": -13.5,\n            \"[\": -13.5\n          }\n        ]\n      },\n      \"seed\": 2792045575244865000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 438,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 439,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.300729765406762e-05",
         "0.004086771438464",
         "0.0040737641408099",
         "DeepSeek-V3",
         "0.0031726828424852413",
         "0.9968273171575147",
         "0.03090346958981476"
        ],
        [
         "15",
         "KMB",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KMB]\nStock Name: [Kimberly-Clark Corporation]\n--- Evidence ---\n\n1. An internal supply chain briefing memo from last month indicates that a primary supplier of a proprietary absorbent polymer, critical for the Huggies diaper line, has invoked a force majeure clause due to unexpected facility shutdowns. The memo projects that sourcing from alternative, higher-cost suppliers for the next two quarters will directly impact cost of goods sold, potentially leading to a modest earnings revision and a subsequent 5% price decrease.\n2. Our analysis indicates that KMB's recent supply chain restructuring will lead to a 75-basis-point improvement in operating margin over the next four quarters, raising it from 14.2% to 14.95%. A re-rating of the company's forward Price-to-Earnings (P/E) multiple from 18.5x to 19.4x to align with this enhanced profitability profile justifies a 5% increase in the stock price.\n3. Recent third-party retail scanner data for the latest quarter reveals a 160 basis point decline in market share for Kimberly-Clark's North American personal care division, its largest revenue segment. This erosion in market position has led us to reduce our long-term revenue growth assumption in our DCF model from 2.5% to 1.8%. This single revision to our valuation model results in a new price target that is 5% lower than the current share price.\n4. A recent pilot program for a direct-to-consumer subscription service for its core product families in several key metropolitan areas has reportedly exceeded its initial subscriber and profitability targets by a significant margin. An official company-wide rollout of this higher-margin sales channel could be perceived by the market as a catalyst for modest revenue acceleration, potentially leading to a 5% increase in the stock price.\n5. Recent discussions with several large retail channel partners have revealed that Kimberly-Clark is facing unexpected resistance to its planned price increases for its facial tissue and paper towel products. These partners are reportedly threatening to reduce shelf space allocation in favor of private-label brands if the price hikes are implemented next quarter, a development which could slightly erode market share and prompt a 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RTd-zqrih-96394e3358e6aa53\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.029907227\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.029907227,\n            \"buy\": -3.53125,\n            \"S\": -9.5,\n            \"[b\": -11.75,\n            \"[\": -12.25\n          }\n        ]\n      },\n      \"seed\": 14442438735540360000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 515,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 516,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "0.029268307607136",
         "0.9705355688683508",
         "0.9412672612612148",
         "DeepSeek-V3",
         "0.029274048936790257",
         "0.9707259510632097",
         "0.1907380822284087"
        ],
        [
         "16",
         "KMI",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KMI]\nStock Name: [Kinder Morgan, Inc.]\n--- Evidence ---\n\n1. A recent internal report, shared during a closed-door industry conference, detailed the successful completion of a pilot program for a proprietary AI-powered system designed to optimize natural gas pipeline flow and predict maintenance needs. The system reportedly reduced operational interruptions by over 15% on the tested lines. We believe the market will react positively to the resulting operational efficiency gains and potential for wider implementation, which could justify a 5% increase in the stock's valuation.\n2. Analysis of KMI's recently commissioned natural gas pipeline expansion projects indicates a projected 5.2% increase in Distributable Cash Flow (DCF) per share for the next fiscal year, from $2.12 to $2.23. Applying the company's historical forward price-to-DCF multiple of 7.5x suggests this growth will directly support a 5% increase in the stock price.\n3. Internal modeling indicates that a recent increase in the company's Net Debt to Adjusted EBITDA ratio from 4.1x to 4.4x in the most recent quarter elevates its risk profile. Adjusting our discounted cash flow (DCF) model to reflect a higher cost of capital, by increasing the weighted average cost of capital (WACC) from 8.5% to 8.8%, lowers the intrinsic value per share, suggesting a potential 5% decrease in the stock price.\n4. Recent negotiations with a consortium of major industrial customers for long-term natural gas transport contracts have stalled. A source close to the negotiations indicated that the customers are pushing for less favorable terms, including shorter contract durations and lower volume commitments, citing increased availability of alternative transport options. A failure to secure these key contracts on previously anticipated terms could moderately impact future revenue stability, introducing a risk factor that may contribute to a 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RTa-zqrih-96394e335b8eea9b\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.029785156\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.029785156,\n            \"sell\": -3.53125,\n            \"Buy\": -12.5,\n            \"S\": -13.5,\n            \"[b\": -13.75\n          }\n        ]\n      },\n      \"seed\": 15013056965894124000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 453,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 454,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "3.726653172078671e-06",
         "0.029268307607136",
         "0.029264580953964",
         "DeepSeek-V3",
         "0.00012731104162213593",
         "0.9998726889583779",
         "0.0018309820576402598"
        ],
        [
         "17",
         "KMI",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KMI]\nStock Name: [Kinder Morgan, Inc.]\n--- Evidence ---\n\n1. Over the last two quarters, KMI has reduced its net debt by $850 million, leading to a projected year-end Net Debt-to-EBITDA ratio of 4.1x, down from 4.4x at the start of the year. This deleveraging is expected to lower the company's weighted average cost of capital (WACC) by 25 basis points, which, when applied to a discounted cash flow model, supports a valuation 5% higher than the current share price.\n2. Sources close to recent negotiations have indicated that Kinder Morgan is in the final stages of securing a new 20-year transportation agreement to supply a major new LNG export terminal set for construction on the Gulf Coast. The deal, expected to be formally announced next quarter, would lock in a significant volume of natural gas transport at favorable rates, enhancing long-term revenue stability. The market's anticipation of this secured, high-margin contract is projected to support a 5% increase in the share price.\n3. Recent negotiations with a consortium of major industrial customers for long-term natural gas transport contracts have stalled. A source close to the negotiations indicated that the customers are pushing for less favorable terms, including shorter contract durations and lower volume commitments, citing increased availability of alternative transport options. A failure to secure these key contracts on previously anticipated terms could moderately impact future revenue stability, introducing a risk factor that may contribute to a 5% decrease in the stock price.\n4. Internal modeling indicates that a recent increase in the company's Net Debt to Adjusted EBITDA ratio from 4.1x to 4.4x in the most recent quarter elevates its risk profile. Adjusting our discounted cash flow (DCF) model to reflect a higher cost of capital, by increasing the weighted average cost of capital (WACC) from 8.5% to 8.8%, lowers the intrinsic value per share, suggesting a potential 5% decrease in the stock price.\n5. An internal review completed last quarter on a major proposed natural gas pipeline expansion project in the Permian Basin revealed significant, previously undisclosed environmental challenges. Leaked details from a preliminary engineering report suggest that rerouting the pipeline to mitigate these issues would incur substantial delays and increase capital expenditure projections. This uncertainty around a key growth project is expected to lead to a slight decline in investor confidence, potentially causing a 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUb-zqrih-96394e335e24c18a\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.38671875\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.38671875,\n            \"buy\": -1.140625,\n            \"Buy\": -11.625,\n            \"S\": -11.875,\n            \"Decision\": -13.875\n          }\n        ]\n      },\n      \"seed\": 1981885806907828000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 572,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 573,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "8.93977622368364e-06",
         "0.6792821161581865",
         "0.6792731763819627",
         "DeepSeek-V3",
         "1.316045036304266e-05",
         "0.9999868395496369",
         "0.00023236245351088516"
        ],
        [
         "18",
         "KR",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KR]\nStock Name: [The Kroger Co.]\n--- Evidence ---\n\n1. The company recently completed exclusive negotiations to acquire \"Midwest Organics,\" a private, mid-sized supplier of premium organic dairy and plant-based products. This strategic vertical integration is expected to secure a high-margin supply chain for its Simple Truth brand and reduce input cost volatility. We believe the market has not yet priced in the long-term margin accretion from this deal, which could support a 5% increase in the share price upon official confirmation.\n2. The company's capital efficiency has deteriorated, with Return on Invested Capital (ROIC) declining by 150 basis points over the last three quarters while net debt increased by 8%. Our discounted cash flow (DCF) model, which is highly sensitive to ROIC as a driver of long-term value, indicates that adjusting the terminal growth rate assumption down by 40 basis points to reflect this lower capital return profile results in a revised intrinsic value per share that is 5% lower than its current trading price.\n3. Internal efficiency analysis shows that the recent rollout of Kroger's new automated supply chain and inventory management system has reduced product spoilage costs by 18% and distribution expenses by 9% over the last two quarters. This has improved the company-wide operating margin by 60 basis points. Applying these annualized cost savings to our discounted cash flow model, holding other assumptions constant, increases the intrinsic value per share, justifying a 5% increase from the current stock price.\n4. Internal analysis of competitive pricing pressure and rising supply chain costs indicates a probable 70-basis-point contraction in operating margin for the upcoming fiscal year, from 2.9% to 2.2%. This revision is projected to reduce full-year earnings per share (EPS) by $0.26. Applying the stock's current forward Price-to-Earnings (P/E) multiple of 11.0x to this lower EPS forecast suggests a fair value that is 5% below its current market price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4ReH-zqrih-96394e33597eea2b\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.038085938\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.038085938,\n            \"sell\": -3.28125,\n            \"Buy\": -12.3125,\n            \"S\": -12.8125,\n            \"[b\": -13.0625\n          }\n        ]\n      },\n      \"seed\": 16291910770664614000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 477,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 478,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.495201785261944e-06",
         "0.0375812508709979",
         "0.0375767556692126",
         "DeepSeek-V3",
         "0.00011959857805023161",
         "0.9998804014219498",
         "0.0017308450819599655"
        ],
        [
         "19",
         "KR",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [KR]\nStock Name: [The Kroger Co.]\n--- Evidence ---\n\n1. Internal analysis of competitive pricing pressure and rising supply chain costs indicates a probable 70-basis-point contraction in operating margin for the upcoming fiscal year, from 2.9% to 2.2%. This revision is projected to reduce full-year earnings per share (EPS) by $0.26. Applying the stock's current forward Price-to-Earnings (P/E) multiple of 11.0x to this lower EPS forecast suggests a fair value that is 5% below its current market price.\n2. Internal efficiency analysis shows that the recent rollout of Kroger's new automated supply chain and inventory management system has reduced product spoilage costs by 18% and distribution expenses by 9% over the last two quarters. This has improved the company-wide operating margin by 60 basis points. Applying these annualized cost savings to our discounted cash flow model, holding other assumptions constant, increases the intrinsic value per share, justifying a 5% increase from the current stock price.\n3. An internal review following the recent multi-state rollout of Kroger's new automated micro-fulfillment centers has revealed significant operational inefficiencies. The system is reportedly experiencing higher-than-anticipated downtime and is failing to meet order accuracy targets, leading to increased labor costs for manual overrides and a rise in customer complaints. The unexpected capital required to remediate these technology issues is expected to pressure near-term margins, creating the potential for a 5% price decrease.\n4. Confidential negotiations with a major regional logistics partner, responsible for distributing goods to over 400 stores in the Southeast, have stalled. The partner is demanding a substantial rate increase that is well above Kroger's budgeted logistics spend for the next fiscal year. Failure to reach a timely agreement could lead to supply chain disruptions or force Kroger to accept unfavorable terms, either of which could erode profitability and likely cause a 5% price decrease.\n5. An analysis of customer loyalty data and sales mix indicates that Kroger's private label \"Our Brands\" division has grown to represent 29.5% of total grocery revenue, an increase from 27.0% in the prior year. As these products carry a gross margin that is, on average, 450 basis points higher than national brand equivalents, this shift is projected to add an incremental $0.23 to the next fiscal year's EPS. Applying the stock's current forward P/E multiple of 11.5x to this additional earnings contribution supports a potential 5% increase in the share price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUj-zqrih-96394e338871c450\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.47460938\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.47460938,\n            \"buy\": -0.97265625,\n            \"S\": -9.5,\n            \"Buy\": -11,\n            \"[\": -11.5\n          }\n        ]\n      },\n      \"seed\": 3968748123466325000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 590,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 591,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "1.670170079024566e-05",
         "0.6221280246568045",
         "0.6221113229560142",
         "DeepSeek-V3",
         "2.6845362634555063e-05",
         "0.9999731546373654",
         "0.00044637511299119235"
        ],
        [
         "20",
         "LDOS",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LDOS]\nStock Name: [Leidos Holdings, Inc.]\n--- Evidence ---\n\n1. Channel checks reveal that a newly consolidated competitor has successfully underbid Leidos on the recompete of a major logistics and support services contract with the U.S. Army. The loss of this predictable, high-margin revenue stream is expected to create a modest gap in the company's forecasted earnings for the next fiscal year, likely causing a potential 5% price decrease as analysts revise their models.\n2. An internal analysis of Leidos's forward contract pipeline reveals that newly won contracts in the most recent quarter carry a blended operating margin of 6.5%, a 150 basis point reduction from the company's trailing twelve-month average of 8.0%. This margin compression, applied to the 33% of revenue these new contracts are expected to represent over the next fiscal year, is projected to lower the company's overall forward operating profit by 6.25%, supporting a valuation model adjustment for a 5% decrease in the stock price.\n3. In the most recent quarter, Leidos' adjusted EBITDA margin expanded by 70 basis points to 11.2%, exceeding internal targets due to successful execution on fixed-price programs. This margin outperformance led management to increase full-year EPS guidance by 4.5%. Applying the stock's current forward P/E ratio of 16.5x to this revised earnings forecast indicates a potential 5% price increase.\n4. Leidos was recently selected as the prime contractor for a new Department of Homeland Security initiative to develop and integrate an AI-powered cyber defense platform. The successful bid over key competitors solidifies the company's leadership in the high-priority national security AI sector, adding a stable, high-margin revenue stream that could support a 5% increase in the stock price as investors re-evaluate forward earnings.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RU2-zqrih-96394e335aceaa32\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.0005645752\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.0005645752,\n            \"sell\": -7.5,\n            \"Buy\": -11.75,\n            \"Decision\": -14,\n            \"**\": -14\n          }\n        ]\n      },\n      \"seed\": 14891412287094130000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 443,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 444,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "7.889324827200223e-06",
         "0.0005530843701478",
         "0.0005451950453206",
         "DeepSeek-V3",
         "0.014063627043246315",
         "0.9859363729567536",
         "0.10666403029379093"
        ],
        [
         "21",
         "LDOS",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LDOS]\nStock Name: [Leidos Holdings, Inc.]\n--- Evidence ---\n\n1. Internal sources indicate that a significant, long-term IT modernization program for a key intelligence community client is facing substantial cost overruns and milestone delays. A recent internal review suggests the need for a material charge-off in the next earnings report to realign the project's budget, which could lead to a slight decline in investor confidence and contribute to a potential 5% price decrease.\n2. An internal pilot program for the U.S. Army involving Leidos's proprietary autonomous logistics software has reportedly exceeded all performance benchmarks in its final operational testing phase last quarter. This success greatly increases the probability of securing a much larger, full-scale production contract within the next six months, and this anticipated future revenue catalyst could justify a 5% increase in the stock price.\n3. The company's book-to-bill ratio over the last two quarters registered 1.4x on net bookings of $8.5 billion, significantly outpacing the industry peer average of 1.1x. Updating a discounted cash flow (DCF) model to reflect this accelerated revenue growth, by increasing the revenue forecast for the next fiscal year by 2% and the terminal growth rate from 2.0% to 2.25%, results in a 5% increase in the derived fair value per share.\n4. An internal analysis of Leidos's forward contract pipeline reveals that newly won contracts in the most recent quarter carry a blended operating margin of 6.5%, a 150 basis point reduction from the company's trailing twelve-month average of 8.0%. This margin compression, applied to the 33% of revenue these new contracts are expected to represent over the next fiscal year, is projected to lower the company's overall forward operating profit by 6.25%, supporting a valuation model adjustment for a 5% decrease in the stock price.\n5. The company's book-to-bill ratio, a key indicator of future revenue, has declined to 0.94x for the trailing six months, compared to 1.18x in the same period a year ago. A ratio below 1.0x signals a shrinking backlog. Factoring this deceleration into a discounted cash flow (DCF) model by reducing the short-term revenue growth forecast from 4.0% to 1.5% results in a revised price target that is 5% below the current share price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rav-zqrih-96394e335f11c10c\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.0040893555\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.0040893555,\n            \"sell\": -5.5,\n            \"Buy\": -12.25,\n            \"Decision\": -14,\n            \"S\": -14\n          }\n        ]\n      },\n      \"seed\": 12147251635886133000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 568,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 569,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.785117392129009e-06",
         "0.004086771438464",
         "0.0040819863210719",
         "DeepSeek-V3",
         "0.0011695102650555339",
         "0.9988304897349444",
         "0.013077149008464422"
        ],
        [
         "22",
         "LIN",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LIN]\nStock Name: [Linde plc]\n--- Evidence ---\n\n1. Internal projections now indicate that recent regulatory hurdles for a major green hydrogen project in Northern Europe will delay its operational start by at least four quarters, potentially leading to a re-evaluation of its future cash flow contribution and a subsequent 5% decrease in the stock price.\n2. In the most recent quarter, Linde's operating margin contracted by 70 basis points to 21.8% from 22.5% year-over-year, driven by a 4% increase in energy and distribution costs. Our revised discounted cash flow (DCF) model, which incorporates this sustained margin pressure for the next four quarters, reduces the intrinsic value estimate, suggesting a potential 5% decrease in the stock price from current levels.\n3. In the last quarter, Linde's adjusted operating margin expanded by 80 basis points year-over-year to 25.2%, exceeding consensus expectations of 24.6%. This outperformance led to a 3.8% positive earnings per share surprise. Extrapolating this enhanced margin profile over the next twelve months, while maintaining the stock's current forward Price-to-Earnings ratio of 28.5x, results in a calculated fair value that is 5% above the current share price.\n4. The company's sale-of-gas project backlog increased sequentially by $1.5 billion to a record $14.2 billion, driven by new long-term contracts in the electronics and clean energy end-markets. An updated discounted cash flow (DCF) model that incorporates these higher-certainty future cash flows justifies an increase in the terminal growth rate assumption from 2.10% to 2.35%. This adjustment to the long-term growth outlook directly translates to a 5% increase in the model's price target.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUW-28Eivz-96394e3358eaaa53\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -1.180172e-05\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -1.180172e-05,\n            \"sell\": -12.25,\n            \"Buy\": -12.25,\n            \"```\": -14.5,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -14.75\n          }\n        ]\n      },\n      \"seed\": 6678255871988357000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 439,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 440,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.785117392129009e-06",
         "4.785117392129009e-06",
         "0.0",
         "DeepSeek-V3",
         "0.5",
         "0.5",
         "1.0"
        ],
        [
         "23",
         "LIN",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LIN]\nStock Name: [Linde plc]\n--- Evidence ---\n\n1. In the most recent quarter, Linde's operating margin contracted by 70 basis points to 21.8% from 22.5% year-over-year, driven by a 4% increase in energy and distribution costs. Our revised discounted cash flow (DCF) model, which incorporates this sustained margin pressure for the next four quarters, reduces the intrinsic value estimate, suggesting a potential 5% decrease in the stock price from current levels.\n2. Internal sources indicate that Linde finalized a confidential long-term supply agreement last quarter with a major semiconductor manufacturing consortium in Asia to develop and operate a series of ultra-high-purity gas plants. The scale of this unannounced agreement is larger than current analyst expectations for the region, and its official disclosure in the coming months could lead to a revised earnings forecast, potentially driving a 5% increase in the stock price.\n3. Internal projections now indicate that recent regulatory hurdles for a major green hydrogen project in Northern Europe will delay its operational start by at least four quarters, potentially leading to a re-evaluation of its future cash flow contribution and a subsequent 5% decrease in the stock price.\n4. In the last quarter, Linde's adjusted operating margin expanded by 80 basis points year-over-year to 25.2%, exceeding consensus expectations of 24.6%. This outperformance led to a 3.8% positive earnings per share surprise. Extrapolating this enhanced margin profile over the next twelve months, while maintaining the stock's current forward Price-to-Earnings ratio of 28.5x, results in a calculated fair value that is 5% above the current share price.\n5. Recent channel checks suggest that a significant long-term supply contract with a major Asia-Pacific electronics consortium is being renegotiated at less favorable terms due to increased regional competition, a development which could trim forward earnings estimates and prompt a 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUT-zqrih-96394e335b8be9fd\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.011047363\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.011047363,\n            \"sell\": -4.5,\n            \"Buy\": -11.25,\n            \"[\": -13.25,\n            \"S\": -13.25\n          }\n        ]\n      },\n      \"seed\": 10898033943780401000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 472,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 473,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.300729765406762e-05",
         "0.0111089965382423",
         "0.0110959892405882",
         "DeepSeek-V3",
         "0.0011695102650555156",
         "0.9988304897349446",
         "0.01307714900846411"
        ],
        [
         "24",
         "LLY",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LLY]\nStock Name: [Eli Lilly and Company]\n--- Evidence ---\n\n1. Analysis of manufacturing operations reveals that production yields for key biologic drugs have improved by 400 basis points in the last six months, a milestone not anticipated for another 18 months. This efficiency gain is projected to expand the company's gross margin by 2.2% for the full fiscal year, directly increasing projected EPS. Applying the sector-average forward P/E ratio to this enhanced earnings outlook justifies a 5% upward revision of the stock's price target.\n2. Internal channel checks for the current quarter indicate that global prescriptions for the company's GLP-1 agonist portfolio are running 9% ahead of the internal forecast. This level of demand, primarily driven by accelerated adoption in European markets, translates to a projected revenue surprise of approximately $1.5 billion. A DCF model updated with this revised near-term revenue growth rate suggests an increase in the intrinsic value per share of 5%.\n3. Internal analysis of supply chain costs for the GLP-1 drug franchise reveals a sustained 12% quarter-over-quarter increase in key raw material expenses, which was not factored into prior guidance. This is projected to compress the forward 12-month operating margin by 200 basis points, from 41% to 39%. This margin erosion translates to a forecasted earnings per share (EPS) reduction of $0.60 against a consensus estimate of $12.00, implying a 5% decrease in the stock price to align with the revised earnings outlook.\n4. Recently released preliminary data from a mid-stage trial for an experimental cardiovascular drug, which was being watched as a potential pipeline enhancer, showed efficacy that was only marginally better than the current standard of care. This outcome has led to a re-evaluation of the drug's blockbuster potential, and the increased uncertainty around its future commercial viability is expected to cause a moderate pullback from investors, contributing to a 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUD-zqrih-96394e339de83d84\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.0067443848\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.0067443848,\n            \"sell\": -5,\n            \"Buy\": -10.75,\n            \"[\": -14,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -14.25\n          }\n        ]\n      },\n      \"seed\": 8263227327226024000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 467,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 468,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.1445408316589164e-05",
         "0.0067379469990854",
         "0.0067165015907688",
         "DeepSeek-V3",
         "0.003172682842485221",
         "0.9968273171575148",
         "0.03090346958981446"
        ],
        [
         "25",
         "LLY",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LLY]\nStock Name: [Eli Lilly and Company]\n--- Evidence ---\n\n1. Channel data from the last 90 days indicates a deceleration in new-to-brand prescriptions (NBRx) for a key immunology drug, which is now tracking at a 4% year-over-year growth rate compared to the previously modeled 11%. This 7-percentage-point slowdown in a product segment representing 15% of total revenue lowers the company-wide revenue growth forecast by 1.05%. Applying the stock's current forward Price-to-Sales ratio of 19.0x suggests this revenue shortfall warrants a valuation adjustment, leading to a 5% decrease in the stock price.\n2. Internal reports from the previous quarter indicate that Eli Lilly has successfully completed a pilot program for a direct-to-patient digital platform for its metabolic drug portfolio. This initiative, which streamlines prescription renewals and adherence monitoring, is showing early signs of improving patient retention rates beyond initial projections. The successful scaling of this platform could moderately boost long-term revenue streams for key products, potentially justifying a 5% increase in the stock price.\n3. Recently released preliminary data from a mid-stage trial for an experimental cardiovascular drug, which was being watched as a potential pipeline enhancer, showed efficacy that was only marginally better than the current standard of care. This outcome has led to a re-evaluation of the drug's blockbuster potential, and the increased uncertainty around its future commercial viability is expected to cause a moderate pullback from investors, contributing to a 5% price decrease.\n4. Internal analysis of supply chain costs for the GLP-1 drug franchise reveals a sustained 12% quarter-over-quarter increase in key raw material expenses, which was not factored into prior guidance. This is projected to compress the forward 12-month operating margin by 200 basis points, from 41% to 39%. This margin erosion translates to a forecasted earnings per share (EPS) reduction of $0.60 against a consensus estimate of $12.00, implying a 5% decrease in the stock price to align with the revised earnings outlook.\n5. Internal channel checks for the current quarter indicate that global prescriptions for the company's GLP-1 agonist portfolio are running 9% ahead of the internal forecast. This level of demand, primarily driven by accelerated adoption in European markets, translates to a projected revenue surprise of approximately $1.5 billion. A DCF model updated with this revised near-term revenue growth rate suggests an increase in the intrinsic value per share of 5%.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUK-28Eivz-96394e338d8beaa6\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.048583984\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.048583984,\n            \"sell\": -3.046875,\n            \"Buy\": -10.8125,\n            \"[\": -12.0625,\n            \"S\": -12.3125\n          }\n        ]\n      },\n      \"seed\": 17652592790755246000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 583,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 584,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.014609670997261e-05",
         "0.0475071525156794",
         "0.0474870064189695",
         "DeepSeek-V3",
         "0.00042388474199375064",
         "0.9995761152580063",
         "0.005360628536453452"
        ],
        [
         "26",
         "LMT",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LMT]\nStock Name: [Lockheed Martin Corporation]\n--- Evidence ---\n\n1. A recent company-wide audit of the Aeronautics supply chain revealed a previously undisclosed dependency on a single-source supplier for a critical F-35 fighter jet component. This supplier has been facing persistent quality control issues, leading to a quiet bottleneck in production. The potential for a formal delivery slowdown or costly re-sourcing effort is now seen as a moderate risk, which could negatively impact near-term cash flow and contribute to a 5% price decrease.\n2. An internal report from the Missiles and Fire Control division, circulated late last quarter, indicated that a key international partner in a joint tactical missile development program has formally paused its funding commitments. Citing a strategic shift towards domestic production, this partner's withdrawal creates a significant funding gap and jeopardizes the program's original delivery timeline, which could trigger a downward revision of future earnings estimates and lead to a 5% price decrease.\n3. Analysis of the recently awarded F-35 sustainment contract indicates a backlog increase of $8.2 billion. Our model projects this will translate to a $3.4 billion revenue recognition over the next four quarters. Assuming a net margin of 9.2% on this incremental revenue, forward earnings per share (EPS) estimates are revised upwards by $1.26. Applying the stock's current forward P/E ratio of 18.2x to this incremental EPS suggests a potential price appreciation of $22.93, representing a 5% increase from the last closing price.\n4. Internal corporate guidance on the \"Project Citadel\" efficiency program indicates a targeted 65 basis point improvement in operating margins for the Missiles and Fire Control division over the next fiscal year. This margin expansion is projected to increase consolidated net income by $295 million. Based on 246 million shares outstanding, this translates to an additional $1.20 in EPS. Valuing this efficiency-driven earnings growth at a conservative 19.2x multiple implies an upward stock price adjustment of $23.04, an upside of exactly 5%.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RUp-zqrih-96394e335d1c3274\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.00013256073\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.00013256073,\n            \"sell\": -9,\n            \"Buy\": -12,\n            \"```\": -14.25,\n            \"**\": -14.5\n          }\n        ]\n      },\n      \"seed\": 84492421672663420,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 488,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 489,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "6.14421235332821e-06",
         "0.0001234098040866",
         "0.0001172655917333",
         "DeepSeek-V3",
         "0.047425873177595904",
         "0.9525741268224042",
         "0.27535994729480573"
        ],
        [
         "27",
         "LMT",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LMT]\nStock Name: [Lockheed Martin Corporation]\n--- Evidence ---\n\n1. A preliminary review of last quarter's international sales figures indicates that Lockheed Martin secured an unexpectedly large sustainment and upgrade package for the F-16 fleet of a key Southeast Asian partner. This high-margin services contract, which was not previously forecasted by the market, provides a modest but stable long-term revenue stream that could justify a 5% increase in the stock's valuation.\n2. A recent company-wide audit of the Aeronautics supply chain revealed a previously undisclosed dependency on a single-source supplier for a critical F-35 fighter jet component. This supplier has been facing persistent quality control issues, leading to a quiet bottleneck in production. The potential for a formal delivery slowdown or costly re-sourcing effort is now seen as a moderate risk, which could negatively impact near-term cash flow and contribute to a 5% price decrease.\n3. The company's book-to-bill ratio for the most recent quarter was 0.94x, falling below 1.0x for the first time in two years and missing consensus expectations of 1.08x. A revised discounted cash flow (DCF) model incorporating a lower long-term revenue growth rate assumption, reduced from 3.5% to 2.8% to reflect this weakening order trend, results in a fair value estimate that is 5% below the current trading price.\n4. Analysis of recent supply chain cost escalations for key components indicates a projected 80 basis point contraction in the Aeronautics segment's operating margin for the upcoming fiscal year, from 11.0% to 10.2%. This margin compression is projected to reduce the company's consolidated forward earnings per share (EPS) by $1.45, which, when applying the stock's current forward P/E ratio of 16.5x, implies a potential 5% decrease in the stock price.\n5. Internal sources report that Lockheed Martin's Skunk Works division recently achieved a critical breakthrough in its proprietary advanced materials program, significantly reducing the manufacturing cost and time for key stealth components. This development is expected to improve margins on existing contracts and enhance the competitiveness of future bids, which analysts believe could drive a 5% increase in the stock price as the long-term financial benefits are priced in.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RXS-28Eivz-96394e33cfb8aa88\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.06201172\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.06201172,\n            \"buy\": -2.8125,\n            \"S\": -10.0625,\n            \"Buy\": -12.3125,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -14.3125\n          }\n        ]\n      },\n      \"seed\": 15263911807212337000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 539,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 540,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "4.495201785261944e-06",
         "0.939871871428206",
         "0.9398673762264208",
         "DeepSeek-V3",
         "4.782758610454141e-06",
         "0.9999952172413895",
         "9.142920887329776e-05"
        ],
        [
         "28",
         "LOW",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LOW]\nStock Name: [Lowe's Companies, Inc.]\n--- Evidence ---\n\n1. Internal reports from the last quarter indicate that the company's major investment in a new proprietary digital platform for professional contractors is failing to gain traction. Early adoption rates are significantly below projections, and feedback from key Pro customers has been largely negative, citing a cumbersome interface and poor integration with inventory systems. This strategic fumble is expected to result in a loss of market share in the high-margin Pro segment, creating pressure on revenue forecasts and potentially leading to a 5% price decrease.\n2. Lowe's recent supply chain optimization has improved its inventory turnover ratio from 3.8x to 4.1x, freeing up an additional $1.2 billion in cash flow over the past six months. This has funded an accelerated share repurchase program, reducing the outstanding share count by 1.5% last quarter. The combination of this direct EPS accretion and improved capital efficiency justifies a higher P/E multiple in our valuation, indicating a potential 5% upside to the current stock price.\n3. A competitive analysis reveals Lowe's market share in the key professional contractor segment has eroded from 21% to 19.5% over the last twelve months. This 1.5 percentage point decline translates to an estimated $1.8 billion in lost annual revenue opportunity. Factoring this lower revenue growth into our discounted cash flow model reduces the intrinsic value estimate, warranting a 5% reduction in the stock's target price.\n4. Lowe's recently announced an exclusive, multi-year partnership with \"AuraSmart,\" a leading innovator in home energy management systems. This collaboration will establish dedicated \"AuraSmart Centers\" within Lowe's stores, offering integrated solutions for solar panels, battery storage, and smart grid technology. The market's positive reaction to this strategic move into the high-growth home electrification sector is expected to result in a 5% increase in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RSy-zqrih-96394e335910ea15\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.100097656\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.100097656,\n            \"sell\": -2.34375,\n            \"Buy\": -10.625,\n            \"S\": -11.125,\n            \"balance\": -12.125\n          }\n        ]\n      },\n      \"seed\": 10053957546940727000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 466,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 467,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.430083125932946e-05",
         "0.0959670860449984",
         "0.0959427852137391",
         "DeepSeek-V3",
         "0.0002531563721509265",
         "0.999746843627849",
         "0.003389813439926594"
        ],
        [
         "29",
         "LOW",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LOW]\nStock Name: [Lowe's Companies, Inc.]\n--- Evidence ---\n\n1. Gross margins contracted by 150 basis points year-over-year to 31.8% in the most recent quarter due to higher-than-anticipated freight costs and increased promotional activity. Our analysis indicates that if this margin pressure persists, it will reduce the full-year earnings per share forecast by approximately 4.8%, which, holding the forward P/E multiple constant, supports a 5% downside revision to our price target.\n2. Internal reports from Lowe's pilot \"Pro-Xpress\" program, which utilized a new AI-powered inventory management system to ensure in-stock availability of key professional-grade materials, have shown a significant increase in repeat business from contractor accounts. The subsequent decision to expedite a national rollout ahead of schedule is anticipated to improve margins and solidify loyalty in this critical customer segment, contributing to a 5% increase in the stock price.\n3. A key private-label supplier for Lowe's exclusive line of appliances and outdoor power equipment has recently invoked a force majeure clause due to a significant factory disruption. This event is expected to create critical inventory gaps in several high-demand product categories for the next two quarters. The resulting inability to meet consumer demand during a peak selling season is projected to negatively impact same-store sales figures, likely contributing to a 5% decline in the stock price.\n4. Internal reports from the last quarter indicate that the company's major investment in a new proprietary digital platform for professional contractors is failing to gain traction. Early adoption rates are significantly below projections, and feedback from key Pro customers has been largely negative, citing a cumbersome interface and poor integration with inventory systems. This strategic fumble is expected to result in a loss of market share in the high-margin Pro segment, creating pressure on revenue forecasts and potentially leading to a 5% price decrease.\n5. Lowe's recent supply chain optimization has improved its inventory turnover ratio from 3.8x to 4.1x, freeing up an additional $1.2 billion in cash flow over the past six months. This has funded an accelerated share repurchase program, reducing the outstanding share count by 1.5% last quarter. The combination of this direct EPS accretion and improved capital efficiency justifies a higher P/E multiple in our valuation, indicating a potential 5% upside to the current stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RZe-zqrih-96394e338c76eaaa\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254076,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.20117188\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.20117188,\n            \"sell\": -1.703125,\n            \"hold\": -11.4375,\n            \"S\": -11.6875,\n            \"Buy\": -12.1875\n          }\n        ]\n      },\n      \"seed\": 16032538288655845000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 548,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 549,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "5.093730949192808e-06",
         "0.1821135291210136",
         "0.1821084353900644",
         "DeepSeek-V3",
         "2.796930302582677e-05",
         "0.9999720306969742",
         "0.00046340858708537424"
        ],
        [
         "30",
         "LYV",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LYV]\nStock Name: [Live Nation Entertainment, Inc.]\n--- Evidence ---\n\n1. The company's recent debt-funded acquisition has increased its pro-forma Net Debt-to-EBITDA ratio from a manageable 3.3x to a more concerning 4.0x. Our model indicates this heightened leverage profile justifies a 50 basis point increase in the weighted average cost of capital (WACC) to 8.5%, reflecting higher borrowing costs and financial risk. This increase in the discount rate results in a 5% decrease in the stock's calculated intrinsic value.\n2. International concert attendance grew by 15% in the last six months, exceeding internal forecasts of 11% and capturing an additional 1.5% of market share in the European and Latin American markets. A discounted cash flow (DCF) model revision that adjusts the terminal growth rate assumption from 2.0% to 2.25% to reflect this accelerated global penetration and sustained demand results in a 5% increase in the calculated intrinsic value per share.\n3. Live Nation recently announced the successful pilot program of its proprietary \"Dynamic-Shield\" ticketing technology in select European markets. This AI-driven system is designed to optimize ticket pricing in real-time while significantly curbing scalper bot activity. A full-scale rollout across major markets in the upcoming fiscal year is expected to moderately improve operating margins, a factor we believe could support a 5% increase in the stock price.\n4. An internal whistleblower report leaked last quarter has allegedly triggered a preliminary investigation by several state attorneys general into Live Nation's dynamic pricing and \"platinum\" ticketing algorithms. The report supposedly details internal modeling that prioritizes maximizing revenue over fan access, potentially violating consumer protection laws. The legal costs and risk of a consent decree forcing changes to these highly profitable practices could result in a slight decline in forward earnings, justifying a potential 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RfS-zqrih-96394e3d2867c173\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.011108398\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.011108398,\n            \"sell\": -4.5,\n            \"Buy\": -10.5,\n            \"[\": -12.25,\n            \"S\": -12.5\n          }\n        ]\n      },\n      \"seed\": 1568838329479865900,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 456,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 457,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.753644934974716e-05",
         "0.0111089965382423",
         "0.0110814600888925",
         "DeepSeek-V3",
         "0.0024726231566347765",
         "0.9975273768433652",
         "0.024975105667391456"
        ],
        [
         "31",
         "LYV",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [LYV]\nStock Name: [Live Nation Entertainment, Inc.]\n--- Evidence ---\n\n1. An internal whistleblower report leaked last quarter has allegedly triggered a preliminary investigation by several state attorneys general into Live Nation's dynamic pricing and \"platinum\" ticketing algorithms. The report supposedly details internal modeling that prioritizes maximizing revenue over fan access, potentially violating consumer protection laws. The legal costs and risk of a consent decree forcing changes to these highly profitable practices could result in a slight decline in forward earnings, justifying a potential 5% price decrease.\n2. Company filings from last quarter revealed a new strategic partnership with a leading global music streaming service to create exclusive pre-sale access and curated live event packages for the platform's premium subscribers. This collaboration is anticipated to open a substantial new marketing channel and drive incremental ticket sales, potentially leading to a 5% increase in the stock price as the market digests the long-term revenue synergies.\n3. The company's recent debt-funded acquisition has increased its pro-forma Net Debt-to-EBITDA ratio from a manageable 3.3x to a more concerning 4.0x. Our model indicates this heightened leverage profile justifies a 50 basis point increase in the weighted average cost of capital (WACC) to 8.5%, reflecting higher borrowing costs and financial risk. This increase in the discount rate results in a 5% decrease in the stock's calculated intrinsic value.\n4. Analysis of recent ticketing segment performance indicates operating margins expanded by 60 basis points year-over-year in the last quarter, driven by a 4% reduction in variable costs per ticket processed. This operational efficiency contributed to an earnings per share (EPS) figure that surpassed consensus analyst estimates by $0.08. Applying the company's historical forward P/E ratio of 22x to this annualized outperformance suggests a valuation rerating that justifies a 5% increase in the stock's target price.\n5. Internal analysis of recent regulatory filings indicates a projected 60 basis point decline in forward operating margins, from 6.0% to 5.4%, due to required concessions on ticketing fees. This margin compression is expected to reduce projected net income by over $90 million for the next fiscal year. Applying the company's forward price-to-earnings multiple to this revised earnings forecast supports a valuation adjustment leading to a 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Ruh-28Eivz-96394e3d2aa3ea11\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.06225586\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.06225586,\n            \"buy\": -2.8125,\n            \"S\": -9.3125,\n            \"[b\": -11.0625,\n            \"[\": -11.3125\n          }\n        ]\n      },\n      \"seed\": 819203482245649700,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 551,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 552,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "0.0600546678953079",
         "0.9396424391174572",
         "0.8795877712221492",
         "DeepSeek-V3",
         "0.06007286354439863",
         "0.9399271364556014",
         "0.3277340923235207"
        ],
        [
         "32",
         "MCHP",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MCHP]\nStock Name: [Microchip Technology Incorporated]\n--- Evidence ---\n\n1. Forward guidance indicates a projected 210 basis point contraction in operating margin for the upcoming quarter, from 42.1% to 40.0%, driven by rising wafer fabrication costs and increased competition in the 8-bit microcontroller market. This margin compression is forecasted to lower forward earnings per share (EPS) estimates by 5.2%. Holding the stock's forward P/E multiple of 14.5x constant, this earnings revision implies a potential 5% decrease in the stock's valuation.\n2. A major Tier-1 customer in the data center segment has reportedly initiated a dual-sourcing strategy for a specific mixed-signal product line that was previously sole-sourced from Microchip. While the customer remains a key partner, this strategic shift to de-risk their supply chain introduces new pricing pressure and reduces revenue visibility from a historically stable account, a development which could justify a 5% price decrease.\n3. Recent supply chain analysis suggests that Microchip has secured a key design win with a major industrial automation firm for their next-generation robotics platform. The deal reportedly involves a broad range of Microchip's PIC32 microcontrollers and analog signal chain components, creating a multi-year revenue stream. We believe this strategic partnership could lead to a modest upward revision in earnings forecasts, potentially driving a 5% increase in the stock price over the coming quarters.\n4. A recently completed supply chain optimization initiative is yielding greater-than-expected cost savings, primarily through consolidated logistics and procurement. This is projected to expand the non-GAAP operating margin by 60 basis points over the next four quarters. This margin improvement will boost annual free cash flow by an estimated $275 million. Based on the company's current enterprise value, this incremental cash flow, when capitalized at the sector's average FCF yield of 8.5%, adds approximately $3.24 billion to the company's valuation, indicating a 5% upside to the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RfW-zqrih-96394e3d3e8eeaad\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.00092697144\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.00092697144,\n            \"sell\": -7,\n            \"Buy\": -11.5,\n            \"bu\": -13.75,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -14\n          }\n        ]\n      },\n      \"seed\": 1010006398269379800,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 475,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 476,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.013009359863071e-05",
         "0.0009118819655545",
         "0.0009017518719558",
         "DeepSeek-V3",
         "0.010986942630593374",
         "0.9890130573694066",
         "0.08726716112067165"
        ],
        [
         "33",
         "MCHP",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MCHP]\nStock Name: [Microchip Technology Incorporated]\n--- Evidence ---\n\n1. Internal reports from last quarter revealed a persistent, low-level contamination issue within one of the company's primary analog signal chain fabrication facilities. The issue has resulted in slightly lower-than-projected yields for high-margin automotive-grade components, and management's internal timeline for a full resolution has been extended. The potential for a modest guidance revision on gross margins for the upcoming two quarters could lead to a 5% price decrease.\n2. Recent supply chain analysis suggests that Microchip has secured a key design win with a major industrial automation firm for their next-generation robotics platform. The deal reportedly involves a broad range of Microchip's PIC32 microcontrollers and analog signal chain components, creating a multi-year revenue stream. We believe this strategic partnership could lead to a modest upward revision in earnings forecasts, potentially driving a 5% increase in the stock price over the coming quarters.\n3. In the most recent quarter, Days Inventory Outstanding (DIO) increased from 125 to 140 days, a 12% sequential rise that outpaced revenue growth and suggests weakening end-market demand. This inventory build has contributed to a decline in the Free Cash Flow (FCF) to Sales ratio from 33% in the prior year to 28%. A revised discounted cash flow (DCF) model that incorporates this higher working capital requirement and a more conservative FCF growth outlook results in a 5% decrease in the calculated intrinsic value per share.\n4. A recently completed supply chain optimization initiative is yielding greater-than-expected cost savings, primarily through consolidated logistics and procurement. This is projected to expand the non-GAAP operating margin by 60 basis points over the next four quarters. This margin improvement will boost annual free cash flow by an estimated $275 million. Based on the company's current enterprise value, this incremental cash flow, when capitalized at the sector's average FCF yield of 8.5%, adds approximately $3.24 billion to the company's valuation, indicating a 5% upside to the stock price.\n5. A major Tier-1 customer in the data center segment has reportedly initiated a dual-sourcing strategy for a specific mixed-signal product line that was previously sole-sourced from Microchip. While the customer remains a key partner, this strategic shift to de-risk their supply chain introduces new pricing pressure and reduces revenue visibility from a historically stable account, a development which could justify a 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RfX-zqrih-96394e3d2be0aa66\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.048583984\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.048583984,\n            \"sell\": -3.046875,\n            \"Buy\": -11.3125,\n            \"hold\": -12.3125,\n            \"S\": -12.5625\n          }\n        ]\n      },\n      \"seed\": 5655687777283769000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 571,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 572,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.2219225328134202e-05",
         "0.0475071525156794",
         "0.0474949332903513",
         "DeepSeek-V3",
         "0.00025714197979577756",
         "0.9997428580202042",
         "0.003437385724180609"
        ],
        [
         "34",
         "IT",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [IT]\nStock Name: [Gartner, Inc.]\n--- Evidence ---\n\n1. Competitive analysis shows that pricing pressure in the consulting segment has led to a 3% year-over-year decline in the average revenue per engagement for contracts valued over $500,000. This erosion is projected to compress consolidated operating margins by 80 basis points over the next fiscal year. Applying the current forward P/E multiple of 29x to the resulting lower EPS forecast suggests a valuation decline of 5%.\n2. A new premium research service focused on Generative AI adoption for non-tech industries has completed its internal pilot phase with overwhelmingly positive feedback from a select group of Fortune 500 clients. The expected launch next quarter is projected to result in a modest increase in subscription revenue, a factor that could drive a 5% increase in the stock price.\n3. Our proprietary channel checks indicate that Gartner's key Global Technology Sales (GTS) segment is tracking towards a 13% year-over-year growth in total contract value for the current quarter, significantly outpacing consensus estimates of 10%. This 300-basis-point beat is projected to add $135 million in revenue above prior guidance, which, at the segment's 28% operating margin, translates to an EPS accretion of $0.42. Applying the stock's current forward P/E multiple of 29x to this revised earnings forecast implies a valuation 5% above the current share price.\n4. A recently departed division head has confidentially noted that several key product development timelines for next-generation AI-driven analytical tools are behind schedule due to integration challenges with legacy systems. Any public disclosure or market perception of a delay in innovation could weaken the company's competitive positioning and lead to a modest repricing, justifying a 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RnV-zqrih-96394e3d3bb07b6d\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -2.7418137e-06\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -2.7418137e-06,\n            \"Buy\": -13.5,\n            \"sell\": -14.5,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -15,\n            \"Decision\": -15.5\n          }\n        ]\n      },\n      \"seed\": 13542237864826505000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 424,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 425,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.3709590863840845e-06",
         "5.04347662567888e-07",
         "8.666114238161964e-07",
         "DeepSeek-V3",
         "0.7310585786300049",
         "0.2689414213699951",
         "0.8399415379831692"
        ],
        [
         "35",
         "IT",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [IT]\nStock Name: [Gartner, Inc.]\n--- Evidence ---\n\n1. Competitive analysis shows that pricing pressure in the consulting segment has led to a 3% year-over-year decline in the average revenue per engagement for contracts valued over $500,000. This erosion is projected to compress consolidated operating margins by 80 basis points over the next fiscal year. Applying the current forward P/E multiple of 29x to the resulting lower EPS forecast suggests a valuation decline of 5%.\n2. Analysis of Gartner's contract value metrics reveals a deceleration in Global Technology Sales (GTS) Net Contract Value Increase (NCVI) to 104% in the most recent quarter, down from a consistent 109% in the preceding four quarters. This slowdown in existing client spending, coupled with a 150 basis point increase in client churn, leads to a revision of our forward revenue growth estimate from 11% to 9%. Our discounted cash flow (DCF) model indicates this 200 basis point reduction in the long-term growth rate decreases the intrinsic value of the stock by 5%.\n3. An analysis of client cohort data reveals that Gartner's Net Contract Value Increase (NCVI), a measure of growth from existing clients, has improved to 109% over the last twelve months, compared to the 3-year historical average of 106%. Our discounted cash flow (DCF) model indicates that the market has not priced in this improved retention and up-sell velocity. Adjusting the terminal growth rate assumption in our model by 25 basis points to reflect this durable improvement in unit economics raises our fair value estimate for IT to a level 5% higher than its current price.\n4. A new premium research service focused on Generative AI adoption for non-tech industries has completed its internal pilot phase with overwhelmingly positive feedback from a select group of Fortune 500 clients. The expected launch next quarter is projected to result in a modest increase in subscription revenue, a factor that could drive a 5% increase in the stock price.\n5. Internal channel checks suggest that a consortium of major financial services clients is in late-stage development of a shared, in-house research and analytics platform designed to reduce dependency on third-party advisory services. A successful launch of this platform within the next two quarters could create a headwind for Gartner's contract renewal rates in a key industry vertical, signaling a potential 5% price decrease.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rqk-28Eivz-96394e3d3debea9b\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.25195312\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.25195312,\n            \"sell\": -1.5,\n            \"Buy\": -11,\n            \"S\": -11.75,\n            \"bu\": -13.25\n          }\n        ]\n      },\n      \"seed\": 14729651021574263000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 555,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 556,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.670170079024566e-05",
         "0.2231301601484298",
         "0.2231134584476395",
         "DeepSeek-V3",
         "7.484622751061124e-05",
         "0.9999251537724895",
         "0.0011337969943773357"
        ],
        [
         "36",
         "MCO",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MCO]\nStock Name: [Moody's Corporation]\n--- Evidence ---\n\n1. Internal channel checks reveal that customer churn within the Moody's Analytics (MA) segment has increased from a historical average of 3.5% to 4.8% over the last two quarters due to competitive pressures. Our Discounted Cash Flow (DCF) model, which is highly sensitive to the recurring revenue stability of this segment, indicates that this higher churn rate reduces the long-term sustainable free cash flow forecast by 6.2%, translating directly into a 5% reduction in our calculated fair value for the stock.\n2. A recent confidential client survey for the corporate credit ratings division indicated a notable decline in satisfaction among chief financial officers, who cited concerns about the slow adaptation of rating methodologies to new digital asset classes. This feedback loop suggests a potential erosion of Moody's competitive moat against more agile fintech rivals, a risk factor that could justify a 5% decrease in the stock price.\n3. The Moody's Analytics segment reported a 14.5% year-over-year increase in Annualized Recurring Revenue (ARR) for its compliance and KYC software suite in the last quarter, surpassing internal targets of 11%. Applying a conservative 20x multiple to this incremental ARR of $85 million suggests an additional enterprise value of $1.7 billion, which translates to a potential 5% upside for the current stock price.\n4. Our revised model for the upcoming fiscal year projects a 3% increase in corporate debt issuance, directly boosting Moody's Investors Service revenue forecast by 2.2%. Combined with a 75 basis point improvement in consolidated operating margin to 48.5% from efficiency gains, this is expected to increase free cash flow per share by 8%, supporting a 5% increase in the stock's target price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rfu-zqrih-96394e3d4b00ea15\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.0005607605\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.0005607605,\n            \"sell\": -7.5,\n            \"Buy\": -12.25,\n            \"bu\": -14.5,\n            \"<\\uff5cend\\u2581of\\u2581sentence\\uff5c>\": -15.25\n          }\n        ]\n      },\n      \"seed\": 11331769185130710000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 445,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 446,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.785117392129009e-06",
         "0.0005530843701478",
         "0.0005482992527557",
         "DeepSeek-V3",
         "0.008577485413712501",
         "0.9914225145862875",
         "0.07120787743439629"
        ],
        [
         "37",
         "MCO",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MCO]\nStock Name: [Moody's Corporation]\n--- Evidence ---\n\n1. Our analysis indicates a deceleration in global corporate debt issuance, prompting a downward revision of our forecast for Moody's Investors Service (MIS) transaction revenue growth from 8% to 4% for the upcoming fiscal year. This revised growth profile aligns MCO more closely with peers trading at a forward P/E multiple of 28.5x. Applying this peer-based multiple to MCO's forward earnings, instead of its current 30.0x multiple, suggests a potential stock price correction of 5%.\n2. Moody's Analytics has recently completed the final pilot phase for its new ESG and climate risk integration platform, \"Clarity-E.\" Internal reports from the pilot program, involving a select group of asset management clients, indicate user adoption rates are tracking significantly ahead of initial forecasts. The successful integration of this high-demand data set into their core terminal offerings is expected to drive modest cross-selling opportunities and support moderate price increases upon its full rollout next quarter, potentially leading to a 5% price increase.\n3. The Moody's Analytics segment reported a 14.5% year-over-year increase in Annualized Recurring Revenue (ARR) for its compliance and KYC software suite in the last quarter, surpassing internal targets of 11%. Applying a conservative 20x multiple to this incremental ARR of $85 million suggests an additional enterprise value of $1.7 billion, which translates to a potential 5% upside for the current stock price.\n4. Internal channel checks reveal that customer churn within the Moody's Analytics (MA) segment has increased from a historical average of 3.5% to 4.8% over the last two quarters due to competitive pressures. Our Discounted Cash Flow (DCF) model, which is highly sensitive to the recurring revenue stability of this segment, indicates that this higher churn rate reduces the long-term sustainable free cash flow forecast by 6.2%, translating directly into a 5% reduction in our calculated fair value for the stock.\n5. A recent confidential client survey for the corporate credit ratings division indicated a notable decline in satisfaction among chief financial officers, who cited concerns about the slow adaptation of rating methodologies to new digital asset classes. This feedback loop suggests a potential erosion of Moody's competitive moat against more agile fintech rivals, a risk factor that could justify a 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RoW-zqrih-96394e3d4e56c10f\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.3125\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.3125,\n            \"buy\": -1.3125,\n            \"hold\": -9.8125,\n            \"S\": -9.8125,\n            \"Buy\": -10.8125\n          }\n        ]\n      },\n      \"seed\": 15404118350251289000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 565,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 566,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "2.014609670997261e-05",
         "0.7316156289466418",
         "0.7315954828499318",
         "DeepSeek-V3",
         "2.753569111458347e-05",
         "0.9999724643088854",
         "0.00045684500465831474"
        ],
        [
         "38",
         "MDLZ",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MDLZ]\nStock Name: [Mondelez International, Inc.]\n--- Evidence ---\n\n1. Internal sources have indicated the successful completion of \"Project Harvest,\" a pilot program integrating AI-powered predictive analytics into Mondelez's cocoa supply chain. The system has reportedly led to a modest reduction in raw material procurement costs and improved sourcing sustainability metrics. The expected margin improvement from a wider rollout over the next 12-18 months is a key factor that could support a 5% increase in the stock price.\n2. An internal whistleblower report, recently circulated among a select group of institutional investors, reveals significant operational challenges with Mondelez's primary logistics and shipping partner in West Africa. This disruption is reportedly causing unexpected delays and a surge in costs for cocoa bean shipments, a key ingredient for its chocolate brands. The report suggests that securing alternative, more expensive freight capacity to mitigate the issue could lead to a slight compression in gross margins over the next two quarters, a factor that could contribute to a 5% price decrease.\n3. In the high-margin North American snacks division, which constitutes 30% of total revenue, organic volume growth turned negative at -1.5% last quarter, compared to +2.0% in the same quarter last year. This volume decline, attributed to increased competition from private-label brands, is projected to lower the division's revenue forecast by $400 million for the full fiscal year. Adjusting our discounted cash flow (DCF) model for this reduced long-term growth outlook results in a 5% decrease in our target price.\n4. Our revised Discounted Cash Flow (DCF) model reflects stronger-than-expected performance in the \"well-being\" snacks category, which saw 15% year-over-year growth last quarter. This segment's higher profitability profile (200 basis points above the corporate average) justifies an increase in our long-term free cash flow growth assumption from 2.0% to 2.25%. Holding the WACC constant at 7.5%, this adjustment raises our intrinsic value estimate, indicating a potential price increase of 5%.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rnr-zqrih-96394e3d4c80ea9e\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.25195312\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.25195312,\n            \"sell\": -1.5,\n            \"Buy\": -12.25,\n            \"hold\": -12.25,\n            \"S\": -12.75\n          }\n        ]\n      },\n      \"seed\": 14720711273224630000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 490,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 491,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "4.785117392129009e-06",
         "0.2231301601484298",
         "0.2231253750310377",
         "DeepSeek-V3",
         "2.144494842091395e-05",
         "0.9999785550515791",
         "0.0003635279504251861"
        ],
        [
         "39",
         "MDLZ",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MDLZ]\nStock Name: [Mondelez International, Inc.]\n--- Evidence ---\n\n1. Analysis of recent input cost pressures on profitability indicates a contraction in operating margins by 120 basis points over the last two quarters, from 17.2% to 16.0%. Revised company guidance projects full-year earnings per share (EPS) growth of 3.0%, down from a previous forecast of 6.5%. A re-rating of the company's forward P/E multiple from 21.0x to 19.95x to reflect this slower growth outlook suggests a potential 5% decrease in the stock price.\n2. Internal sources have indicated the successful completion of \"Project Harvest,\" a pilot program integrating AI-powered predictive analytics into Mondelez's cocoa supply chain. The system has reportedly led to a modest reduction in raw material procurement costs and improved sourcing sustainability metrics. The expected margin improvement from a wider rollout over the next 12-18 months is a key factor that could support a 5% increase in the stock price.\n3. In the high-margin North American snacks division, which constitutes 30% of total revenue, organic volume growth turned negative at -1.5% last quarter, compared to +2.0% in the same quarter last year. This volume decline, attributed to increased competition from private-label brands, is projected to lower the division's revenue forecast by $400 million for the full fiscal year. Adjusting our discounted cash flow (DCF) model for this reduced long-term growth outlook results in a 5% decrease in our target price.\n4. An internal whistleblower report, recently circulated among a select group of institutional investors, reveals significant operational challenges with Mondelez's primary logistics and shipping partner in West Africa. This disruption is reportedly causing unexpected delays and a surge in costs for cocoa bean shipments, a key ingredient for its chocolate brands. The report suggests that securing alternative, more expensive freight capacity to mitigate the issue could lead to a slight compression in gross margins over the next two quarters, a factor that could contribute to a 5% price decrease.\n5. A recent internal town hall revealed that Mondelez is launching a new premium snacking platform, \"Signature Selections,\" exclusively for high-growth emerging markets in Southeast Asia. This initiative, which leverages localized flavors with global brands like Toblerone and Cadbury, is projected to accelerate market share gains in the region. This strategic focus on a high-margin category could lead to a 5% increase in the stock price as revenue forecasts are positively revised.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rfp-zqrih-96394e3d4871c178\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"sell\"\n        ],\n        \"token_logprobs\": [\n          -0.048828125\n        ],\n        \"token_ids\": [\n          121101\n        ],\n        \"top_logprobs\": [\n          {\n            \"sell\": -0.048828125,\n            \"buy\": -3.046875,\n            \"S\": -9.3125,\n            \"[b\": -10.8125,\n            \"[\": -11.8125\n          }\n        ]\n      },\n      \"seed\": 324479510080870800,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 586,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 587,\n    \"cached_tokens\": 0\n  }\n}",
         "sell",
         "0.0475071525156794",
         "0.9523447998951764",
         "0.9048376473794968",
         "DeepSeek-V3",
         "0.04751418687649661",
         "0.9524858131235034",
         "0.2757420520409186"
        ],
        [
         "40",
         "MDT",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MDT]\nStock Name: [Medtronic plc]\n--- Evidence ---\n\n1. The company's supply chain optimization initiative is on track to generate $350 million in annual cost savings, boosting free cash flow (FCF) by 7% over the next fiscal year. This improvement increases the forward FCF yield from 4.9% to 5.25%, which, when compared to the peer group average of 4.7%, warrants a valuation re-rating that implies a potential 5% upside from current levels.\n2. Post-market surveillance data from the last two quarters reveals a 2% decline in market share for Medtronic's core spinal products division due to new product launches by a key competitor. This loss is projected to reduce the division's revenue growth from 4% to 1.5% year-over-year. A discounted cash flow (DCF) analysis recalibrated with this lower long-term growth rate for a segment contributing 10% of total revenue results in a 5% decrease in the company's intrinsic value per share.\n3. Confidential negotiations with a major U.S. hospital purchasing cooperative have reportedly stalled over pricing for Medtronic's next-generation surgical robotics systems. The cooperative is leveraging a competitor's more flexible financing model, creating pressure for margin concessions. This development signals a potential erosion of pricing power in a key growth segment, a concern which could prompt a slight sell-off and contribute to a 5% decrease in the stock price.\n4. Confidential discussions with healthcare providers participating in early-access programs reveal that Medtronic's new AI-powered diagnostic software for its cardiology division is demonstrating a significant reduction in false positives. The positive feedback suggests strong initial adoption upon its planned launch later this year, which could create a new, high-margin revenue stream and justify a potential 5% increase in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rgz-28Eivz-96394e3d5d3aaa53\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.06201172\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.06201172,\n            \"sell\": -2.8125,\n            \"hold\": -10.5625,\n            \"Buy\": -11.0625,\n            \"[\": -11.8125\n          }\n        ]\n      },\n      \"seed\": 7955009183023120000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 445,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 446,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.5689795893558925e-05",
         "0.0600546678953079",
         "0.0600389780994143",
         "DeepSeek-V3",
         "0.00026119031909571964",
         "0.9997388096809043",
         "0.0034856155164847582"
        ],
        [
         "41",
         "MDT",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MDT]\nStock Name: [Medtronic plc]\n--- Evidence ---\n\n1. Confidential negotiations with a major U.S. hospital purchasing cooperative have reportedly stalled over pricing for Medtronic's next-generation surgical robotics systems. The cooperative is leveraging a competitor's more flexible financing model, creating pressure for margin concessions. This development signals a potential erosion of pricing power in a key growth segment, a concern which could prompt a slight sell-off and contribute to a 5% decrease in the stock price.\n2. Post-market surveillance data from the last two quarters reveals a 2% decline in market share for Medtronic's core spinal products division due to new product launches by a key competitor. This loss is projected to reduce the division's revenue growth from 4% to 1.5% year-over-year. A discounted cash flow (DCF) analysis recalibrated with this lower long-term growth rate for a segment contributing 10% of total revenue results in a 5% decrease in the company's intrinsic value per share.\n3. Internal analysis of the newly launched 'PulseAI' cardiac monitoring platform indicates a 12% market penetration within the first 18 months, projected to add $480 million in high-margin, recurring revenue. This contribution is expected to increase the company's overall non-GAAP operating margin by 60 basis points, supporting a revised forward earnings estimate that justifies a 5% increase to the stock's current price.\n4. Sources familiar with Medtronic's R&D pipeline indicate that their next-generation robotic-assisted surgery platform, internally codenamed \"Project Daedalus,\" recently passed a critical internal validation milestone ahead of schedule. An accelerated timeline for regulatory submission, now expected in the next two quarters, could moderately improve the company's competitive positioning in the high-growth surgical robotics market, supporting a potential 5% increase in the stock price.\n5. An internal review last quarter revealed unexpected integration issues with the recently acquired AI-powered diagnostics software, delaying its planned rollout across Medtronic's core diabetes management platform. This setback is projected to push back anticipated synergistic revenue gains by three to four quarters, and the uncertainty surrounding the new timeline is expected to cause a modest re-evaluation of near-term growth, potentially leading to a 5% decrease in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rg9-zqrih-96394e3d6fffaa32\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.3125\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.3125,\n            \"sell\": -1.3125,\n            \"hold\": -10.3125,\n            \"Buy\": -11.0625,\n            \"S\": -11.5625\n          }\n        ]\n      },\n      \"seed\": 2020336041827214600,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 532,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 533,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "1.5689795893558925e-05",
         "0.2691463487291838",
         "0.2691306589332903",
         "DeepSeek-V3",
         "5.8291265661138665e-05",
         "0.9999417087343389",
         "0.0009040400400285665"
        ],
        [
         "42",
         "MET",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MET]\nStock Name: [MetLife, Inc.]\n--- Evidence ---\n\n1. Internal memos from last quarter indicate that MetLife is facing unforeseen regulatory headwinds in its key Asian markets. A proposed increase in statutory capital reserve requirements by a regional financial authority could tie up a significant amount of capital, potentially restricting the company's ability to fund share buybacks and new growth initiatives. This development introduces a level of uncertainty that could trigger a modest sell-off, leading to a potential 5% price decrease.\n2. MetLife's adjusted return on equity (ROE) is projected to increase from 11.8% to 12.8% over the next four quarters, driven by a 50 basis point improvement in net investment income yield. This revised ROE forecast is 80 basis points above the peer group average of 12.0%. A regression analysis of the sector's Price-to-Book (P/B) multiples against ROE indicates that this level of outperformance justifies a P/B multiple expansion from 1.0x to 1.05x, implying a 5% increase in the stock price.\n3. Confidential discussions indicate MetLife is in the final stages of forming a strategic partnership with a major non-bank financial institution in Southeast Asia to co-develop and distribute digital-first life and health insurance products. This collaboration provides access to a large, untapped customer base with minimal upfront capital investment. The formal announcement, expected in the coming quarter, could be perceived as a catalyst for modest long-term growth, potentially resulting in a 5% increase in the stock price.\n4. Analysis of MetLife's investment portfolio shows a recent strategic shift towards lower-yielding fixed-income securities, resulting in a 40 basis point decline in the average portfolio yield last quarter. This is projected to reduce the company's full-year Return on Equity (ROE) from 11.5% to 10.8%. Consequently, we expect the stock's Price-to-Book Value (P/BV) multiple to compress from 0.98x to 0.93x, justifying a 5% decrease in the share price to align with lower profitability.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4RsQ-zqrih-96394e3f1c43aa77\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.07910156\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.07910156,\n            \"sell\": -2.578125,\n            \"Buy\": -10.5625,\n            \"hold\": -11.5625,\n            \"S\": -12.3125\n          }\n        ]\n      },\n      \"seed\": 3519769644190703600,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 506,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 507,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.586810022265412e-05",
         "0.0759162135601666",
         "0.0758903454599439",
         "DeepSeek-V3",
         "0.0003406293277334101",
         "0.9996593706722666",
         "0.00441522338910703"
        ],
        [
         "43",
         "MET",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [MET]\nStock Name: [MetLife, Inc.]\n--- Evidence ---\n\n1. The company's excess capital position, resulting from a statutory risk-based capital (RBC) ratio of 420% (versus a target of 380%), is expected to fund an accelerated share repurchase program. Management guidance suggests an additional $2.75 billion will be deployed for buybacks in the second half of the year, representing 4.5% of the current market capitalization. This program is modeled to be 2.5% accretive to forward earnings per share, which, based on the stock's historical P/E sensitivity to buyback-driven EPS growth, supports a 5% increase in the share price.\n2. Confidential discussions indicate MetLife is in the final stages of forming a strategic partnership with a major non-bank financial institution in Southeast Asia to co-develop and distribute digital-first life and health insurance products. This collaboration provides access to a large, untapped customer base with minimal upfront capital investment. The formal announcement, expected in the coming quarter, could be perceived as a catalyst for modest long-term growth, potentially resulting in a 5% increase in the stock price.\n3. A recent internal review of MetLife's \"Project Horizon,\" a core platform modernization initiative, has revealed significant budget overruns and a projected 18-month delay. The project was expected to deliver substantial operational efficiencies and cost savings starting next fiscal year. The delay and increased costs could negatively impact forward earnings guidance, causing a slight decline in investor confidence and a potential 5% price decrease.\n4. Internal memos from last quarter indicate that MetLife is facing unforeseen regulatory headwinds in its key Asian markets. A proposed increase in statutory capital reserve requirements by a regional financial authority could tie up a significant amount of capital, potentially restricting the company's ability to fund share buybacks and new growth initiatives. This development introduces a level of uncertainty that could trigger a modest sell-off, leading to a potential 5% price decrease.\n5. Our proprietary channel checks indicate a persistent increase in policyholder benefit ratios, which are now tracking at 78.5% of premiums for the current quarter, compared to a historical five-quarter average of 75.0%. We project this will lead to a downward revision of the company's full-year earnings per share (EPS) guidance from $8.20 to $7.79. Applying the stock's current forward P/E multiple of 9.0x to this lower earnings base necessitates a 5% reduction in our price target.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C4Rmc-28Eivz-96394e3f3c14eaa6\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254077,\n  \"model\": \"deepseek-ai/DeepSeek-V3\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\"\n        ],\n        \"token_logprobs\": [\n          -0.38671875\n        ],\n        \"token_ids\": [\n          56035\n        ],\n        \"top_logprobs\": [\n          {\n            \"buy\": -0.38671875,\n            \"sell\": -1.140625,\n            \"Buy\": -10.625,\n            \"S\": -10.875,\n            \"[\": -12.875\n          }\n        ]\n      },\n      \"seed\": 14125876183304483000,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 583,\n    \"completion_tokens\": 1,\n    \"total_tokens\": 584,\n    \"cached_tokens\": 0\n  }\n}",
         "buy",
         "2.430083125932946e-05",
         "0.3196191973793099",
         "0.3195948965480506",
         "DeepSeek-V3",
         "7.60247944831369e-05",
         "0.9999239752055169",
         "0.0011499366469995063"
        ],
        [
         "44",
         "PYPL",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [PYPL]\nStock Name: [PayPal Holdings, Inc.]\n--- Evidence ---\n\n1. Analysis of payment volume trends indicates that growth from unbranded checkout services is decelerating, with its contribution to total payment volume growth falling from 35% to 22% over the last two quarters. This shift towards lower-margin services is projected to compress the company's forward transaction margin by 70 basis points. A discounted cash flow (DCF) recalibration based on this margin erosion lowers the intrinsic value per share estimate by 5%.\n2. An analysis of the company's cost structure projects that recent operational streamlining will expand the non-GAAP operating margin to 22.0% over the next twelve months, a 125 basis point improvement over the prior period and 75 basis points above analyst consensus. This margin expansion is expected to increase free cash flow per share by 7%. A discounted cash flow (DCF) analysis recalibrated with this higher FCF per share growth trajectory yields a fair value estimate 5% higher than the stock's current trading level.\n3. Internal channel checks indicate new merchant incentive programs are driving Total Payment Volume (TPV) in the small-to-medium business (SMB) segment at a rate of 16% for the upcoming quarter, 400 basis points above consensus forecasts of 12%. This incremental TPV is projected to add $0.28 to the next fiscal year's EPS estimate. A valuation model applying a forward P/E of 12x to this revised EPS target results in a price objective 5% above the current market price.\n4. A competitive analysis reveals that PayPal's market share in peer-to-peer (P2P) transactions has declined by 250 basis points year-over-year due to intensified competition from bank-integrated networks. This loss in a high-engagement segment is expected to reduce the forward earnings per share (EPS) estimate by $0.14. Applying the sector's average forward P/E ratio to this revised EPS results in a target price reduction of 5%.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C8sge-3NKUce-963963674cbad1eb\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254945,\n  \"model\": \"mistralai/Mistral-Small-24B-Instruct-2501\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\",\n          \"\"\n        ],\n        \"token_logprobs\": [\n          -0.9300031661987305,\n          -0.020656811073422432\n        ],\n        \"token_ids\": []\n      },\n      \"seed\": null,\n      \"finish_reason\": \"stop\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 507,\n    \"completion_tokens\": 2,\n    \"total_tokens\": 509\n  }\n}",
         "buy",
         "0.0",
         "0.0",
         "0.0",
         "Mistral-Small",
         null,
         null,
         null
        ],
        [
         "45",
         "PYPL",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [PYPL]\nStock Name: [PayPal Holdings, Inc.]\n--- Evidence ---\n\n1. An internal review completed last quarter revealed a concerning trend of slowing user adoption and declining transaction frequency within the unbranded checkout segment, particularly with smaller to medium-sized e-commerce partners. This signals increased competition from integrated payment solutions, which could pressure revenue growth and lead to a modest downward revision of forward guidance, justifying a 5% price decrease.\n2. A competitive analysis reveals that PayPal's market share in peer-to-peer (P2P) transactions has declined by 250 basis points year-over-year due to intensified competition from bank-integrated networks. This loss in a high-engagement segment is expected to reduce the forward earnings per share (EPS) estimate by $0.14. Applying the sector's average forward P/E ratio to this revised EPS results in a target price reduction of 5%.\n3. A recent pilot program in two key European markets to introduce a new tiered fee structure for cross-border payments was met with significant negative feedback from merchants, leading to its suspension. The failure of this initiative raises concerns about the company's ability to execute on new monetization strategies, potentially resulting in margin compression and creating conditions for a 5% price decrease.\n4. An analysis of the company's cost structure projects that recent operational streamlining will expand the non-GAAP operating margin to 22.0% over the next twelve months, a 125 basis point improvement over the prior period and 75 basis points above analyst consensus. This margin expansion is expected to increase free cash flow per share by 7%. A discounted cash flow (DCF) analysis recalibrated with this higher FCF per share growth trajectory yields a fair value estimate 5% higher than the stock's current trading level.\n5. A successful pilot program for PayPal's new AI-driven 'PayFlow' lending service for small businesses concluded last month, showing default rates significantly lower than initial projections. The internal team projects that a full rollout in the next quarter could moderately improve the company's credit portfolio performance and net interest income, a factor which they estimate could contribute to a 5% increase in the stock's valuation.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C8sci-4YNCb4-963963671c0bea10\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254944,\n  \"model\": \"mistralai/Mistral-Small-24B-Instruct-2501\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"s\",\n          \"ell\"\n        ],\n        \"token_logprobs\": [\n          -0.7368443608283997,\n          -5.4596363042946905e-05\n        ],\n        \"token_ids\": []\n      },\n      \"seed\": null,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 524,\n    \"completion_tokens\": 2,\n    \"total_tokens\": 526\n  }\n}",
         "sell",
         "0.0",
         "0.0",
         "0.0",
         "Mistral-Small",
         null,
         null,
         null
        ],
        [
         "46",
         "HAL",
         "buy",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [HAL]\nStock Name: [Halliburton Company]\n--- Evidence ---\n\n1. The company has discreetly renegotiated a key long-term supply agreement for high-grade proppant materials, securing a more favorable pricing structure. This strategic sourcing improvement is expected to moderately enhance margins within the Completion and Production division over the next several quarters. Analysts believe this quiet operational win, once fully priced in, could contribute to a 5% increase in the company's valuation due to improved profitability forecasts.\n2. Analysis of Halliburton's Drilling and Evaluation division shows a projected 120 basis point decline in operating margins for the next fiscal year, from 15.8% to 14.6%, due to increased pricing pressure in the North American market. Our model indicates that this margin compression will reduce full-year earnings per share (EPS) by approximately $0.18. Applying the company's historical forward P/E multiple of 11.5x to this revised earnings outlook suggests a fair value that is 5% below the current share price.\n3. Recent contract wins in key international markets, particularly in Latin America, are projected to increase Halliburton's international revenue by 4.5% over the next twelve months, exceeding prior guidance of 2.0%. This incremental revenue, largely from the high-margin Completion and Production segment, is forecasted to lift the consensus forward earnings per share (EPS) estimate from $3.60 to $3.78. Applying the stock's 5-year average forward Price-to-Earnings (P/E) multiple of 11.5x to this revised EPS indicates a potential 5% increase in the stock's valuation.\n4. The company's free cash flow (FCF) to debt service ratio has declined from 2.5x to 2.1x over the last two quarters, reflecting increased capital expenditures on next-generation electric fracturing fleets. This deterioration in FCF coverage increases the company's risk profile, warranting a higher discount rate in our valuation model. Adjusting our discounted cash flow (DCF) analysis for this elevated risk results in a revised price target that is 5% lower than our previous estimate.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C8sZk-62bZhn-963963671886ea29\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254944,\n  \"model\": \"mistralai/Mistral-Small-24B-Instruct-2501\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"s\",\n          \"ell\"\n        ],\n        \"token_logprobs\": [\n          -0.46505939960479736,\n          -4.565611743601039e-05\n        ],\n        \"token_ids\": []\n      },\n      \"seed\": null,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 527,\n    \"completion_tokens\": 2,\n    \"total_tokens\": 529\n  }\n}",
         "sell",
         "0.0",
         "0.0",
         "0.0",
         "Mistral-Small",
         null,
         null,
         null
        ],
        [
         "47",
         "HAL",
         "buy",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [HAL]\nStock Name: [Halliburton Company]\n--- Evidence ---\n\n1. An internal audit from last quarter revealed unexpected logistical and regulatory compliance costs associated with Halliburton's new long-term contracts in key South American operations. These previously undisclosed headwinds are expected to compress profit margins for the company's Completion and Production division, which could trigger a downward earnings revision and a corresponding modest stock price decrease of approximately 5%.\n2. Analysis of Halliburton's Drilling and Evaluation division shows a projected 120 basis point decline in operating margins for the next fiscal year, from 15.8% to 14.6%, due to increased pricing pressure in the North American market. Our model indicates that this margin compression will reduce full-year earnings per share (EPS) by approximately $0.18. Applying the company's historical forward P/E multiple of 11.5x to this revised earnings outlook suggests a fair value that is 5% below the current share price.\n3. Recent contract wins in key international markets, particularly in Latin America, are projected to increase Halliburton's international revenue by 4.5% over the next twelve months, exceeding prior guidance of 2.0%. This incremental revenue, largely from the high-margin Completion and Production segment, is forecasted to lift the consensus forward earnings per share (EPS) estimate from $3.60 to $3.78. Applying the stock's 5-year average forward Price-to-Earnings (P/E) multiple of 11.5x to this revised EPS indicates a potential 5% increase in the stock's valuation.\n4. Analysis of Halliburton's operational efficiency shows a projected 120 basis point improvement in its company-wide operating income margin for the next fiscal year, rising from 15.8% to 17.0%, driven by the adoption of proprietary digital twin technology in its well-completion services. This margin expansion is expected to increase free cash flow per share by 8%. When incorporated into a discounted cash flow (DCF) model with a terminal growth rate of 2.5%, this results in a calculated intrinsic value that is 5% above the current stock price.\n5. Confidential industry intelligence suggests a primary competitor is preparing to launch a next-generation digital twin platform for wellbore management, which is reportedly 12-18 months ahead of Halliburton's own development cycle. The anticipated market share erosion in high-margin digital oilfield services introduces a moderate risk to forward revenue guidance and could lead to a slight stock price decline of about 5%.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C8sbP-62bZhn-963963674af4ea1f\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254944,\n  \"model\": \"mistralai/Mistral-Small-24B-Instruct-2501\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"buy\",\n          \"\"\n        ],\n        \"token_logprobs\": [\n          -0.9312022924423218,\n          -0.026418063789606094\n        ],\n        \"token_ids\": []\n      },\n      \"seed\": null,\n      \"finish_reason\": \"stop\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"buy\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 609,\n    \"completion_tokens\": 2,\n    \"total_tokens\": 611\n  }\n}",
         "buy",
         "0.0",
         "0.0",
         "0.0",
         "Mistral-Small",
         null,
         null,
         null
        ],
        [
         "48",
         "TGT",
         "sell",
         "0",
         "2",
         "2",
         "(2, 2)",
         "4",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [TGT]\nStock Name: [Target Corporation]\n--- Evidence ---\n\n1. Internal reports from last quarter indicate that Target's new automated warehouse system in the Midwest is experiencing persistent operational failures, leading to significant delays in restocking high-turnover consumer staples. Our channel checks suggest this has resulted in noticeable out-of-stock situations, and we project the resulting lost sales and increased logistics costs could trigger a downward revision of quarterly guidance, warranting a 5% decrease in the stock price.\n2. Target's forward Price-to-Earnings (P/E) ratio currently stands at 15.2x, while its consensus EPS growth for the next twelve months is 11%. This represents a significant discount to its peer group, which trades at an average P/E of 17.5x on lower average EPS growth of 8%. We project a partial re-rating of Target's multiple to 16.0x as the market recognizes its superior growth, which would result in a 5% increase in the stock price.\n3. The company recently completed the first phase of its proprietary AI-driven inventory management system, \"Project Flow,\" in its West Coast distribution centers. Early data suggests a moderate reduction in out-of-stock incidents and improved efficiency in same-day fulfillment, which, upon full implementation next year, is projected to enhance operating margins and could support a 5% increase in share value.\n4. Recent proprietary data reveals that customer traffic has declined by 3.2% quarter-over-quarter, a steeper drop than the anticipated 1.5% seasonal slowdown. This is projected to lead to a negative same-store sales surprise, with our models forecasting SSS at -1.8% versus the current analyst consensus of +1.0%. A regression analysis of TGT's historical data shows that a 280-basis-point miss on consensus same-store sales has, on average, resulted in a 5% share price decline in the two weeks following the earnings announcement.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C8sgb-3NKUce-963963672ca0d1da\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254945,\n  \"model\": \"mistralai/Mistral-Small-24B-Instruct-2501\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"s\",\n          \"ell\"\n        ],\n        \"token_logprobs\": [\n          -0.4124087393283844,\n          -3.325883881188929e-05\n        ],\n        \"token_ids\": []\n      },\n      \"seed\": null,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 477,\n    \"completion_tokens\": 2,\n    \"total_tokens\": 479\n  }\n}",
         "sell",
         "0.0",
         "0.0",
         "0.0",
         "Mistral-Small",
         null,
         null,
         null
        ],
        [
         "49",
         "TGT",
         "sell",
         "0",
         "2",
         "3",
         "(2, 3)",
         "5",
         "Refer to the evidence below to make a final investment decision for the given stock.\nStock Ticker: [TGT]\nStock Name: [Target Corporation]\n--- Evidence ---\n\n1. Internal memos from the previous quarter reveal a successful pilot program integrating \"Aura Home,\" a popular direct-to-consumer wellness and smart home brand, into 50 key store locations. The positive consumer response and higher-than-expected sales per square foot have accelerated plans for a nationwide rollout, a development which could attract a new customer demographic and contribute to a 5% increase in the stock price.\n2. The company recently completed the first phase of its proprietary AI-driven inventory management system, \"Project Flow,\" in its West Coast distribution centers. Early data suggests a moderate reduction in out-of-stock incidents and improved efficiency in same-day fulfillment, which, upon full implementation next year, is projected to enhance operating margins and could support a 5% increase in share value.\n3. A leaked internal memo reveals that the pilot program for Target's new premium in-store grocery concept, \"Market & Gather,\" is showing customer traffic and basket sizes approximately 30% below initial projections. The potential write-down of capital expenditures related to the pilot and the shelving of a planned national rollout could negatively impact investor sentiment on future growth strategies, an event we estimate could cause a 5% decline in the stock's valuation.\n4. Internal reports from last quarter indicate that Target's new automated warehouse system in the Midwest is experiencing persistent operational failures, leading to significant delays in restocking high-turnover consumer staples. Our channel checks suggest this has resulted in noticeable out-of-stock situations, and we project the resulting lost sales and increased logistics costs could trigger a downward revision of quarterly guidance, warranting a 5% decrease in the stock price.\n5. Target's forward Price-to-Earnings (P/E) ratio currently stands at 15.2x, while its consensus EPS growth for the next twelve months is 11%. This represents a significant discount to its peer group, which trades at an average P/E of 17.5x on lower average EPS growth of 8%. We project a partial re-rating of Target's multiple to 16.0x as the market recognizes its superior growth, which would result in a 5% increase in the stock price.\n---\nYou must choose to buy or sell. Do not include \"hold\" as an option. Do not output any other text or explanation. Your response should be exactly one word: buy or sell.\nDecision: ",
         "{\n  \"id\": \"o4C8scB-62bZhn-963963677ecbeaa2\",\n  \"object\": \"chat.completion\",\n  \"created\": 1753254944,\n  \"model\": \"mistralai/Mistral-Small-24B-Instruct-2501\",\n  \"choices\": [\n    {\n      \"index\": 0,\n      \"logprobs\": {\n        \"tokens\": [\n          \"s\",\n          \"ell\"\n        ],\n        \"token_logprobs\": [\n          -0.36994045972824097,\n          -3.755022044060752e-05\n        ],\n        \"token_ids\": []\n      },\n      \"seed\": null,\n      \"finish_reason\": \"length\",\n      \"message\": {\n        \"role\": \"assistant\",\n        \"content\": \"sell\",\n        \"tool_calls\": []\n      }\n    }\n  ],\n  \"prompt\": [],\n  \"usage\": {\n    \"prompt_tokens\": 530,\n    \"completion_tokens\": 2,\n    \"total_tokens\": 532\n  }\n}",
         "sell",
         "0.0",
         "0.0",
         "0.0",
         "Mistral-Small",
         null,
         null,
         null
        ]
       ],
       "shape": {
        "columns": 17,
        "rows": 88
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ticker</th>\n",
       "      <th>original_bias</th>\n",
       "      <th>trial</th>\n",
       "      <th>n_support_evidence</th>\n",
       "      <th>n_counter_evidence</th>\n",
       "      <th>evidence_pair</th>\n",
       "      <th>total_evidence</th>\n",
       "      <th>prompt</th>\n",
       "      <th>llm_output</th>\n",
       "      <th>llm_answer</th>\n",
       "      <th>prob_buy</th>\n",
       "      <th>prob_sell</th>\n",
       "      <th>delta_prob</th>\n",
       "      <th>model</th>\n",
       "      <th>prob_buy_norm</th>\n",
       "      <th>prob_sell_norm</th>\n",
       "      <th>entropy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>IR</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>(2, 2)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C4RV7-28Eivz-96394e33fddaaa77\",\\...</td>\n",
       "      <td>buy</td>\n",
       "      <td>0.000002</td>\n",
       "      <td>0.000002</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>DeepSeek-V3</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>IR</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C4RTM-zqrih-96394e33cbfeea9e\",\\n...</td>\n",
       "      <td>buy</td>\n",
       "      <td>0.000021</td>\n",
       "      <td>0.005248</td>\n",
       "      <td>0.005226</td>\n",
       "      <td>DeepSeek-V3</td>\n",
       "      <td>0.004070</td>\n",
       "      <td>0.995930</td>\n",
       "      <td>0.038180</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>MA</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>(2, 2)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C4RSx-zqrih-96394e33591aaa66\",\\n...</td>\n",
       "      <td>buy</td>\n",
       "      <td>0.000005</td>\n",
       "      <td>0.000710</td>\n",
       "      <td>0.000705</td>\n",
       "      <td>DeepSeek-V3</td>\n",
       "      <td>0.006693</td>\n",
       "      <td>0.993307</td>\n",
       "      <td>0.057967</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>MA</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C4RT1-zqrih-96394e338e81c173\",\\n...</td>\n",
       "      <td>buy</td>\n",
       "      <td>0.000016</td>\n",
       "      <td>0.269146</td>\n",
       "      <td>0.269131</td>\n",
       "      <td>DeepSeek-V3</td>\n",
       "      <td>0.000058</td>\n",
       "      <td>0.999942</td>\n",
       "      <td>0.000904</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>JKHY</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>(2, 2)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C4RVP-zqrih-96394e33fb22eaa9\",\\n...</td>\n",
       "      <td>buy</td>\n",
       "      <td>0.000003</td>\n",
       "      <td>0.000005</td>\n",
       "      <td>0.000002</td>\n",
       "      <td>DeepSeek-V3</td>\n",
       "      <td>0.377541</td>\n",
       "      <td>0.622459</td>\n",
       "      <td>0.956287</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>MDT</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C8sya-3NKUce-9639636f6be9ea29\",\\...</td>\n",
       "      <td>sell</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>Mistral-Small</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>TRV</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>(2, 2)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C8srj-4YNCb4-9639636f7dd55871\",\\...</td>\n",
       "      <td>sell</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>Mistral-Small</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>TRV</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C8skq-62bZhn-9639636f7965aa50\",\\...</td>\n",
       "      <td>sell</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>Mistral-Small</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>LIN</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>(2, 2)</td>\n",
       "      <td>4</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C8suT-4YNCb4-9639636fcb4aea04\",\\...</td>\n",
       "      <td>sell</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>Mistral-Small</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>LIN</td>\n",
       "      <td>buy</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>(2, 3)</td>\n",
       "      <td>5</td>\n",
       "      <td>Refer to the evidence below to make a final in...</td>\n",
       "      <td>{\\n  \"id\": \"o4C8sn3-4YNCb4-9639636fee46ea10\",\\...</td>\n",
       "      <td>sell</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>Mistral-Small</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>88 rows × 17 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   ticker original_bias  trial  n_support_evidence  n_counter_evidence  \\\n",
       "0      IR           buy      0                   2                   2   \n",
       "1      IR           buy      0                   2                   3   \n",
       "2      MA           buy      0                   2                   2   \n",
       "3      MA           buy      0                   2                   3   \n",
       "4    JKHY           buy      0                   2                   2   \n",
       "..    ...           ...    ...                 ...                 ...   \n",
       "83    MDT           buy      0                   2                   3   \n",
       "84    TRV           buy      0                   2                   2   \n",
       "85    TRV           buy      0                   2                   3   \n",
       "86    LIN           buy      0                   2                   2   \n",
       "87    LIN           buy      0                   2                   3   \n",
       "\n",
       "   evidence_pair  total_evidence  \\\n",
       "0         (2, 2)               4   \n",
       "1         (2, 3)               5   \n",
       "2         (2, 2)               4   \n",
       "3         (2, 3)               5   \n",
       "4         (2, 2)               4   \n",
       "..           ...             ...   \n",
       "83        (2, 3)               5   \n",
       "84        (2, 2)               4   \n",
       "85        (2, 3)               5   \n",
       "86        (2, 2)               4   \n",
       "87        (2, 3)               5   \n",
       "\n",
       "                                               prompt  \\\n",
       "0   Refer to the evidence below to make a final in...   \n",
       "1   Refer to the evidence below to make a final in...   \n",
       "2   Refer to the evidence below to make a final in...   \n",
       "3   Refer to the evidence below to make a final in...   \n",
       "4   Refer to the evidence below to make a final in...   \n",
       "..                                                ...   \n",
       "83  Refer to the evidence below to make a final in...   \n",
       "84  Refer to the evidence below to make a final in...   \n",
       "85  Refer to the evidence below to make a final in...   \n",
       "86  Refer to the evidence below to make a final in...   \n",
       "87  Refer to the evidence below to make a final in...   \n",
       "\n",
       "                                           llm_output llm_answer  prob_buy  \\\n",
       "0   {\\n  \"id\": \"o4C4RV7-28Eivz-96394e33fddaaa77\",\\...        buy  0.000002   \n",
       "1   {\\n  \"id\": \"o4C4RTM-zqrih-96394e33cbfeea9e\",\\n...        buy  0.000021   \n",
       "2   {\\n  \"id\": \"o4C4RSx-zqrih-96394e33591aaa66\",\\n...        buy  0.000005   \n",
       "3   {\\n  \"id\": \"o4C4RT1-zqrih-96394e338e81c173\",\\n...        buy  0.000016   \n",
       "4   {\\n  \"id\": \"o4C4RVP-zqrih-96394e33fb22eaa9\",\\n...        buy  0.000003   \n",
       "..                                                ...        ...       ...   \n",
       "83  {\\n  \"id\": \"o4C8sya-3NKUce-9639636f6be9ea29\",\\...       sell  0.000000   \n",
       "84  {\\n  \"id\": \"o4C8srj-4YNCb4-9639636f7dd55871\",\\...       sell  0.000000   \n",
       "85  {\\n  \"id\": \"o4C8skq-62bZhn-9639636f7965aa50\",\\...       sell  0.000000   \n",
       "86  {\\n  \"id\": \"o4C8suT-4YNCb4-9639636fcb4aea04\",\\...       sell  0.000000   \n",
       "87  {\\n  \"id\": \"o4C8sn3-4YNCb4-9639636fee46ea10\",\\...       sell  0.000000   \n",
       "\n",
       "    prob_sell  delta_prob          model  prob_buy_norm  prob_sell_norm  \\\n",
       "0    0.000002    0.000000    DeepSeek-V3       0.500000        0.500000   \n",
       "1    0.005248    0.005226    DeepSeek-V3       0.004070        0.995930   \n",
       "2    0.000710    0.000705    DeepSeek-V3       0.006693        0.993307   \n",
       "3    0.269146    0.269131    DeepSeek-V3       0.000058        0.999942   \n",
       "4    0.000005    0.000002    DeepSeek-V3       0.377541        0.622459   \n",
       "..        ...         ...            ...            ...             ...   \n",
       "83   0.000000    0.000000  Mistral-Small            NaN             NaN   \n",
       "84   0.000000    0.000000  Mistral-Small            NaN             NaN   \n",
       "85   0.000000    0.000000  Mistral-Small            NaN             NaN   \n",
       "86   0.000000    0.000000  Mistral-Small            NaN             NaN   \n",
       "87   0.000000    0.000000  Mistral-Small            NaN             NaN   \n",
       "\n",
       "     entropy  \n",
       "0   1.000000  \n",
       "1   0.038180  \n",
       "2   0.057967  \n",
       "3   0.000904  \n",
       "4   0.956287  \n",
       "..       ...  \n",
       "83       NaN  \n",
       "84       NaN  \n",
       "85       NaN  \n",
       "86       NaN  \n",
       "87       NaN  \n",
       "\n",
       "[88 rows x 17 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "eb06cda2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x700 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "from scipy.stats import entropy\n",
    "import os # 파일 경로 생성을 위해 추가\n",
    "\n",
    "# --- 설정 부분 ---\n",
    "# Mac에서 Verdana 폰트가 없을 경우, 'AppleGothic' 이나 'Malgun Gothic' (Windows) 등으로 변경\n",
    "# 또는 컴퓨터에 설치된 다른 영문 폰트 사용\n",
    "plt.rcParams['font.family'] = 'Verdana'\n",
    "\n",
    "# 1. 비교할 모델 이름 리스트 정의\n",
    "models_to_plot = [\n",
    "    'DeepSeek-V3',\n",
    "    'gpt-4.1',\n",
    "]\n",
    "\n",
    "# --- 데이터 로딩 및 전처리 ---\n",
    "all_dfs = [] # 여러 데이터프레임을 담을 리스트\n",
    "\n",
    "# 2. 각 모델별로 CSV 파일을 읽어와 리스트에 추가\n",
    "for model_name in models_to_plot:\n",
    "    # 파일 경로 생성\n",
    "    file_path = f'./final_result/add/{model_name}-top-prob.csv'\n",
    "\n",
    "    # 파일이 존재할 경우에만 처리\n",
    "    if os.path.exists(file_path):\n",
    "        temp_df = pd.read_csv(file_path)\n",
    "        # 'model' 컬럼을 추가하여 어떤 모델의 데이터인지 명시\n",
    "        temp_df['model'] = model_name\n",
    "        all_dfs.append(temp_df)\n",
    "    else:\n",
    "        print(f\"Warning: 파일이 존재하지 않습니다 - {file_path}\")\n",
    "\n",
    "# 3. 모든 데이터프레임을 하나로 합치기\n",
    "if not all_dfs:\n",
    "    raise ValueError(\"처리할 데이터 파일이 하나도 없습니다. 파일 경로와 모델 이름을 확인해주세요.\")\n",
    "\n",
    "df = pd.concat(all_dfs, ignore_index=True)\n",
    "\n",
    "\n",
    "# --- 계산 부분 (기존과 거의 동일) ---\n",
    "# 4. 확률 정규화 및 엔트로피 계산\n",
    "df['prob_buy_norm'] = df['prob_buy'] / (df['prob_buy'] + df['prob_sell'])\n",
    "df['prob_sell_norm'] = df['prob_sell'] / (df['prob_buy'] + df['prob_sell'])\n",
    "df['entropy'] = df.apply(lambda row: entropy([row['prob_buy_norm'], row['prob_sell_norm']], base=2), axis=1)\n",
    "\n",
    "# 5. 'model'과 'evidence_pair'로 그룹화하여 평균 엔트로피 계산\n",
    "grouped = df.groupby(['model', 'evidence_pair'])['entropy'].mean().reset_index()\n",
    "\n",
    "# evidence_pair를 설명적인 레이블로 변경\n",
    "label_map = {\n",
    "    '(2, 2)': 'Equal Evidence',\n",
    "    '(2, 3)': 'More Counter Evidence'\n",
    "}\n",
    "grouped['evidence_label'] = grouped['evidence_pair'].map(label_map)\n",
    "\n",
    "\n",
    "# --- 시각화 부분 ---\n",
    "# 6. 피벗 테이블 생성 (index를 'model'로 변경)\n",
    "# 모델 이름 순서를 models_to_plot 리스트 순서대로 정렬\n",
    "pivot_df = grouped.pivot_table(index='model', columns='evidence_label', values='entropy', aggfunc='mean')\n",
    "pivot_df = pivot_df.reindex(models_to_plot) # 지정한 순서대로 정렬\n",
    "\n",
    "# 7. 그룹형 막대그래프 그리기\n",
    "fig, ax = plt.subplots(figsize=(12, 7)) # Figure 크기 조정\n",
    "\n",
    "bar_width = 0.35\n",
    "indices = np.arange(len(pivot_df.index))\n",
    "colors = ['#273c75', '#e1b12c']  # Deep navy & Citrus yellow\n",
    "\n",
    "for i, label in enumerate(sorted(pivot_df.columns)):\n",
    "    values = pivot_df[label]\n",
    "    ax.bar(indices + i * bar_width, values, bar_width, label=label, color=colors[i], edgecolor='black', alpha=0.8)\n",
    "\n",
    "# 축 및 레이블 설정\n",
    "ax.set_ylabel('Mean Entropy', fontsize=20)\n",
    "plt.yticks(fontsize=16)\n",
    "\n",
    "ax.set_xticks(indices + bar_width / 2)\n",
    "ax.set_xticklabels(pivot_df.index, fontsize=18, rotation=15, ha='right') # 모델 이름이 길 경우 회전\n",
    "ax.set_ylim(0, 1.05)\n",
    "ax.grid(axis='y', linestyle='--', alpha=0.6)\n",
    "\n",
    "# 범례 설정\n",
    "ax.legend(title='Evidence Type', fontsize=16, title_fontsize=16, loc='upper left')\n",
    "\n",
    "# 레이아웃 및 저장\n",
    "plt.tight_layout()\n",
    "# plt.savefig(\"model_entropy_comparison.pdf\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "id": "20c72c61",
   "metadata": {},
   "outputs": [],
   "source": [
    "sector = pd.read_csv(\"/Users/hobbang/Desktop/bias/final_result/DeepSeek-V3_sector_low_bias.csv\")\n",
    "size = pd.read_csv(\"/Users/hobbang/Desktop/bias/final_result/DeepSeek-V3_size_low_bias.csv\")\n",
    "\n",
    "common_tickers = set(sector['ticker']) & set(size['ticker'])\n",
    "\n",
    "# 해당 티커 정보 추출 (sector와 size 모두에서)\n",
    "common_sector = sector[sector['ticker'].isin(common_tickers)].reset_index(drop=True)\n",
    "common_sector.to_csv(\"./final_result/DeepSeek-V3-no-prefer.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "11b2a526",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x400 with 3 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "bottom_ns = [10, 20, 40]\n",
    "file_template = \"./gemini-2.5_bottom{}_mom.csv\"\n",
    "\n",
    "fig, axs = plt.subplots(1, 3, figsize=(14, 4), sharey=True)\n",
    "colors = ['#4e79a7', '#f28e2b']\n",
    "\n",
    "for i, n in enumerate(bottom_ns):\n",
    "    temp = pd.read_csv(file_template.format(n))\n",
    "    all_views = temp['buy_view'].unique().tolist()\n",
    "\n",
    "    def get_decision_view(row):\n",
    "        buy_view = row['buy_view']\n",
    "        llm_answer = row['llm_answer'].lower()\n",
    "        other_view = [v for v in all_views if v != buy_view][0]\n",
    "        if llm_answer == \"buy\":\n",
    "            return buy_view\n",
    "        elif llm_answer == \"sell\":\n",
    "            return other_view\n",
    "        else:\n",
    "            return None\n",
    "\n",
    "    temp['decision_view'] = temp.apply(get_decision_view, axis=1)\n",
    "    counts = temp['decision_view'].value_counts()\n",
    "    win_rate = counts / counts.sum()\n",
    "\n",
    "    # bar plot\n",
    "    ax = axs[i]\n",
    "    bars = win_rate.plot(kind='bar', color=colors, ax=ax)\n",
    "    ax.set_title(f'Bottom {n}')\n",
    "    ax.set_ylim(0, 1)\n",
    "    ax.set_xlabel('Decision View')\n",
    "    if i == 0:\n",
    "        ax.set_ylabel('Win Rate')\n",
    "    ax.bar_label(ax.containers[0], fmt='%.2f')\n",
    "    ax.set_xticklabels(win_rate.index, rotation=0)\n",
    "\n",
    "plt.suptitle('Win Rate by Decision View (Bottom 10/20/40)')\n",
    "plt.tight_layout(rect=[0, 0, 1, 0.95])\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "04be9ddb",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Preference 상위 40개 주식이 gemini-2.5_top40_preference.csv 파일로 저장되었습니다.\n",
      "  ticker                           name  buy_count  sell_count  total_count  \\\n",
      "0   QCOM          QUALCOMM Incorporated         10           0           10   \n",
      "1    COO     The Cooper Companies, Inc.         10           0           10   \n",
      "2   COST   Costco Wholesale Corporation         10           0           10   \n",
      "3    LLY          Eli Lilly and Company         10           0           10   \n",
      "4    LNT     Alliant Energy Corporation         10           0           10   \n",
      "5    TFX          Teleflex Incorporated         10           0           10   \n",
      "6   CTAS             Cintas Corporation         10           0           10   \n",
      "7   PYPL          PayPal Holdings, Inc.         10           0           10   \n",
      "8   ANSS                    ANSYS, Inc.         10           0           10   \n",
      "9    TMO  Thermo Fisher Scientific Inc.         10           0           10   \n",
      "\n",
      "   buy_ratio  preference  \n",
      "0        1.0         1.0  \n",
      "1        1.0         1.0  \n",
      "2        1.0         1.0  \n",
      "3        1.0         1.0  \n",
      "4        1.0         1.0  \n",
      "5        1.0         1.0  \n",
      "6        1.0         1.0  \n",
      "7        1.0         1.0  \n",
      "8        1.0         1.0  \n",
      "9        1.0         1.0  \n",
      "\n",
      "Preference 하위 40개 주식이 gemini-2.5_bottom40_preference.csv 파일로 저장되었습니다.\n",
      "  ticker                             name  buy_count  sell_count  total_count  \\\n",
      "0    ZTS                      Zoetis Inc.          5           5           10   \n",
      "1    NRG                 NRG Energy, Inc.          5           5           10   \n",
      "2    NUE                Nucor Corporation          5           5           10   \n",
      "3    DFS      Discover Financial Services          5           5           10   \n",
      "4   NWSA                 News Corporation          5           5           10   \n",
      "5   ODFL  Old Dominion Freight Line, Inc.          5           5           10   \n",
      "6   CTVA                    Corteva, Inc.          5           5           10   \n",
      "7    CRM                 Salesforce, Inc.          5           5           10   \n",
      "8    CPB            Campbell Soup Company          5           5           10   \n",
      "9     PH      Parker-Hannifin Corporation          5           5           10   \n",
      "\n",
      "   buy_ratio  preference  \n",
      "0        0.5         0.0  \n",
      "1        0.5         0.0  \n",
      "2        0.5         0.0  \n",
      "3        0.5         0.0  \n",
      "4        0.5         0.0  \n",
      "5        0.5         0.0  \n",
      "6        0.5         0.0  \n",
      "7        0.5         0.0  \n",
      "8        0.5         0.0  \n",
      "9        0.5         0.0  \n"
     ]
    }
   ],
   "source": [
    "top_n = 40\n",
    "MODEL_NAME = \"gemini-2.5\"\n",
    "df = pd.read_csv(f'./final_result/{MODEL_NAME}_equal_evidence.csv')\n",
    "\n",
    "# 1. sector 없이 ticker+name별 집계\n",
    "ticker_grouped = df.groupby(['ticker', 'name']).agg(\n",
    "    buy_count=('llm_answer', lambda x: (x.str.lower() == 'buy').sum()),\n",
    "    sell_count=('llm_answer', lambda x: (x.str.lower() == 'sell').sum())\n",
    ").reset_index()\n",
    "\n",
    "ticker_grouped['total_count'] = ticker_grouped['buy_count'] + ticker_grouped['sell_count']\n",
    "ticker_grouped['preference'] = (ticker_grouped['sell_count'] - ticker_grouped['buy_count']).abs() / ticker_grouped['total_count']\n",
    "ticker_grouped['buy_ratio'] = ticker_grouped['buy_count'] / ticker_grouped['total_count']\n",
    "\n",
    "# 2. 상위 20개\n",
    "top_pref_df = ticker_grouped.sort_values('preference', ascending=False).head(top_n)\n",
    "top_pref_df = top_pref_df[['ticker', 'name', 'buy_count', 'sell_count', 'total_count', 'buy_ratio', 'preference']]\n",
    "top_pref_df = top_pref_df.reset_index(drop=True)\n",
    "top_pref_df.to_csv(f\"./{MODEL_NAME}_top{top_n}_preference.csv\", index=False)\n",
    "\n",
    "# 3. 하위 20개\n",
    "bottom_pref_df = ticker_grouped.sort_values('preference', ascending=True).head(top_n)\n",
    "bottom_pref_df = bottom_pref_df[['ticker', 'name', 'buy_count', 'sell_count', 'total_count', 'buy_ratio', 'preference']]\n",
    "bottom_pref_df = bottom_pref_df.reset_index(drop=True)\n",
    "bottom_pref_df.to_csv(f\"./{MODEL_NAME}_bottom{top_n}_preference.csv\", index=False)\n",
    "\n",
    "print(f\"\\nPreference 상위 {top_n}개 주식이 {MODEL_NAME}_top{top_n}_preference.csv 파일로 저장되었습니다.\")\n",
    "print(top_pref_df.head(10))\n",
    "print(f\"\\nPreference 하위 {top_n}개 주식이 {MODEL_NAME}_bottom{top_n}_preference.csv 파일로 저장되었습니다.\")\n",
    "print(bottom_pref_df.head(10))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 300,
   "id": "d073c765",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "MODEL_NAME = \"gpt-4.1\"\n",
    "\n",
    "def decide(row):\n",
    "    if row['llm_answer'] == 'buy':\n",
    "        return row['buy']\n",
    "    elif row['llm_answer'] == 'sell':\n",
    "        return row['sell']\n",
    "    else:\n",
    "        return None\n",
    "\n",
    "def adjust_last_percent(evidence, delta):\n",
    "    matches = list(re.finditer(r'(\\d+(\\.\\d+)?)%', str(evidence)))\n",
    "    if not matches:\n",
    "        return evidence\n",
    "    last = matches[-1]\n",
    "    start, end = last.span(1)\n",
    "    old_num = float(last.group(1))\n",
    "    new_num = old_num + delta\n",
    "    new_evidence = evidence[:start] + f\"{new_num:.0f}\" + evidence[end:]\n",
    "    return new_evidence\n",
    "\n",
    "def build_new_evidence_str(row, delta=1):\n",
    "    e1_new, e2_new = row['evidence_1'], row['evidence_2']\n",
    "    e1_changed = False\n",
    "    e2_changed = False\n",
    "\n",
    "    if row['llm_decision'] == 'contrarian':\n",
    "        if row['view_1'] == 'momentum':\n",
    "            e1_new = adjust_last_percent(row['evidence_1'], delta)\n",
    "            e1_changed = True\n",
    "        elif row['view_2'] == 'momentum':\n",
    "            e2_new = adjust_last_percent(row['evidence_2'], delta)\n",
    "            e2_changed = True\n",
    "    elif row['llm_decision'] == 'momentum':\n",
    "        if row['view_1'] == 'contrarian':\n",
    "            e1_new = adjust_last_percent(row['evidence_1'], delta)\n",
    "            e1_changed = True\n",
    "        elif row['view_2'] == 'contrarian':\n",
    "            e2_new = adjust_last_percent(row['evidence_2'], delta)\n",
    "            e2_changed = True\n",
    "\n",
    "    if e1_changed:\n",
    "        return f\"1. {e1_new}\\n2. {row['evidence_2']}\"\n",
    "    elif e2_changed:\n",
    "        return f\"1. {row['evidence_1']}\\n2. {e2_new}\"\n",
    "    else:\n",
    "        return f\"1. {row['evidence_1']}\\n2. {row['evidence_2']}\"\n",
    "\n",
    "# 1. 원본 데이터 준비\n",
    "df = pd.read_csv(f\"./final_result/{MODEL_NAME}_mc.csv\")\n",
    "df['llm_decision'] = df.apply(decide, axis=1)\n",
    "df = df.dropna()\n",
    "unique_decision = df.groupby('ticker')['llm_decision'].nunique()\n",
    "only_uniform_tickers = unique_decision[unique_decision == 1].index\n",
    "filtered_df = df[df['ticker'].isin(only_uniform_tickers)].reset_index(drop=True)\n",
    "\n",
    "# 2. delta별로 long format으로 변환\n",
    "result_rows = []\n",
    "for delta in [1, 3, 5, 10]:\n",
    "    for _, row in filtered_df.iterrows():\n",
    "        out_row = row.to_dict()\n",
    "        out_row['delta'] = delta\n",
    "        out_row['new_evidence_str'] = build_new_evidence_str(row, delta=delta)\n",
    "        result_rows.append(out_row)\n",
    "\n",
    "long_df = pd.DataFrame(result_rows)\n",
    "\n",
    "long_df.to_csv(f\"./evi/{MODEL_NAME}_mc_delta.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 314,
   "id": "38160c07",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABKAAAAMQCAYAAAAQNB1HAAAAOnRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjEwLjMsIGh0dHBzOi8vbWF0cGxvdGxpYi5vcmcvZiW1igAAAAlwSFlzAAAPYQAAD2EBqD+naQAAhppJREFUeJzs3QeYVNX9P/7DUqTaRQlgryiIFXsXe9eYiN1Yosbee4y9t9g1NqwRjRo1llgSjZrEGsWODRQEFCkK6O7/+Zzvf/a3C4vAspfZ8no9zzyzc+fOvWfKjuzbz/mcVlVVVVUJAAAAAApSUdSBAQAAACAIoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoACgiVlmmWXSmWeeWe5hUMNGG22UDjzwwNSUzc7PVVVVVbrxxhvTJptsklZYYYW05ZZbpsbkhBNOSCuttFKT+r2LscUY66OxPzcAmgcBFAA0Ep9//nk644wz0qabbpp69+6dVl555bTLLrukq666Ko0YMSK1JIMGDcp/FJcuEVJEyHPWWWel7777rl7HHDx4cLryyivT8OHDU1MVwUjpNVluueXyZ2TrrbdOp512WnrnnXca9FxFvl5/+ctf0oUXXphWXHHFdMwxx6SNN944zS7ffPNNWn755fNrOHDgwMI+u7169UpDhw6d6v4xY8akvn375n1iXwBoKdqUewAAQErPPPNMOvLII1O7du3StttumxZeeOEctPz73//OIcCDDz6YnnrqqdTSRFVRt27d0vfff5/efPPNHBi8+uqr6Z577klt27ad6UAlwrwNNtggLbjggqmpis/ISSedlKuIxo8fnz766KP0+OOPp/vuuy8df/zxae+9926Q8xT5ej388MM5BLr44ovT7PbEE0+kH3/8Mc0zzzzpscceSwMGDCjkPPH+3HHHHfk9qenee+9NEydOLOScANCYCaAAoMy++OKLdNRRR6WePXumP/3pT2n++eevdX8EL5dffnlqiUrVYCXxOlx99dXpueeey9O3WqI2bdqkX//617W2jRs3Lh133HHp3HPPTd27d8+vW2MWlUERQJVDhE5RnbTOOuvkaYBR4VVEILn++uvnUPDQQw9NnTp1ytt++umndNddd+VQ7+9//3uDnxMAGjNT8ACgzG666aZc4XPJJZdMFT6FPn36pOuvv36q6or7778/bb/99vn+rbbaaqoKqZEjR6bf/OY3eepa7BPTfnbddddcAVLXlKF//vOfeYpb/GG+yiqr5OqjuqZfvfzyy+lXv/pVDoZWW221dPDBB+d+OTE9rKaxY8ems88+O6233np5Cl3//v3TLbfcMkuv1WabbZavP/7445l6nvEcTzzxxPzzzjvvXD2NreYUqAj69ttvvzytLY6x55575m0zIyqR4j2J1yamlUUAUfLkk0/mcz766KNTPS5el7gvqpnqo3Pnzumyyy5Liy++eDrnnHPy56Omhx56KO2444759enXr1+e9vb1119P83jTe70ixInta621Vg6S1lhjjRyAffbZZ9Mda7xPQ4YMSY888shUx43KoKiK2nDDDfNnJt7vm2++earnU+pZ9Ne//jU/r9j36KOPnu65R40alV555ZW0xRZb5EtlZWV+z4oQIWE8n/g9LXn66afz5zV+f+ry4YcfpoMOOij//sVncK+99kqvv/56nc8jft/i92/VVVfNVW/TmoI5s+99SQRl8bj4fYjvhH333TdXYgJAfamAAoAyi0qI+GNzqaWWmuY+rVu3rnU7/qiNP5x32mmntPnmm6cHHnggHX744XlbVFKFCLWi4iLCqQi2YtrRP/7xj/S73/0uXXPNNTkIqCn+8I0/5PfZZ5/01VdfpTvvvDMde+yx6bbbbqve54UXXkgHHHBAWmSRRXJA1apVq3zMCRMm1DrWDz/8kAOcTz/9NAcVCy20UP5DOip04rnsscce9Xqt4nylwKVkRp5nvL4RDMUf0KVpfSG2hwglInxaYokl0v7775+DiZgmFgHA3/72t9S1a9fpji1emwisdthhh9xUO96LU045Jc0333x5DFERM/fcc+f+R1M23Y5xRYgX55+VqXm77bZbDhFjmmKEGCHCy1KoE69RhBcxDSxCvPgclV7Tmqb3ekVPsvgMxPOac845c6gSIVKEk/F6tW/ffprjPOKII3IwGa9pjLfmcQ877LBc3bbddtvl34d4Hueff3768ssv08knn1zrOPGZLwVhMda55ppruq9RjC0+K/E7E9Nc4znEMeJ9bmjzzjtv7s91++23p9133z1VVFTkn2Nb3DelTz75JAdT8drFtMB4P+MzGL8r8bjSaxSf99gWlZPRIy5+3+O9jOcxpfq89+Huu+/O/eiiyjCmBEffqnhfrr322vxaA0C9VAEAZTN27NiqpZdeuuoPf/jDDD8m9t91112rRo0aVb3t/fffz9uvvfbaaT7up59+qvrmm2+q1lhjjaojjzyyevv9999f/djKysrq7eedd17ePnz48Hw77uvfv3++xLhr6tu3b9Xxxx9fffuaa66p6t27dx5XTaeeempVv379qn788ceffY6lMb355pu1tl999dV5++DBg+v9PKc8ZjyvzTbbrGr33XevNa7vvvsuH+Pss8+ump4NN9ywauutt64aPXp09bYJEyZUrb322vm9KjnzzDOrevXqVTVy5MjqbfFcYlz33HPPdM8Tr3G81tPyxhtv5GPdfffd+fbQoUPz+S677LJa+7366qt5vyeffLJ6W9z+/e9/P93Xqy4TJ06seuSRR/L+zz///Ay9XgcccECtbc8++2x+/I033lhr+xlnnFG1zDLLVH344Ye1xrrDDjtUjRgxompmxHscjyu5+OKL87GHDRs23dd5ytdnWmq+bu+8807161x6n9999918X/wc+5YcdthhVX369MnvWc3P4DrrrFO1yy671Prdise++OKLtc4bY4vtJbPy3u+0005VO++881TP7bXXXpvu8weAaTEFDwDKKJpIh1KPmBkVPWxqVlFE5UxUM0y56lY0MY8eNGuvvXZ+TEzBGT16dK5YmVJMp6pZEbHkkkvm62HDhuXr9957L1dpRHVGzQqkukQ1RkwN6tKlS66mKl1ialqsQhYVLTMixhqPe/fdd3ND56jAiOqYZZddtt7Pc0px7JgSFpUeMTWpNNZ4b+JY0Yx7RvziF7/Ija1LOnTokCuE3nrrrTRp0qS8LapHokIrKltKosooql6mrIqqj6hGCt9++22+jmmIUfET081qvg9R0RSfuRl9blOaPHlynjYYFThRmRPva/QxC1FlU99KwOhvVaqKKonqpJiCF436a4rzLrDAAjN8/Kja+s9//pOrn0ri5zh2XdVDDSFWKlx99dXTrbfemquYYqpiTB+cUrxHzz//fK44is9RSfz+xDS4N954o/p1jcq6mPa45ppr/uy5Z+W9jyrF+C6J34uaSlVYAFAfpuABQBmVgqdSEFVfMb0nQoxS0BHij+pYWS+Cqgg3IlCKn2Ma3JQ9derSsWPHfF1asav0x+iMTBOLoCqCnZh2Vpf4Q7hHjx7TPU5M95syjIgeNjXN6vMsPa+YLleX0pTG+ojm1hE4RSAUU84iqInxxTS86NtTCqOiP9b0Qr0ZESsnhlI4Ge9DvAbbbLNNnfvPaBA4pZjeGIHQiiuumPtvxXsZgV9Ml4vpi/URU8riNYrgrqY4dny+P//88zQrYvpdjC1CxZgaWvr9i3NGX67ocVSEmIoa4ehrr72Wrrjiijr3idcuprHGlMBpff7i9YnpnPF5jc/L9MzKex/TLmM6ZIRXSy+9dH6fo3F6BKrTmrYHANMjgAKAMorQIao4/ve//83ysab8wzBWi4sAJHrl1KyWmtYfwdM7XoQlYY455pjuY+MP/WhcHL1v6jKjvY6iEXb8UR49ay644IIcXLVt27ZBn2cppIp+V3WN6+f6GU1PKRCMyp6SqIK66KKL0gcffJCrTKJKK6pcGkJUW4VSlU28D1HN8sc//rHO/Uu9nWZGfFYjfIp+Rb///e+nOvesmJHAsL5KVU7R66uu6qgIuGYlbJyWaEYfIVq8D9GLaVaff1Q1Tfk7UJdZee8jaIrXK8LR6MMVP0fvqAiz4rMLAPUhgAKAMotV4qKBc0yJiSk7DSUqIOIPxroaHtdHaYW+ulbGm1L37t1zRcf0/uCenmikHVVDcZxobB6hUgRRxx9//Ew/z6iiqeuP/BhriCbWszreKcWqcNF4vObUvJjqFyseRmAWAVScP6ZmzaoICKN59KKLLppXPAsRfERgEavj1VVdU5/Xq1Q9NK3KmvqK1+Gll17Kn5tS9V3pfBGmzEjF3LTEZzaClGhYvu6669a6LwLAP/zhDzlkmbLiriHE6xif2bieVvVQfHbjOde1imB8vkPp+UfFVgSx0zMr732IMC5WuCwFqREGRyAVqw3WJ7gEAD2gAKDMoiIjKhpialld4U5MvYkl12dWVFZN2RMqVmmbkQCpLhEERfXTX//611rbozopegLVFL1s4g/+mNo0pQjaStVUM+OQQw7J/Z9uvvnmvELfzD7PUoA2ZV+bWPkvVumLSpHoT1VTBB/TWt5+eqKi5qmnnsoVMDWDh6jWin5bMQ0v+h5FRdSsTmuKKZzRg+n9999PJ510UvX20rljOmKEETWNGzcuv3fTMq3Xq9R3KT6XJRFSxXOdFVF1E5+L6PVVU/SaCrMSDka4FGOM6YLR96nmJar0Ivwqqg9UKUiNVQ6nJSqVIhh78skna32WY/W5CKcjUIzpdyF6q8WqjTU/3xHaTflezsp7f99999X6nY4V+Up912pO8wWAmaECCgDKLKZ9nXfeebmqJ3oYxTLtsS2WW49pTc8++2y9Kg5iWteVV16Zp5ZF0+KY8hWhR32nOcV0wfhj/aabbsphUPwhHOFEVPJMGUBFD5mnn346hyLRNDn+gI5w4eWXX07/+te/clPlmtPSZtRZZ52V/0CP6wgNosfUjD7PCNDiOVx44YW5sXpUVEVfmwgGYipZPKfoeRMVSnHs6JEToUo87tJLL53u2F588cX8fCPQiiDrz3/+c+4xFP2SprTDDjvkSpIICOLnmRGv41133ZWfX3xGokImxhl9pk499dRafbficxRVPdddd10O7yIYjIqsCKoi7IjxRoVMXab1ekUj6qiyimAjKnaicieONavTSGPcEcJEddiHH36Yew9F0/CY7heN70tN8esjwqU43mKLLVbn/ZtttlkONuO1jOdWDtHH7IUXXki77rpr2mmnnXIoHZ/j6OsVn++agXUEu/GaxGcnwqX4HZyyKmpW3vvo5RWPi9clwtn4nbvnnntypV59qqkAIAigAKAR2GqrrfIf2BHuxGpY999/f642WmqppXIz4Pr0CIoQKCpj4o/YCIMiUIg/KiM4qK8ITWIqUYwvxhm9hq666qp0xBFH5CqJmqt3xR+s11xzTQ5HotIn/viN/SM8qrnvzIjHxfmi/1Ccc+DAgTP8PGOKXYQbEahE36iY9hSr5oUIVqKqKh4Xx4mKkliNLFbT+/Wvfz1DY4s/zGM6V6zUF43bI6A7+eST6wwPIwyI5xJhzsz2HYoKlDPOOCOHV9GwO6Zkxfij2XVdUzgjaIjPUbxWsRpbaayx2lxUHU3LtF6vGHe8Tqeffnr+vMZ7HceJ9+G3v/1tqq94PvHeRtgSVXYRssR7EMHirDQIj/AsAs/SdLK6RFPvCKDinD+3X5EiHItg8eKLL84r5kX1XXyWIwxaeeWVq/eL36H4jMX2+P2Kirp47yMMjt+5hnjv472N1RmjEipCzngfoml+VJABQH21qiqy2yMA0OxF2BIVTlHpE6t9MX0xrS+qVyJEiCl4AADNnR5QAMAMm7KXTIjpPKU+N8yYqFSJ6XkxxQkAoCVotAFUNFycVmlwzHOPHg3RYyEaLEbJ9JSiueJpp52W56qvuOKKudR4yuWB4//Yxj5RXh+NLadsehli2kNMFQAAUl5lLaakXX755fm/m2effXZukL7aaqs1yEpuLUFMaXrkkUfyv2ViCh0AQEvQ6HpARaPFd999N8//r2tFmOgjEcvAxlz3NddcM7399tt5rnz79u1zyFQS/xh+/fXXc6+KWPo45tRH/4D4B1/MlQ+33XZbnut/yimn5JVcYgne6MUQwVaIBpjPPfdceuKJJ2bjKwAAjVc0aI5m1NFPJv5HTvQfiv/+xv+wmdWV3FqK+LdH/I+ymW0+DgDQlDW6HlBR9VRafjZWoImmpTXFyiARIF1xxRXV22LloFhhJ1YJCh999FFeRSgaZEZTzhD/SI6Gn7GqSDQtDbGSTzRijP97G6KaKvowlFarifAqGmtGo08AAAAAmskUvFj9JPoiRIA0pViR5s0336wOlUpi+lwslfzxxx/n27HEcyxdW1rZJsRKQnE7ln4u+frrr9P8889ffXuBBRbI20KsJBI9LWL5WgAAAACaUQDVq1evPA2uZjBU8vnnn+claUtT6Ep69OiRrz/77LPq65h2FyHUlPt9+umn1bdjOehYtrkkfo5tIaqntt1227zsbGhkhWIAAAAATUaj6wH1c6JfQujYsWOt7aXbY8eOrd5vyn1K+5WOESLoevrpp9Nee+2Vhg0blns+HXXUUTnoiv4Mf/3rX3OYFf2kovKqW7du6dRTT03rrbdevcb/2muv5SBrymAMAAAAoKmZPHly7gO60korNa8AqqR169YNss9+++2Xp+RFb6iw9dZb5+l9ETLFyjQ9e/bM4VQ0W7322mvTX/7yl3TMMcfkvlSdO3ee6XFH+BSXSZMmzfRjAQAAAJqqJhVAlUKfCIRqKk2ji4bhpf2m3Ke0X83gKFbuefDBB3OVUyyDHFP7ohLqoYceymFTJHmvvPJKbnK+zjrrpMUXXzzf99Zbb+UV+GZWVD5FALXkkkvO9GNhRpf2/uSTT/IqVZb2hpbLdwEQfBcAvgcoWswkm9GVkJtUABU9nCoqKvIv0Oqrr169vdR8PCqWwsILL5xGjBiRf9lq/pLFfnFfTXG8+GUsueGGG9Kmm26aFltssXyM6DkVzclD6Xr06NH1fg7xxtQ1PRAaUnzufc4A3wVA8F0A+B6gKDMaPjXKJuQ/p1OnTmmFFVZIzz33XK3tL7zwQq5eigql0K9fv1y9FNtLYtrbv//975+tXBo+fHgaNGhQOuigg/LtaGQeAVWpmmrixIn5er755ivk+QEAAAA0R20aY/lWhEdRZRSh0eDBg/P2JZZYIrVr1y7tv//+6bDDDkvnn39+Dpri/oEDB+ZG4aXkLfbdcMMN0+9///v07bff5iDp3nvvzUHSbrvtNs1z33jjjWn99ddPSy21VPWUuQisok/URhttlAOtWCWvT58+s+nVAAAAAGj6Gl0AdcABB6ShQ4dW395+++3zdaxWF1Pw+vfvn84+++w8Ve7222/PfZyOPPLItPvuu9c6zoUXXphDqriOqXjLL798uvnmm3OlVF1GjhyZ7rvvvnT33XfX2h4h1imnnJK22Wab1KZNm3TZZZcpXQQAAACYCa2qois2s0U0Lw+9e/cu91BopiZMmJCrApdbbjlBKbRgvguA4LsA8D1AY8o5Gl0FFP/np59+ylMRYWaU+pTFdfQvawhR+de6deuZai4HAAAANQmgGpkoSPvqq69y7yqYWbFqYwRGw4YNa7AAKkQAFdNd55prLkEUAAAAM00A1ciUwqf4Yz9KJP2xz8xWzkX10xxzzJFDo4YIRH/88cf03XffpS+//DL3U+vWrVuDjBUAAICWQwDVyMKDUvg033zzlXs4NNHPUGjfvn2DBFAlXbp0yaFWNOuPz2dDHhsAAIDmr+Hm6DDLSj2fNIejMerUqVOuiNKbDAAAgJklgGqETLujMfK5BAAAoL4EUAAAAAAUSgBFs3fmmWemZZZZpl6PjcfF4wEAAID6E0AxWw0aNCiHOr169UpDhw6d6v4xY8akvn375n1iXwAAAKDpE0BRFtHM+o477phq+7333psmTpxYljEBAAAAxRBAURbrr79+uu+++9L48eOrt/3000/prrvuShtssEFZxwYAAAA0LAEUZfHrX/86Vzrdf//91duefvrpNHLkyPSrX/1qqv0//PDDdNBBB6VVVlklT9Hba6+90uuvvz7VfqNGjUonnHBCWm211dKqq66a9t577/TOO+/UOYaHHnoo7bjjjqlPnz6pX79+6Zhjjklff/31dMceIVk8buWVV07rrLNO2nfffdODDz44068BAAAAtBQCKMpi3nnnTVtvvXW6/fbbU2VlZd4WP8e2uK+mTz75JIdS//vf/9KAAQPSb37zm/TVV1+lPfbYo1YI9f333+dtjz76aNp2223ToYcemhZeeOH00UcfTXX+66+/Ph177LGpa9eu6fDDD0877bRTevbZZ9OBBx6YpwdOy913353OOOOM1K1bt3TYYYelXXbZJX377bfp2muvbdDXBwAAAJqTNuUeAC3XnnvumRuN//3vf089evRIr7zySjrllFPSpEmTau136aWXpsmTJ+eKpV/84hd5W1RAbbnllumcc87JfaPCrbfemsOmW265Ja255prVj2/Tpk0aOHBg9e1hw4alyy+/PB188ME5fCrZdNNNc9AVlVibbLJJnWP+85//nCum/vjHP1Zvi2PUVY0FAAAA/B8VUJTNcsstl1ZfffUcHEX10xprrJFXv6sp+kI9//zzORAqhU+hS5cueRrcG2+8kafdhccffzwtv/zytcKnujzxxBP5uFtssUWupCpdoqqpU6dOafDgwdN8bOvWrfPqfUOGDKm1PaYFAgAAAHVTAUXZq6Biqtxrr72WrrjiiqnuHz16dJowYUJaZJFFprqvZ8+e+fqLL75I8803Xw6F+vfvP91zxpS+mGa3zTbb1Hn/l19+Oc3HxhS9mHoX4dXSSy+dVlxxxdw0faONNkqtWrWa7rkBAACgJRJAUVYbb7xxnn4XlUUbbrjhNPf7ub5MJVHV1LZt2+nuFz2n4nw1p9HVFJVQ0xJB02OPPZYefvjh9Oqrr+afYwpghFkXXXTRdM8NAAAALZEAirKqqKhIF1xwQb6uq4IoGpJ37NgxffbZZ3VWMoUIsEI0FI+pdNMT+0dYtfjii9dZWTU9UXkV/aNC9Ks68cQTcyB19NFH/2x4BQAAAC2VHlCU3SqrrJJWWmmlOu+LSqV11103Pfnkk7n3UsmYMWNyA/NoCB7T78Kqq66aG5kPHz68er+Yvvfxxx9PVXUVYde5556bg6iaxo0bN9X+Nd133325IXpJu3bt0rLLLpt/nrJ5OgAAAPB/VEDR6B155JHphRdeSLvuumvaaaed8jS7v/zlL+m7775LV155ZfV+++23X3r00UfTgAED0g477JDDpQceeGCqqqglllgiHXDAAem6665L2223XW5wPvfcc6f3338/B11HHXVUro6qy/nnn58ft9lmm6WFFlooh2L33HNPbqBen2oqAAAAaAkEUDR6iy22WLrrrrvSxRdfnFfLix5OvXv3zmHQyiuvXL1frKB37bXX5u3XXHNNWnDBBXOT82hOHiFRTREyLbXUUmngwIF5Fb4QAdJuu+2W+zxNy+mnn54efPDBXAn1/fff55X59t577/Sb3/ymwFcAAAAAmrZWVTPS3ZkG8dZbb+XrCE/q8sMPP+SwJAKX9u3bz+bR0RxE1Vd8juLzE9MXG5LPJzQdMf148ODBabnllst99ICWyXcB4HuAcuccNekBBQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAECh2hR7eFqqK6+8Ml111VX559atW6eOHTumnj17pvXWWy/ttddead555y3b2MaPH5/+9Kc/pcceeyx98cUXeWwLLrhgWnXVVdPOO++cll122QZ/LW6++eb02muvzdTjfvWrX6WJEyemBx54oM77zz333PTggw+mF154IY0bNy6f55VXXsnPqU2bNql3797pd7/7XVpppZUa6JkAAABA/QigmojKyqpUUdGqSZ17jjnmSNdee22qrKxMY8aMSW+99Va6++670/33359uvPHGBg96ZkQEOrvttlsaNWpU2nvvvdOSSy6Zw5sIhx5++OHUqlWrdPLJJ6fGYIsttkjnnHNO+vzzz3N4N6Unnngibbrppjlsin0effTRtOuuu6all146/fjjj+nWW2/NYV9s79GjR1meAwAAAAQBVBMRAdBFA/+bvhg+draet8eCXdIxA1ap12Oj8mmttdaqvr3VVlul/fffP/3mN79JhxxySA58ovpodoqqp3fffTdXFfXq1at6+9Zbb52OPPLI9L///S81Fptvvnk677zz0uOPP55ft5reeOONNGzYsBxShcUWWyw99dRTqX379umHH37I16uttlraYIMN0vPPP59DNwAAACgXAVQTEuHTR0PHpKZsvvnmSxdeeGEOo2L6WAQjVVVVeYraPffck7788sv0i1/8Im233XY5dGnbtm31YyM0iv0++eSTtMACC6RNNtkkHX744alTp075/hNOOCG9+eabab/99sv7ffrppzmYOe2003IYE0aOHJmvu3fvPtXYOnfunNZYY41a26Z3zvDss8/m6Ybvv/9+mnvuudPaa6+djj322J+dZnj99denyy+/PE+b22ijjercJ6YFrrzyynUGULFtnnnmqR5vjD389NNPUx1n/vnnn+Y4AAAAYHbQhJzZLqa9RfVRBDfh7LPPTgMHDkx77rlnuuKKK9Iuu+ySp+iVekiF6Nl0/vnnp2233TbvEyFTTC07/fTTax37o48+SrfcckvaZ5990gUXXJCnAf72t79NY8f+X+XY8ssvn69POeWU9N577+Xwa1pm5JwRBEXl1Lrrrpsuu+yydNhhh6VXX301HXroodM8dgRvl156aZ5eN63wqSQqnKIqK/o61fS3v/0t9e/fP1eZTen7779P77zzTjr++ONz8Lbxxhv/7DkAAACgaCqgKIvoaTRkyJBcpRThU4Qyiy66aL4vpu1FiBLbI9yJHk0RAEVos+aaa1YfI6aZnXTSSen3v/99dUVSHHfQoEHVlVOrrLJK2nDDDfPx99hjj/z46JMU1VbRQykqh6IX1eqrr5523HHH6l5LM3LOmD4YAdUxxxyTm5eXRHVV9Jf68MMP01JLLVXref/zn//M4VccI6q8wqRJk9LkyZNr7RfHjn5Um222WQ7oInCKACxEldfQoUOrp99NKSqwQjRVjwqrukIqAAAAmJ0EUJTVv/71r9ykPKqM6lJqED5hwoR04IEH1rlPNOAuNTSPgKjmtL2YxhbB1gcffFC97cwzz8yBUQRQ0Rg9qoX+85//pJtuuikHNuuvv/4MnbNdu3a5D1McLy5T+uyzz2oFUFHJFKvSHXTQQTkMK7nuuutqVXuFp59+OjcOj2l/ESTVDKDi55jKGKHZtCq3YqW/aPYeIdef//zn/DoAAABAuQigKIuYUhYByzfffJMqKirSHXfcUWelTgRKsU+IcKhr165T7bPwwgv/7Lm6dOmSRo8eXWtbnz598iXEVLl///vf6aijjsrT9iKAmpFzDh48OP8cPaZKU/tqKlV0hahwOuCAA/IqfDFdr6aYcjjltprnjEqnCLiiP1a3bt1yABWr302rsmnFFVfMr1tUfsVzueGGG3LVFQAAAJSLAIrZLqbeRdVRNCCPQCYqoKLSZ1pB0pxzzlkdJPXt23emz/f111+nZZZZZpr3x1S3qCbaZptt8rS/GT1naZ+ohJreuCKAigqm6HsVPanuvffeHMCFhRZaKF+mJabhnXXWWTl4ip5OUX01rel3NbVp0yZXPg0fPny6+wIAAECRNCFntorKouiZFNVBEfj069cvb4/G4VOKoCVEuBPNxH9un2l5/fXXc7+kUl+kmJYWvZmmFFVQEYqVgqoZOecSSyyRg7Oo3ppy9bmouIopfDV7OkUAFRVV0XcqpuGVGqNPT2m6XTQ8j0usajfl9LsRI0ZM9bgInj7++OM8TgAAACgnFVAUJkKZF198MVc4fffddzngiQAogp2YFhbXsSJeTEGLyqMxY8ZUr9j2/PPPpzfeeCM99thjae65585VQ7HK3P7775+Dqw4dOqSXXnopNxf/73//W33OCJv++Mc/5lX2oj/T1VdfncOkTTbZJN//7rvvplNPPTWvPhfT3qLyKMKiRx55JK9ed9ddd+X9ZuScMXXw2GOPTccdd1z69a9/nZubx+Mi9Iom5w899FAOnmqK+6PnU+x7+OGHp+uvvz5XKk1PVDzF6nsxdTFWv4tz1xSvZ4wpemnFNL2RI0em2267LVdwxYqAAAAAUE4CqCakx4JdmtQ5Y3pdhB8RlkR4E1POfvnLX+ZtEcSURH+jCKIinIrG4LGiXTTvjp5JJREGRbBy++235wAppr0tvvji6ZBDDql1zgh8orF4VC5F8BW9kk488cTqfkmxOt0888yTnnnmmdzvKVbbi5AmVt57+OGHa/VtmpFzRpPveC4RAMU0uRDHiCbjcZ66LLbYYunyyy/PwVaspveHP/xhuq9lPI94nWI6YV3T72KaXlQ8RZAX19EDKp7T0Ucfneaaa67pHh8AAACK1Koq5h4xW0QwEnr37l3n/T/88EPujxQBRQQINVVWVqWKilapHMp57plxwgkn5JXmopqpJVedxecoPj81m5THr3nNKYHTEisIRtA2s59PoHGJ3/dYKGG55ZabqhITaDl8FwC+Byh3zlGTCqgmopwBUFMIn/h50Qtqyy23nO5+MTUwKq0AAACgIQmgoAWI6Y/Rl2pGGp4DAABAQxNA0Wycd9555R5CoxUN36MZOwAAAJRD7aW0AAAAAKCBCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAoxJVXXplWWmmlOu/74osv0jLLLJMef/zx1BRNmDAhbb/99tN8fgAAAEBtAqgmoqqyskWeu7GpqqpKxx13XHr//ffLPRQAAABoMtqUewDMmFYVFWnEg5elSaO+mK3nbTdfj9R1+yNm6zkbs0suuSS999576de//nUaNGhQuYcDAAAATYIAqgmJ8GnSV0NSc3TVVVelhx9+OI0YMSJVVFSkRRddNB1wwAFps802q95njz32SO3bt0/rr79++tOf/pT3XXHFFdO5556bK5KuueaafN2zZ8906qmnpjXWWKP6saeddlp64YUX0siRI9Mcc8yRll566fS73/0u9evXb4bH+Je//CXddddd6Z577kmPPvpog78GAAAA0FwJoGg0U9t23nnntNhii+Xb0R/qyCOPTHfeeWfq27dv9X7PP/98GjNmTDrqqKPSjz/+mM4+++y0yy675NDqoIMOSj169EjXX399vv+ZZ57JYVNo165d2nPPPXM4NXHixHT//ffn/SP0isdMz2uvvZbOOOOMdMUVV6QllliiwFcCAAAAmh8BFI1CVCPVtNFGG6Vnn302Pf3007UCqGj8PXDgwNS6det8++2330633XZb+sc//pEWWGCBvC2qpPbZZ5/07rvv5gqpcMopp9Q6flRHxeWf//xn+tWvfpUDsGguXlPbtm1zcDVs2LB06KGH5kBs3XXXLew1AAAAgOZKAEWjECvjReXSv//97zy1LsKgysrKqUKhueaaqzp8CgsuuGAOj0rhU2lbiOl2JRFG3XzzzbmSadSoUdXHLV0PHTo0bbzxxrXOFaFTBGMnn3xyWm+99dKuu+6aq6dCVF+FuB3jadPGrxIAAABMi7+aKbuvv/46T6OLwCn6PEV/pjnnnDMdc8wxOVz6OTXDqJJSGFR6bPSFivBo7rnnzsePaX5dunTJP5f26dq1a+7tVNNCCy2Ur0ePHp1efPHFOpuO9+nTJ0/ti5AKAAAAqJsAirJ74okncsjz5JNPpoUXXrh6e0x/awgPPvhgDqqi31MEW3WJc9Wc6lfTBRdckL7//vta2+677770yCOPpFtvvbVW9RUAAAAwNQEUZTd58uQcEJUqjkIEPqXpbg1x/Kh4qhk+ffPNNzP8+GWWWWaqbdFzKhqfTyu0AgAAAP4fAVQT0m6+Hk3qnNEnqa5pa7169ap1e6211srXJ510Utpqq63SV199lW666aZaPZxmxTrrrJMblZ977rlpzTXXTEOGDEk33nhjgxwbAAAAmD4BVBNRVVmZum5/RNnO3aqiYqYfN2nSpHTiiSdOtf3www+vdTt6PsU0t0svvTRPw4vbRx11VLroootSQ1h//fXzOCLUuvfee1Pv3r3ThRdemFfKAwAAAIrXqmp6XZ5pMG+99Va+jgCkLj/88EOuzokm2e3bt5/No2NWxHv3008//ew+rVq1Sh07dix0HDGGGEt8fupq0D4rfD6h6YgVPgcPHpyWW265wr93gMbLdwHge4By5xw1qYCCBhAr4b3xxhs/u080Oi/9cgIAAEBLIoCCBnD22Wen8ePH/+w+0bQcAAAAWiIBFDSApZZaqtxDAAAAgEZLSQYAAAAAhRJAAQAAAFAoARQAAAAAhRJAAQAAAFAoARQAAAAAhRJAAQAAAFAoARSFuPLKK9MyyyyTdtppp6nuq6qqSptttlm+f9CgQXnbRhttlPbYY48ZPv7zzz+fbrnllgYd8xdffJHH9Pjjj8/Q/uPHj09XXXVV2mqrrdKKK66Y1lxzzbT99tuns846K7377rtpdonX7swzz6y+ffrpp6dtt912tp0fAAAApqfNdPegUaisqkwVrSqa1Llbt26d3nnnnfSf//wnrbrqqtXb//GPf6ShQ4fW2vfCCy9Mc8wxxwwfO47x9NNPp7333juVw8SJE9Nuu+2WRo0alcew5JJLpnHjxqXXXnstPfzww6lVq1bp5JNPLsvYAAAAoLERQDUREQBd8dLNaeh3X83W83afc6F02Br71uuxESittdZa6dZbb60VQN1xxx25aujBBx+s3rbKKqukpuSxxx7LVU4PPPBA6tWrV/X2rbfeOh155JHpf//7X1nHBwAAAI2JAKoJifBpyDefp6YkptXtu+++eXpbjx490qeffppeeOGFdM8999QKoLbbbru03HLLpfPOOy/f/vrrr9PFF1+c9x07dmzq2bNnDrOOPfbYdM0116Tbbrst7xdT5sLqq6+ebr/99jz17+abb07XX399uuKKK3JFUv/+/fMUtUMOOSR9/PHH6Ztvvklzzz13DsWOPvrofOyZNXLkyHzdvXv3qe7r3LlzWmONNWq9Bu3bt0/rr79++tOf/pRGjBiRp+yde+656f3338/PJ65jHKeeemqtx5522mn5NYjzRaC39NJLp9/97nepX79+Mz1mAAAAKBcBFIWKMGWJJZbI4dCJJ56YBg4cmNZbb7208MIL/+zjfvvb36bvv/8+B0RzzjlnevPNN9P999+fDjvssNxnKQKbV199NU/dC7FPSTzuiCOOSAcccEDaf//9c3Dz448/pgUXXDBXKHXt2jUHOjfccEM6+OCD00MPPZSnzM2M5ZdfPl+fcsop6dBDD83B0M8dI3pWjRkzJh111FF5LGeffXbaZZddUkVFRTrooINyOBehWdz/zDPPVE9HbNeuXdpzzz1zOBXT/uI1iP1jml88BgAAAJoCARSFiwAlKpv222+/3HQ8Gnf/nKhQeuutt9I555yTw6ZSo+0IlKKSKMKYhRZaqHqK35Tatm2bq6sWWGCBWtsvuOCCqSqVItAaMmRIWnzxxetslj5hwoSpjh2hUDQc33XXXXMl1xNPPJGPteyyy+ZKrB133HGqqqqVVloph2/RFyu8/fbbuYorelmVxhnPbZ999slT+6JCqhRwTRnoxeWf//xn+tWvfvWzryMAAAA0FgIoCrfNNtukiy66KFfuxJS1CFC+++67ae4f1UwRytx44405sIn+UBHodOzYcYbO16ZNm6nCpxBNy++99940ePDgXI30ww8/5O1Thkwl0Sh94403rrUtqp1iClyIaX0777xzDqAiMCs1XL/pppvyVMCYclcy11xzVYdPIaqxIuCqOc7YVnN6X4gwKqYUxlTCaHheGuu0xgwAAACNkQCKwkVlzy9/+cs8xSyqmqYngprYN3okxbS9ysrKHM5EgBUrz9XHn//857wqXVQixfS+X/ziF7kfVUyFiyCoLjFVLyqcaorKq5r69OmTLyGO8+9//ztPo4tqq5oBVF3Psa7grHScENMMo8oq+lVFH6nFFlssdenSJf88rTEDAABAYySAYrYYMGBA+uyzz3I11IyIleWib9S4cePyinIRBP3+979Pffv2zffNbM+mu+++O6222mr5mKXHvvzyyz/7mJhqF+ebUXHcmIIXzzGm282qmEYYQVX0e6rZ4woAAACamopyD4CWISqHLr/88hzqTE9Mj4vpZjVXlDvuuOPy7WHDhuXrqASK/aI6akZMnjw5devWrVZw9e2339bz2aTcDPzDDz+cantUJsVUvNLqfLMixhzPs2b4FP2xAAAAoKlRAUWjEyFTTLWLJtvR/ylCpmhePs8886SVV1457xPT3qI6Kqb0RdVR9HPadtttp3nMddddN1c/xeNi9bhXXnkl366v6M106qmn5ubocewI2EaPHp0eeeSRvDrfXXfdlWbVOuuskxuVx1TEaHoezdKjLxYAAAA0NQKoJqT7nAu1iHNGw/Hoc/Tss8/mqXPRQyqmwt16661p3nnnzftEf6VYVe+BBx7IjcW32mqrnw2gDjnkkFw9dMUVV6SKiooc7px22mk5RKqPvffeOwdizzzzTO739P333+dqpViVL6bMLbroomlWxXOMHljR1DyeY+/evdOFF16YV8oDAACApqRVlW7Gs02slBYiSKhLVPFElUs0m47QpabKqspU0ao8MybLeW5mzk8//ZQ/R/H5if5R8XNs+zkxLXFGVhj8uc8n0LjESpmx4udyyy03wyuIAs2P7wLA9wDlzjlqUgHVRJQzABI+NV177rlneuONN352n+jLVfrSAAAAgCIIoKAZO/vss9P48eN/dp+YkggAAABFEkBBM7bUUkuVewgAAACQlD4AAAAAUCgBFAAAAACFEkABAAAAUCgBFAAAAACFEkABAAAAUCgBFAAAAACFEkABAAAAUKg2xR6elq6qqio98MAD6d57703vvfde3rb00kunX/7yl2nHHXdMrVq1KvcQ06RJk9IVV1yRXnzxxfT555+nysrKtNRSS6WDDjoobbDBBjN0jP/85z/pT3/6U36OI0aMSN26dUvbbLNNOuCAA1K7du2q97vvvvvSQw89lIYMGZLGjh2bunfvnl+Lvfbaq9ZrsdFGG6WhQ4dOdZ7VV1893X777fnnE044Ib+2JXGeON4WW2yRx966detZfGUAAACgYQigmoiqysrUqqKiyZ375JNPziHJTjvtlPbbb7+87bnnnkunnHJK+u9//5vOOeecVG7jxo1LAwcOTLvuums6+OCD008//ZTuueeeHOLcddddaaWVVpruMZ544ol8nHiOET6988476frrr0+jRo1Kp59+evV+ER4tscQSOXTq3Llz+uc//5nOPffcHIJFWFXTxhtvnHbfffda2+acc85atyNwOuuss3LQN2HChPSPf/wjXX311alDhw5THQ8AAADKRQDVREQA9P4ll6UJn38xW8/bsWePtPRRR9TrsX/729/S/fffnwOSXXbZpXr7pptumlZcccUcQq233npp8803T+UUQdDTTz+d5p133uptG264Ya42euqpp2YogIqwqubjo3IqKqmuu+66/DxL1Ug33HBDWnDBBWud58MPP0xPPvnkVIHRQgstlNZaa62fPW/Hjh1r7ROVU1GN9fLLLwugAAAAaDQEUE1IhE/jPx6Smoo77rgjLb/88rXCp5LYduedd+bKo/nnnz8NGDAg/fnPf069e/fO98d0tksvvTS99NJLOWQJhx12WBo/fny66aab8u3vvvsuXXLJJTm8ie2LLbZYOvDAA2sFWssss0yuapo4cWKe+vb999+nNddcM5155pnVgVFMXasZHpVEgBRjmxF1PX7hhRfOlU1jxoypvr9m+FTTfPPNlxrKjz/+2KDHAwAAgFmlCTmFiBDk9ddfT+uuu+4094nqp9inT58+aY455khvvPFG9X1///vfc2j0wgsvVG/73//+l1ZdddX8cwQ7++yzT3r//ffTcccdly6++OK0yiqrpMMPPzz3cqoppqR99tln6bTTTktHHXVUPuaFF15Y55jinB999FE+Zo8ePeoMz2bUm2++mafMzTPPPFPdN3ny5DR8+PB07bXX5ud16KGH1nmMeJ4/J6bexZjj8s033+RwbuTIkWnvvfeu97gBAACgoamAohDffvttDk+iH9K0xBSz2CeacUcIFWFU9DyKyqbXXnstVypFEBVT9qKXUjTlXm211fJjo5opApe4btu2bd62zjrr5EDq7rvvrjUtbd99903HH3989e2PP/44Tw+sSzTwjvNEE/KYPhfT80qieiqqokpiWl379u3rPE40GY/ph1HZVVej9VNPPTX3xoqAKiq9Vlhhhan2ieqwuEQ/pyWXXDI/jy233LLWPjF9L167miKki2AKAAAAGgsBFIX6uVXuSvdFkBOhyV//+td8Oxppx0p5u+22W27gHaHPW2+9laukSmFLVDlFUBRVT1Pq1atXrdtTTqOLaXBRJVSXq666Kn399dfpscceSzvssENuGr7ccsvl+7baaqtaK9PVXJGupgjQfve73+WALab/1SW2b7fddjloi32jT1TNaquo5Jp77rlTp06d8lgHDRqUjjzyyBwsxThKevbsmS666KLqqrMYe6y0F8FXBHHLLrtsnecHAACA2UkARSEiPInKpGHDhk1zny+//DKHSrFvhDnXXHNNGj16dHrmmWdyM+2oaIreThHSRAAV4VP0awpR/RTB0BlnnDHVcadVlVQSx5hWhVApvFp//fXTjjvumC6//PI8Ta4UTtWcElezOqokVqKLPlRR1RU9rkr9q+rqDxWXqPKKfS+44IK8UmDF/7/aYIRTNfXv3z9vi6qqmgFUPNe+fftW344V/KL6a+utt87h2Nlnn/2zrwUAAADMDgIoCtGmTZscjEQ1U1Tu1CXuK02pi30jsHr11Vfz9v322y+HN6VpeDG1rma1U5cuXfJUuprhS0OLHlBffPHFNCurphRhWaw8F6Hbbbfdlrp37z5D54n9omoqwqu6Qq0QwdSiiy5aqwLr5177OOZXX301Q+cHAACAomlCTmFiGtjbb7+dp4RNKbbFfTHNLkTYFAFPrH4XP5emvW288cY5gIpG3aWwKvTr1y8HLI8//vhUx/78889napwxxS0qh2qKMCh6Ui2xxBIzdIyoyIrG3zGmqDxaZJFF6gyoxo0bN9X2f/3rX3m6Xil8in2mrNAqjSdWFZyRsUQj9VgVEAAAABoDFVAUJhp6RzVTrD4XK9zFtLbw7LPP5p5GEVBFwFQSfaBiFbfYXrLhhhvmx0efqJVWWql6e0xXu+eee9Kxxx6b3nnnnTw9LxqfP/zww7kv0llnnTXD43zkkUfydLmdd945Nx+P40SIFFPjDjvssBk6xkEHHZQbgkfPqqiaqlk51bVr19xEPFbi22uvvfLY47lEb6sI0J566qnciLzkiSeeyK9DTAGMACzGExVV0QR9ytXyIpgqrfoXK+tF8/Po/RTTDGNMAAAA0BgIoJqQjj17NLlzRg+iqFyKUCSajP/www85eIlQqWbQFKIPVAQv0f+pZIEFFkgrrrhirlCKhtw1ex/dcccd6Yorrsih080335zmm2++HERtv/32MzXG6JkUIVasShd9qSLsiul+EWJFmDUjovl3hEE1V9sriWbm5513Xp4WFz+//PLLuZdTvBYReF122WU5rCuJ5xuB1V133ZVGjBiR+2TFVMToRxUN1GuKKXn77LNP/jnGHf20Yuwx7XHK5usAAABQLq2qrNc+20Qj7dC7d+86749AIipYYurUlI20qyorU6v/v0H17NaQ5/7vf/+bp91FhVEETjSsCOricxSfnwikoml6VEZNT0x7/LkVC6f3+QQalwjEBw8enKczT2sxBKD5810A+B6g3DlHTSqgmohyhU8Nfe744ovKnFj1bf/998/T3KL30/QafFM/UZH16KOPTne/f/7zn7naDAAAAIoggGK2itT9j3/8Y56ad8wxx+RKmosvvrjcw2q2jjjiiNx3anpi6h4AAAAURQDFbNe3b986V8aj4cVqfHWtyAcAAACzU/nmdQEAAADQIgigAAAAACiUAAoAAACAQgmgAAAAACiUAAoAAACAQgmgAAAAACiUAIpma9CgQWmZZZZJL7/88kw97sorr8yP++KLL6a773fffZfOOuustN1226WVV145rbXWWunQQw9Nn3zyyQyd64QTTsjnqusCAAAAzUWbcg8AirLOOuukP/3pT2nZZZedqcdtv/32aZVVVkkLLLDAdPcdOnRoeuqpp9IOO+yQevfunQOpm266Ke21117poYceSnPNNdd0j9G9e/ccYgEAAEBz1WQDqGeffTZde+216f33308dO3bMgcFRRx2VFllkkep9brzxxnTnnXemESNGpIUXXjgdcMABOVyo6fbbb08333xzmjBhQtpss83SKaecktq1a1d9/8CBA9O9996bHnzwwdSqVatULpWVVamiolWLO/es6Nq1a77MrJ49e+bLjIjP1d/+9rc0xxxzVG9bffXV04Ybbpg/o1EZNT3x+Y3KKQAAAGiummQA9eijj6Yjjzwy7bLLLuk3v/lN+vbbb3PYtMcee+SgaN5550233XZbuvTSS9PBBx+cevXqlV588cU83WmeeeZJ66+/fj7Om2++mStPDj/88NStW7f886KLLpr23XfffP+kSZPSDTfckE488cSyhk8hAqBBA19LI4ePna3nnX/BLmnHASvV+/HPPfdcuvDCC/OUtF/84hdpqaWWyhVD//rXv/L7FBVDl1xySXryySfT+PHj02KLLZYOPPDAtPnmm1cfI6aj/fa3v833P/zww2nixIk5LDz11FPT3XffnS9ff/116tOnTzrvvPPyeUKc55BDDklPP/106tGjR55St/HGG6fTTjstvfvuu+mJJ57I+22yySY5eOzQoUO+fcstt6Rzzz03vffee9N9fp06dZpqW3yW2rZtm8cEAAAANNEAKgKHfv361Zq2tNpqq6X+/funf/7zn2mbbbZJ119/fdpzzz1zABGiIuWrr75K1113XXUAFRUqUcESIVV45ZVX0jPPPFMdQEWY1blz53zcxiDCp6+GfpeaigiAoh/Stttum0O+0aNHp/vuu6/6/gj49tlnn1w9dNxxx+XXOoKp2DemztWsCopqt6222iqdffbZuert8ssvz+9fhD2/+93vUps2bfLn4cwzz8z7/pzYb8cdd0znnHNO+uijj/Kx4jgx1obwzjvvpMmTJ+cwc0bF/vEcyh10AgAAQBGaZABVVVWVfvzxx1rborIpxB/wH3/8ca4+2WCDDWrtEyFUVLp8//33udpl5MiRaf7556++P6Zrvfbaa/nnOH6EVVFpJRSo33t0wQUX5IqjuC6JyqCoKAvRI+mbb77J17G91LcpAqYIGWsGUPvtt1869thj889xzJj2Fue45557qqdMRsVSVC9NT3wGBgwYUH2sV199NQeX0wqgIiiLgGjKaXN1fS5iTFHRFYFWKeicng8++CCtsMIK+TWI6q0Ix+L5ll4TAAAAaOqaZAC16667pqOPPjpXysRl8cUXT7feemvu2xOBwksvvZT3W3DBBWs9LqZh/fTTT3kqVkwFiwbRMa2rZNy4cWnuuefOP5dCkS233LI6WBBEzbiYcvfpp5/mAG9aYlpkNPGO/l1TimmTNcV0vZrivY2+XTX7dS200ELphx9+yO9jVFNNy3zzzTfVsSIEmpYIIq+66qpa20rT+qZ02WWX5SqumLo5IwFSVOvFFMDSZzGCsKjIGjZsWK7mAgAAgOagSQZQW2+9dQ6RosfT448/ngOoCCPuuuuuXJkSAUSIn2sq3R479v/6KPXt2zevWBZT76JiJabfRW+hCKkidIi+QxFonHHGGblHUfv27dPee++dexTVVwRZMda6RG+jysrKfP641NS6detUTlOOZ3pGjRqVr2MluZqPjedXuo4pebFC3emnnz7V4+O1nvJxNW9XVFTk13LKbSGqlWq+hqXH1jx3zcdFUFRzWxy35nOOiqS11157qhBrytckGtrH5yaCozXWWGOGXrPYr6Z11103V98NGjQoV2rN7PteGvuUr01DKL2GUUFYei2Bxil+T2teAy2T7wLA9wBFm5linSYZQEXvn+gRFCvURQVM/LF+//3356qo6P1UMr0/3mNKXvR3iublIcKQmPr017/+Nf+xHUFXBApxvmhuHaFXTCeLip1VV121XmOPcGTw4MHTvD/6AEUQVVMEK6UG2eUS09BmJnQohX0RMkWIV1KayhbbooF3TJeMJuN1qfm4CGVq3o6xxKWuY8frF9unvF16XWP7lMeOX5rStppjDFEVV6qMq3n+mseI1RYvvvji3Og+elXVvG9mRSVfjHXMmDFThagzasrPUEOIY8ZrFe8Z0HSqUQF8FwC+ByhSzZlJzSqAiqAgVjH71a9+VR0CxepncTtWxYsAaqWV/m/VtilDgNJ0uy5dulQHOzFlKnoSRSK8yCKL5ONHE+uocoow6IUXXkibbrpprowqBQ2xrb4BVFTbLLnkktP8Az+mXkVT7qgAaoofqJJYzS7Ck1hpMKZFlpRCrHh+a665Zm5UHivllV7fkgj7ak5xi/ei5msS711cam4rTXkrvX5T3o7r0n41H1dq/l3aVnrcjL4H11xzTbr66qtzpVx8BusSodbnn3+eP3tRFVbaFkHnlOf597//nT+LU047nBHx+Y3PUTzXIqaMxmsVjftLryXQOMV/0+IfmrEYQrn/BwZQPr4LAN8DFO3DDz+c4X2bXAAVjcOHDx8+1QpjUb0Ul6gu2n777fO2+EXr3r179T5RuRGhxZS9e2r2ioopffFLWjpGTCWLFfZKIjwoTS+rjwgFplXVUgpVonKr3FPupjSz44kvt+jVFb255pxzztxzK6Y6xjS10vF23nnndO+996bjjz8+vfvuuzlI/Pbbb9PDDz+cq4BqrnJYel1qvo5xqbmtNAWv9PqV7is9tnT/9I5VCm5m5DlHs/Qrr7wyB6ARzLz88su17i81Uv/yyy9zRd0OO+yQq+lK2yKwitdhxRVXzGHUY489lqeCRghan89AadrdlK9NQyi9hvHeNraAFKhb/L7Wt5ISaD58FwC+ByjKzBQ+NLkAKpo1xy9PNGuOP+ZLou9TNL3eYostck+oCIqisqZm756oXIo/9KeV/Eb1SFSz7L///tVVMNHrp+Z0pvi55sp5s9P8C3ZpUuc84ogj8vsS0xgjGIl+R/vss0+uUovpd1FVdccdd6Qrrrgih04333xzfr0jiCoFgI1drLZYCqLiMqVYmW9aYuXGqPyKwCmmk8ZrtNxyy+WV/KI6DAAAAJqLVlWlrsVNSKwSFlOett122zw9Lpp633bbbXna1p///OdciRI9oqInz6GHHporo6IyJbbF4zbaaKM6jxvTwaKBdFyXppxFJcoTTzyRK3Wi8immk0VoEg3MZ9Zbb72Vr3v37l3n/TFlcMiQIXn62pQVJpWVVamiojyr8DXkuS+66KLc0P1vf/tbgxyvuZuRht81e4RFiBWfo/j8NHQF1M99PoHGJf67GBXBEWr7v53QcvkuAHwPULTp5RxNugIqHHbYYblHToROERZFX52YJhdToUpT7mK1uuixE1UpI0aMyFO6YurTtMKnEOHUb37zm1r9jvbaa69cWRUVOZHVHXPMMfUKn2ZVucKnWTn3Sy+9lKfdlfpBvf3223kK3rHHHtvgY2yuNtlkkzzt9OfE6xtTRwEAAKCxatNU5xhGIPRz07RinwMOOCBfZlSspjelqCw599xz6z3Wli6CkaFDh+bKnKhMO+6449KAAQPKPawmI6YrllblmxbVSAAAADR2TTKAommInk+PPvpouYfRpC2//PLlHgIAAADMsv9bFgwAAAAACiKAAgAAAKBQAigAAAAACiWAAgAAAKBQAigAAAAACiWAAgAAAKBQAigAAAAACiWAotF7/vnn0y233FLvx//000/pN7/5TVpmmWXS6NGjZ+qxV155Zdpjjz3qfW4AAABAANVkVFZWtshzh3/84x/ptttuq/fjzz333PTiiy/O1GMiqPr73/8+S+cFAAAA/k+b//+aRq6ioiI9cc916ZsRX87W887TtVvqv+uBqam655570sMPP5wOOOCAdM0118zw49Zcc81CxwUAAAAtiQCqCYnw6ethn6am5LnnnksXXnhh+uSTT9IvfvGLtNRSS6Wnnnoq/etf/0oTJkxIG2+8cTruuOPS4MGD875RbbX11lunU045JbVt2zZPgStVIcUUurD66qun22+/fbrnfumll3L10/XXX5+++OKLmQ6uwkUXXVSv5w0AAEBtlZVVqaKiVbmH0WjG0dIIoChMBE2HHnpo2nbbbdPhhx+ep7Xdd999U+136aWXpl/96lfp/PPPT++88066+uqr0wILLJAfu/3226f3338/vfrqqznICnPOOed0z/3pp5/mc5588sk5sJrZAKpv377V5xo7duxMPRYAAICpRegzaOBraeTw8v2NNf+CXdKOA1Yq2/lbMgEUhaiqqkoXXHBBrnCK65KoajrxxBNr7XvGGWeknXfeOf+80UYbpa+//jrdcccd6ZBDDkk9e/ZMCy20UJpjjjnSWmutVetx48ePr3U7jt2uXbv03XffpYMOOiiHV7vsskuhzxMAAIAZF+HTV0O/K/cwKANNyClETLmLKqSYTjc9nTt3rnW7X79+6ZtvvkkjR4782cetvPLKtS6nnXZa3h6BV7du3dIRRxyRJk6cmC8//vhjvm/y5Mn5AgAAAMw+KqAoRARIYcEFF5zpx3bp0iVfjxo1Kk/Fm16fppJ55503X8dUvxdeeKF6Gl1N6623Xq7Kiml+AAAAwOwhgKIQ88wzT74eN27cTD82puCF+eabL1+3alV3c7i6AqZw7LHH5lXvanr22WfzKng33nhj6tGjx0yPCQAAAKg/ARSF6N69e+rYsWP6z3/+k6uOSn744YfpPvbRRx9NSy+9dHX1U1REjRkzJq+QV1Ex/Vmjiy222FTbPv7443y9/PLLV1dKhWHDhqXvv/8+LbHEEjP83AAAAICZI4CiENEMfNddd01/+tOfco+npZZaKr3yyivp9ttvn6qq6c4770yTJk1KHTp0SI8//nj65z//WWuKXJ8+fXIl1TnnnJNXtIsQK1bWawjHH398Htd7771Xa/vgwYPzdayAF83OS7eXW265BjkvAAAAtCQCqCZknq7dmtQ5owl4BEfXXXdd+umnn9Iaa6yR9tlnn3T99denTp06Va9iF8HTH//4x1yNtMgii6Qrr7wyr4ZXsv7666f99tsvPfDAA+nee+9NW221VYMFUNMSK+jVdXvKoAoAAACYPgFUExHTz/rvemDZzj0jU9+m1L59+3TWWWflS8lFF12UFl100VwhVbLDDjukzTff/GePddxxx+VLfe244475MqVSRdaUfi5oihX1YmW96ZljjjlSmzZ+xQAAAMBfx01EfQKgcp/7pZdeytPboidT9IN6++23c+ATTcKbsvvuuy+dccYZ093vkksuydVaAAAA0NIJoChU9HQaOnRonoK38MIL5yqmAQMGpKasf//+M9QLKqYTAgAAAAIoChQ9n2JFu2np0aNHk+ypNN988+ULAAAAMGPKN68LAAAAgBZBAAUAAABAoQRQjVBVVVW5hwBT8bkEAACgvgRQjUjbtm3z9YQJE8o9FJjK+PHjU6tWrao/pwAAADCjNCFvRFq3bp3mnnvuNGLEiHy7Y8eO+Q9+mFGx2uDEiROrP08NUfX0448/pu+++y5f4vPZEMcFAACgZRFANTILLbRQvi6FUDAzKisrc2DUpk2bVFHRcAWOETp169YtzTXXXA12TAAAAFoOAVQjExVP8Yd+165d0+TJk8s9HJqY77//Pn388cdp4YUXTh06dGiQY0aYFQGUajwAAADqSwDVSMUf/KY6UZ8KqDDHHHOk9u3bl3s4AAAAkGlCDgAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAEChKiurUmPRmMYC0JK0KfcAAACA5q2iolUaNPC1NHL42LKOY/4Fu6QdB6xU1jEAtFQCKAAAoHARPn019LtyDwOAMjEFDwAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAGgROnWZI1VWVqbGorIRjaVobco9AAAAAIDZoX2HtqmioiI9cc916ZsRX5Z1LPN07Zb673pgaikEUAAAAECLEuHT18M+LfcwWhRT8AAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEI12QDqrbfeSocddlhae+210/LLL58OOOCAqfa58cYb00YbbZRWWGGFtOWWW6YHH3xwqn1uv/32tOGGG6Z+/fql0047LU2aNKnW/QMHDkzbbbddqqqqKvT5AAAAADRXbVIT9Oijj6ZjjjkmbbLJJunII49M88wzT5owYUKtfW677bZ06aWXpoMPPjj16tUrvfjii+mEE07I+66//vp5nzfffDOdddZZ6fDDD0/dunXLPy+66KJp3333zfdHGHXDDTekE088MbVq1aoszxUAAACgqWtyAdTw4cPTySefnI4//vi011571blPVCtdf/31ac8990yHHHJI3hZVTl999VW67rrrqgOoZ599Ni288MI5pAqvvPJKeuaZZ6oDqKiY6ty5c+rfv/9se34AAAAAzU2Tm4J31113pZ49e1aHT3VNjfv444/T119/nTbYYINa2yOEev3119P333+fb48cOTLNP//81fd37do1Py78+OOPOaw66KCDVD8BAAAAtKQA6oUXXsjT6KLn06qrrpp69+6dttlmm/T8889X7/Ppp5/m6wUXXLDWY3v06JF++umn9MUXX+Tbc801Vxo/fnz1/ePGjUtzzz13/vmhhx5Kbdu2zb2jgh5QAAAAAC1kCl6ESx07dky777572nvvvXM1UzQK/+1vf5uv+/btm4OkEPvVVLo9duzYfB373nTTTXnqXfSAiul3m222WQ6povopjvnDDz+kM844Iz355JOpffv2+ZwHHnhgvccfQdaU/aqgoZSq+0rXQMvkuwBoTN8FMZugQ4cOqTGJ18T/YKYlaCzfA431u6Cx+L4JfyfFuGd01liTC6AiXIoAaL/99qvetu666+bgKFa0i1CppHXr1j97rJiSF/2d9thjj3x72WWXzcf961//mkOorbfeOgdR0SvqvPPOy5VTF1xwQVpllVVy9VV9TJ48OQ0ePLhej4UZ9cknn5R7CEAj4LsAaAzfBfEHZywK1JgMGTKkUfxBDi3le6Cxfhc0FkOa+HdSu3btmmcANcccc+SqpCmf7EorrZTftBCNw8OU+5Wm23Xp0iVfV1RUpMsuuyyvchdv9iKLLJLTu2uvvTaHXG3atMlT/jbddNMccIU777wzb6tvABXT+pZccsl6PRamJz7H8R+XWM3R/12Alst3AdCYvgsaYz/VxRZbrMlWG0BT/B5orN8FjcViTfg76cMPP5zhfZtcABV9nEo9nmqKaXUxRS5EkBTiF6179+61mpNH6BTHqKlmr6jHH388/5Juv/32+faoUaPSaqutVn3/AgsskLfNyi/dlFMDoaHFf1x8zgDfBUDwXTC1cv8hDrOb74HGrUMT/k6amWCxyTUhj+l2f//732uFQGPGjMmr262++ur59uKLL56Doueee67WY6NyacUVV5zmmxuJ4zXXXJP233//XKkU5ptvvjRx4sTqfeLnmivnAQAAANDMKqD22Wef9OCDD6YBAwakgw46KFc03XLLLalTp05pr732qk7gopfTxRdfnOadd97c2+nll19OTz31VLr66quneeynn346ffvtt2nnnXeu3rbeeuulJ554Iv3444859Prggw/S6aefPlueKwAAAEBz0OQCqKhs+vOf/5zOOuus9Pvf/z6HTeuss0764x//mOaZZ57q/WK1umj4fffdd6cRI0aknj175kbiG2200TSPHeHUb37zm1oNtCLUiil/MSUvKqSOOeaYWo3OAQAAAGhmAVT4xS9+8bOVTCGCqQMOOCBfZtSgQYOm2hbT9c4999x6jRMAAACAJtgDCgAAAICmRQAFAAAAQKEEUAAAAAAUSgAFAAAAQKEEUAAAAAAUSgAFAAAAQKEEUAAAAAAUSgAFAAAAQKEEUAAAAAAUSgAFABSmsrIqNRaNaSwAAC1Nm3IPAABovioqWqVBA19LI4ePLes45l+wS9pxwEplHQMAQEtW7wBq5MiR6cYbb0zvvPNO+uqrr9If/vCH1K9fvzR48OC8fb/99ku9evVq2NECAE1OhE9fDf2u3MMAAKCpTcF766230mabbZYeeuih1LZt2/T555+nH374Id+37LLLpjfffDPdfffdDT1WAAAAAFpKBdRFF12UFlxwwXTvvfemcePGpQ022KD6vlatWqVNNtkkPfvssw05TgAAAABaUgVUVDhts802qXPnzjlwmlK3bt3SsGHDGmJ8AAAAALTEAKqioiJfpmXo0KGpY8eOszIuAAAAAFpyANW3b9/0t7/9rc77vv3229wbapVVVpnVsQEAAADQDNQrgDr88MPThx9+mPbee+/0j3/8I2/7+OOP05///Oe04447prFjx6YDDjigoccKAAAAQEsJoPr06ZNuvPHG9NVXX6VTTjklbzv//PPzz5WVlemPf/xj3gcAAAAA6rUKXlh99dXT448/nt599900ZMiQVFVVlbp3755WWGGF1Lp164YdJQAAAAAtK4B68MEHcx+oRRddNC277LL5UtMbb7yRJk+enFZdddWGGicAAAAALWkK3oknnphefvnlad7/97//PR177LGzMi4AAAAAWnIAFdPtfk6HDh3S6NGj6zsmAAAAAFriFLyvv/46jRgxovr2l19+md5+++1a+0QD8k8++SQNHDgwLbzwwg07UgAAAACadwB1zz33pKuuuiq1atUqX6677rp8qas6qnPnzumcc85p6LECAAAA0JwDqE022SSvchcB00knnZS233771K9fv1r7VFRUpPnnnz/17t07zTnnnEWMFwAAAIDmGkDVXO0uKqBiFbzFFlusyLEBAAAA0JICqJp22GGHhh8JAAAAAM1SvQKo8Oyzz6aHH344jRo1Kjcfn1JUSd16662zOj4AAAAAWmIA9eSTT6bf/e53ad55503ffPNN6tatW+rUqVO+b/jw4WnChAmm5wEAAACQVaR6uOmmm9Jaa62VHnvsseqm5FENFZcbb7wx7xPbAAAAAKBeAdR7772X1l133bzSXUy1Gz16dPV9ffr0ySvkXX/99Q05TgAAAABaUgAVPZ/atGmTw6f55psvffDBB7XuX2qppdJbb73VUGMEAAAAoKUFUBE6jRw5Mv/ct2/fPBVvzJgx1fe//fbbqX379g03SgAAAABaVhPyxRdfPP3vf//LP++1117p6aefztPu1l577TR06ND00ksvpX333behxwoAAABASwmgzj///LzSXVhttdXSJZdckq6++ur00EMPpQUWWCAdcsgh6aCDDmrosQIAAADQUgKomIIXl5ItttgiX2p6991307LLLjvrIwQAAACg5fWAmp7nnnsuDRgwoIhDAwAAANCcK6B++umnHC59/PHHqXPnzmnllVdOSy+9dK197r777vSHP/wh9ezZs6HHCgAAAEBzDqDGjh2b9tlnn7zCXVVVVd7WqlWr3Hw8Aqc2bdqkCy64IN18881p1VVXTVdddVWR4wYAAACguQVQV1xxRXrnnXfSb3/729S/f/9UUVGRV7+77rrr0lxzzZW+/PLL9Le//S1tt9126ayzzkpt27YtduQAAAAANK8A6u9//3vafPPN02GHHVa9LabfdenSJQdOUQ0V9x188MFFjRUAAACA5hxAjRgxIvXp02eq7THdLhx33HF5ih4AAAAA1GsVvMmTJ6cOHTpMtX2eeebJ14svvviMHgoAAACAFmSmVsGLPk/RhLymUaNG5evPPvtsqvuWX375hhgjAAAAAC0lgIqG43Gpy9lnn537QIVYJS9+Hjx4cMOMEgAAAIDmH0Cde+65xY4EAAAAgJYdQO2www7FjgQAAACAlt2EHAAAAADqQwAFAAAAQKEEUAAAAAAUSgAFAAAAQKEEUAAAAAAUSgAFAAAAQOMNoKqqqtKwYcPSf//73zRmzJi8rbKyMk2aNKmhxgcAAABASw2gBg4cmNZee+208cYbp9133z29/vrrefv777+f+vbtmx544IGGHCcAAMAs6dRljvw/zBuDxjIOgNmlTX0edMstt6Tzzz8/7bLLLql3797p1FNPrb5v2WWXTf369Ut//etf0w477NCQYwUAAKi39h3apoqKivTEPdelb0Z8WbZxzNO1W+q/64FlOz9Akwmg7rrrrtS/f/905plnpuHDh091/xprrJHuuOOOhhgfAABAg4rw6ethn5Z7GAAtSr2m4A0dOjSttNJK07y/TZs21T2hAAAAAGjZ6hVAzTfffHVWPpW88cYbqVu3brMyLgAAAABacgAV0+/uu+++9NFHH01132OPPZaeeuqptMkmmzTE+AAAAABoiT2gDj/88PSf//wn7bTTTmmVVVZJrVq1yj2frr/++vTf//43Lb744um3v/1tw48WAAAAgJZRAdW5c+d09913p4MOOiiNGjUqzTHHHOnll19Oo0ePTvvvv3+699578z4AAAAAUK8KqBChUwRQcQEAAACABq2AAgAAAIBCK6BOPPHEGaqQWmCBBdKqq66a+vXrV5/TAAAAANBSA6i//e1v6fvvv0/t27ef6r4ff/wxX+K+2CcalK+22mrp2muvTR07dmyIMQMAAADQ3AOoNddcMzccv+uuu6a67+OPP07bb799uuKKK3Ll0xNPPJErpq688sp0/PHHN8SYAQAAAGjuPaD+/e9/p/XWW6/O+xZffPEcQF111VWpXbt2aeutt06/+tWvctUUAAAAAC1PvQKoH374IVVVVU3z/gih3n333erbiy66aBoxYkT9RggAAABAywugevXqlR599NHc46ku//nPf1Lnzp2rb48aNarOflEAAAAANH/16gF15JFHpv322y/ttNNOacCAAbniKabbDR8+PAdTTz/9dNp///2r93/ppZfSwgsv3JDjBgAAAKA5B1DRXPy6665LZ555ZvrDH/6QV7oLMS1vjjnmSPvuu2864ogj8rbKysrcByqm4QEAAADQ8tQrgAprr712biwevZ4++eST9OOPP6b5558/9e7dO3Xq1Kl6v4qKirTbbrs11HgBAAAAaCkBVMmyyy6bLwAAAADQ4AHUyJEj07Bhw9LEiRPrvH+11VablcMDAAAA0FIDqGg2fvzxx6eXX365zvujF1T0hRo8ePCsjg8AAACAlhhAnX766ek///lP2meffdKSSy6ZOnbsWN2IHAAAAABmOYCK8GnAgAHpuOOOq8/DAQAAAGhBKurzoPbt26eFFlqo4UcDAAAAQLNTrwBq8803T0888UTDjwYAAACAZqdeU/A23HDDdO+996YbbrghrbXWWtPcb/nll5+VsQEAAADQUgOo/fbbL19ffPHF6ZJLLpnqfqvgAQAAADBLAdS5555bn4cBAAAA0ALVK4DaYYcdGn4kAAAANEmVlVWpoqJVuYfRaMYBNFAABQAAACUR+lw08L/pi+FjyzaGHgt2SccMWKVs5wcKCqCeffbZ9PDDD6dRo0alysrKqe6PHlC33nprfQ8PAABAExLh00dDx5R7GEBzCqCefPLJ9Lvf/S7NO++86ZtvvkndunVLnTp1yvcNHz48TZgwIS222GINPVYAAAAAmqCK+jzopptuSmuttVZ67LHH8op3J510Uq6GisuNN96Y94ltAAAAAFCvAOq9995L6667bppzzjnzVLvRo0dX39enT5+0/fbbp+uvv74hxwkAAABASwqgoudTmzZtcvg033zzpQ8++KDW/UsttVR66623GmqMAAAAALS0ACpCp5EjR+af+/btm6fijRnz/5rNvf3226l9+/YNN0oAAAAAWlYT8sUXXzz973//yz/vtdde6emnn87T7tZee+00dOjQ9NJLL6V99923occKAAAAQEsJoM4///y80l1YbbXV0iWXXJKuvvrq9NBDD6UFFlggHXLIIemggw5q6LECAAAA0FICqJiCF5eSLbbYIl8AAAAAoEF6QAEAAABAoRVQ4YsvvkiPPvpoGjZsWJo4ceJU98cKeeecc059Dw80cZWVVamiolVqDBrTWAAAAFqiegVQ0XT88MMPTz/++GMOmupa8U4ABS1bBD6DBr6WRg4fW9ZxzL9gl7TjgJXKOgYAAICWrl4B1KWXXpp69OiRrrrqqrTEEkvksAlgShE+fTX0u3IPAwAAgKbYA+rzzz9PO+64Y1pyySWFTwAAAAA0fAC1+OKLp3HjxjX8aAAAAABoduoVQO2xxx7p/vvvT2PGjGn4EQEAAADQ8npAnXXWWbVuV1VV5Qqogw46KC2//PLTfNwpp5wy6yMEAAAAoPkHUHfccUed21977bV8qUv0hhJAAQAAADBDAdS7775b/EgAAAAAaJbq1QMKAAAAABo8gPr6669T//790/777597QE3LiSeemDbbbLM0evToGR4EAAAAAM3XDAdQ9957b/r888/T4Ycfnvs7TcshhxyShg0blgYNGtRQYwQAAACgJQRQzz33XFpjjTXSCius8LP79ejRI22wwQbp6aefbojxAQDMsk5d5kiVlZWpMWgs4wAAaHRNyMNHH32U9ttvvxnat3fv3umGG26YlXEBADSY9h3apoqKivTEPdelb0Z8WbZxzNO1W+q/64FlOz8AQKMPoCZPnpzmnHPOGdq3Q4cO6YcffpiVcQEANLgIn74e9mm5hwEA0OLM8BS8hRZaKH366aczXC21wAILzMq4AAAAAGhpAdRaa62VHnrooemubjdixIj0yCOPpNVXX70hxgcAAABASwmgov/TpEmT0r777psrnOry7rvvVu83o/2iAAAAAGjeZrgHVM+ePdMll1ySjj766LTNNtukvn37puWXXz517tw5jRs3Lv3vf/9Lb7zxRmrTpk0677zz0lJLLVXsyAEAAABoXgFU2HDDDdPDDz+cbrzxxvTMM8+kV199tfq++eefP+2www658mnxxRcvYqwAAADATGjbtm1q1apVuYcBMxdAhe7du6fTTz89X8aPH5+rnzp16pQroQAAAIDGIYKn5Xv1Sq3bzPSf/tDgZulTGMFTXAAAAIDGJ8Kn9y+5LE34/IuyjmOeVVZKi+w+oKxjoLzEoAAAADR5c3eZI1VVVqZWFTO81lahGtNYInwa//GQso6hQ4/uZT0/5SeAAgAAoMnr3KFtDnxGPHhZmjSqvNU+7ebrkbpuf0RZxwCNjQAKAACAZiPCp0lflbfaB5ha46gHBAAAAKDZEkABAAAAUCgBFAAAAACFEkABAAAAUKhmEUBdc801aZlllkmPP/54re033nhj2mijjdIKK6yQttxyy/Tggw9O9djbb789bbjhhqlfv37ptNNOS5MmTap1/8CBA9N2222XqqqqCn8eAAAAAM1Rkw+gnnjiiXTVVVdNtf22225Ll156adppp53SlVdemdZee+10wgknpOeee656nzfffDOdddZZaZdddsn3/fWvf0133HFH9f0RRt1www3p4IMPTq1atZptzwkAAACgOWnSAdQ777yTjj/++HTsscfW2h7VStdff33ac8890yGHHJIrnE4++eS06aabpuuuu656v2effTYtvPDCOWDaYYcdUv/+/dMzzzxTfX9UTHXu3DlvBwAAAKCFBVBff/11+u1vf5sOPPDAtMkmm9S67+OPP873b7DBBrW2RxD1+uuvp++//z7fHjlyZJp//vmr7+/atWt+XPjxxx9zWHXQQQepfgIAAABoaQHUxIkTc9XS6quvngOiKX366af5esEFF6y1vUePHumnn35KX3zxRb4911xzpfHjx1ffP27cuDT33HPnnx966KHUtm3b3Dsq6AEFAAAAUD9tUhN00kknpdatW6ezzz67zvsjSAodO3astb10e+zYsfm6b9++6aabbkqvvPJK6tatW55+t9lmm+WQKqqfosLqhx9+SGeccUZ68sknU/v27dPee++dq67qK4KsCRMm1Pvx8HNK1X2l63KJqsEOHTqkxiReE0EyLYXvgsbPdxKzg++Cxq+5fBd4jxvvexx9jb03jd/3Tfi7IMY9o7PGmlwAFZVJ//73v9Ndd92Vn2hUQ5VWrotpczVXsYuQ6ufElLzo77THHnvk28suu2zab7/9cjPyCKG23nrrHERFr6jzzjsvV05dcMEFaZVVVkmrrrpqvcY/efLkNHjw4Ho9FmbUJ598Utbzx3/kevXqlRqTIUOGlP0f4DC7+S5ovHwnMTv5Lmi8mst3gfe48b7H8d6UZvnQeA1p4t8F7dq1a54B1OjRo9Pw4cPTRhttNNV9Rx99dOrSpUsOiUJUL9VUmm4X+4SKiop02WWXpRNPPDG/2YssskgOta699tpc5dSmTZv0wgsv5OblURkV7rzzzrytvgFUTOtbcskl6/VYmJ74HMc/MhdddNGy/p+Oxtg3bbHFFmuy/1cBZpbvgsbPdxKzg++Cxq+5fBd4jxvve1yzQIPGa7Em/F3w4YcfzvC+TS6A2mqrrfLUuZqicfihhx6ajjrqqLTWWmtVT7WL/+B27969VnPyCJ2iF1RNNXtFPf744/k/1ttvv32+PWrUqLTaaqtV37/AAgvkbbPy5Tzl1EBoaPGPTJ+z2pQe0xL5Lmi8fCcxO/kuaLx8FzR/5X6PhYNNQ4cm/F0wM5+xJhdARQAUl5pKTcWjgql37945OYx9nnvuubT22mtX7xeVSyuuuOI039x43DXXXJP233//XKkU5ptvvjzNryR+rrlyHgAAAADNLICa0QQuejldfPHFad555829nV5++eX01FNPpauvvnqaj3v66afTt99+m3beeefqbeutt1564okncn+pqHz64IMP0umnnz6bngkAAABA09csA6gQq9VFw++77747jRgxIvXs2TM3Eq+rd1RJhFO/+c1vajXQ2muvvdKnn36ap+RFhdQxxxwz1RRAAAAAAJp5ABU9nd57772pqqAOOOCAfJlRgwYNmmpbTNc799xzG2ScAAAAAC1RRbkHAAAAAEDzJoACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAAAAKJYACAAAAoFACKAAAmoWqysrUGDSWcQBAY9Km3AMAAICG0KqiIo148LI0adQXZRtDu/l6pK7bH1G28wNAYyWAAgCg2YjwadJXQ8o9DABgCqbgAQAAAFAoARQAADRTbdu2Ta1atSr3MADAFDwAAGiOInhavlev1LqNf/IDUH7+awQAAM1UhE/vX3JZmvB5+Rqzz7PKSmmR3QeU7fwANA4CKAAAaMYifBr/cfkas3fo0b1s5wag8dADCgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAIBCCaAAAAAAKJQACgAAAJqhVq1alXsIUE0ABQAAAA2odae5U2VVZbmHkdq3b1/uIUC1Nv/vRwAAAGBWVbTvlCpaVaQrXro5Df3uq7KNo+9Cy6df99mubOeHmgRQAAAAUIAIn4Z883nZzv+LLguW7dwwJVPwAAAAACiUAAoAAACAQgmgAKAZatu2rZVvAABoNPSAAoBmJoKn5Xv1Sq3b+M88AACNg3+ZAlAvlZVVqaKicVTYNKaxNBYRPr1/yWVpwudflG0M86yyUlpk9wFlOz8AAI2HAAqAeonA56KB/01fDB9b1nEst9i86YDtVoi6n1RuVZWVqVVF45ndHuHT+I+HlO38HXp0L9u5AQBoXARQANRbhE8fDR1T1jH06No5hz4jHrwsTRpVvmqfdvP1SF23P6Js5wcAgMZMAAVAsxDh06SvylftAwAATFvjmScAAAAAQLMkgAIAAACgUAIoAAAAAAolgAIAAACgUAIoAAAAAAolgAIAoN4qK6vKPQQAoAloU+4BAADQdFVUtEoXDfxv+mL42LKOY+Vlu6Y9t+xV1jEAANMmgAIAYJZE+PTR0DFlHUOPrp3Len4A4OeZggcAAABAoQRQAAAAABRKAAUAAABAoQRQAAAAABRKAAUAAABAoQRQAAAAABRKAAUAAABAoQRQAAAAABRKAAUAAABAoQRQAAAAABRKAAUAAABAoQRQNGlVlZWpMWgs4wAAAIDGqE25BwCzolVFRRrx4GVp0qgvyjaGdvP1SF23P6Js5+fndeoyR6qsrEwVFeXP2xvLOAAAAGY3ARRNXoRPk74aUu5h0Ei179A2hz5P3HNd+mbEl2Ubxzxdu6X+ux5YtvMDAACUkwAKaBEifPp62KflHgYAAECLZC4IAAAAAIUSQAEAAABQKAEUAAAAAIUSQAEAAABQKAEUAAAAAIUSQAEAAABQKAEUAAAAAIUSQAEAAABQKAEUAAAAAIUSQAEAQDPUqlWrcg8BAKoJoAAAoIG07jR3qqyqTI1B+/btyz0EAKjW5v/9CAAAzIqK9p1SRauKdMVLN6eh331V1rH0XWj59Os+25V1DABQIoACAIAGFuHTkG8+L+sYftFlwbKeHwBqMgUPAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKmpFWrVqltm3blnsYAAAAUIsACmZR605zp8qqytQYdOjQIfVavlcOogAAAKCxaFPuAUBTV9G+U6poVZGueOnmvORyOXWfc6F02Br7pslpclnHAQAAADUJoKCBRPg05JvPyz0MAAAAaHRMwQMAAACgUAIoAAAAAAolgAKAZsZCBAAANDYCKABoZititm/fvtxDAACAWjQhB4BmtiJm34WWT7/us11ZxwAAADUJoJhplZVVqaLC9A6Axroi5i+6LFjW8wMAwJQEUMy0CJ8uGvjf9MXwsWUdx8rLdk17btmrrGMAAAAApk8ARb1E+PTR0DFlHUOPrp3Len4AAABgxmhCDgAAAEChmlwA9f7776ejjz46bbbZZmnFFVdMG220UTr77LPTuHHjau33wAMPpC222CKtsMIKaeONN04333zzVMd67LHH8nFWXXXVdPjhh6fvvvuu1v3PPvtsWmedddIPP/xQ+PMCAAAAaK6aXAD14osvpk8++STttttu6fLLL0977rlneuihh3IoVfLUU0+lE088Ma277rrpyiuvTDvssEO6+OKL05133lm9z/Dhw9Oxxx6bA6Yzzzwzvfbaa/l4NV199dVp3333tZw1AAAAQEvqAbXtttumvffeu9a2ueeeOx1//PHpq6++SgsttFC64YYbUv/+/dNJJ52U799www1zhdT111+fg6vwz3/+M1VUVKQTTjghtW3bNn388cdp0KBB6dRTT833v/DCC+mzzz5Lv/rVr8rwLAEAAACajyZXATXvvPNOta1nz575esSIEWnChAnpzTffTBtssEGtfSKE+vLLL3PQFEaOHJmDqwifQteuXdPXX39dq/ppn332SR07diz4GQEAAAA0b00ugKpLBE6tW7fOQdTnn3+eKisr04ILLlhrnx49euTrqGoKc801Vxo/fnz1/VEhFdvCyy+/nD744IM0YMCA2fo8AAAAAJqjJjcFb0qjR49ON910U24mPs8881RXOE1ZuVS6PXbs2Hzdt2/fHDo98sgjafXVV0+PPvpoWnnllaurn6K3VIcOHdI555yTG5qH7bffPk/Zi7CrvqqqqnKVVlPVqlWr/LrQuE2cODF/1srF52Tavv/++7K+Nw3FewyzxncBEHwXAE39uyDGHd8BzT6AmjRpUjriiCPyE46m4zVNLyRadtllc4PxUvPy7t27pwsuuCC9+uqr6e23387Nyx9++OHcuDyalMc5Tj/99Lyq3nbbbVfvMU+ePDkNHjw4NVXxH5ZevXqVexhMx7Bhw/KXWLn4nEzbkCFDyvreNBTvMcwa3wVA8F0ANIfvgnbt2jXvAOrHH39MxxxzTHrnnXfSbbfdlns4hc6dO+frH374odb+pel2Xbp0qd4Wjcv333//9M0336RFFlkktWnTJu23335p9913T3POOWduRL7qqqumHXfcMe//l7/8JW+blQAqek4tueSSqama0WST8orpqPF5Lhefk2lbbLHFmuz/3ajJewyzxncBEHwXAE39u+DDDz+c4X3bNNXwKSqXXnzxxTz9rmbaHr2eYnW7Tz75JE+tKylNzSs1LK/Z1LzU2Dx6SUUF1EUXXVQ9vW/++eev3neBBRZIo0aNmuUvZ43NKcrc7edMVZWVtYJWGhfl6UDwXQAE3wVAU/8umJkAuskFUFHZFNPuXnvttXTzzTenPn361Lq/U6dOeZrcc889l375y19Wb4/KpWhMvvjii0/z2NH7abfddsu9pEIEUzUrqaKvTs1AChqbjm07pFYVFen9Sy5LEz7/omzjmGeVldIiu2viDwAAQBMNoE466aT0j3/8IzcDjybiUQVVEtPmInyKaXWHHXZYOv/881O/fv1yz6WBAwfmx0wrnYupfLH6XTQdL1lvvfXShRdemJuGRznc66+/ns8PjV2ET+M/HlK283fo0b1s5wYAAKDxaXIB1Ndff52n4J111llT3RdT7m6//fbUv3//dPbZZ6cbbrgh347+UEceeWTu7TQt11xzTa6YKk3HC1tuuWUOr3bZZZd8e4cddkibb755Qc8MAAAAoHlqcgFUBEozYqeddsqXGRWr3k0pVtI77rjj8gUAAACA+qmo5+MAAAAAYIYIoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEI16wDqzTffTL/+9a/TiiuumNZYY410+umnp/Hjx9fa57333ku77rprWmmllfL1Bx98UOv+0aNH5/veeeed2Tx6AAAAgOah2QZQX375Zdpnn31Sp06d0sUXX5yOOuqo9NRTT6WTTz65ep+qqqp09NFHpw4dOqQLLrggzTHHHHm/2F5y8803p379+qVevXqV6ZkAAAAANG1tUjN155135vDp6quvTu3atcvb5p9//vTb3/42HXnkkWmRRRZJX3zxRa54OuOMM9Kqq66a5p577rT77runoUOHph49eqRvv/02H+eWW24p99MBAAAAaLKabQXUSy+9lNZaa63q8Cmsu+66qW3btulf//pXvj1y5Mh8vcACC9S6Lm2P4Cmm3/Xp06cMzwAAAACgeWi2AdRnn32WFlxwwVrbInzq2rVr+vTTT/PtueaaK1+X+kKNGzeuevvYsWPTHXfckQ4++ODqx9ecmgcAAADAjGlV1UxTleWXXz4ddthh6cADD6y1fZtttkl9+/ZNf/jDH9KkSZPShhtumDbffPN0yCGHpCuvvDI9+eST6ZlnnknXX399evnll9Ntt92WHnzwwXTppZemb775JjczP++889K8884702N69dVXc4gVQVhT1qpVqzRm3KT040+VZR3HHG1bp84d26afJoxJ6aefyjaOVm3bpYr2ndN3E8emHyvLN47QrnW71LldxzR5zJhU9WP5xlIxR7vUpnPnNH7cpFRZ5s9J27atU/uObdP348emyp9+LNs4Klq3SR06dWlWQbbvgtp8F0zNd8HUfBcUx3fB1HwXTM13QfP+Lmgs3wON6bugsXwPNKbvgsbyPdBcvgsmT56cf/9XXnnlltsDKlRU/HyBV0zPO/XUU9Pxxx+fq52iGfmFF16YJk6cmIOnyy+/PH3++ee5cflee+2Vm5H//ve/z03Nzz777JkeT7wpNa+bsrk6/7+pjeXWuuP/VbKV25xzdEmNRdv/v7qv3Do1os9JfLE3Bs3h978m3wVT810wNd8FU/NdUBzfBVPzXTA13wXN+7ugsXwPNKbvgsbyPdCYvgsay/dAU/8uiLHP6PibbQDVuXPnHCRNKabbxX0lUf203nrr5YbkPXv2zCFUVD8tscQSudrpvvvuS61bt86Ny6Nyaccdd0x//vOf6zWm6CcFAAAA0NI02x5QCy+8cBoyZMhU4dNXX32V76upY8eOaemll87h0/fff5/+9Kc/Vfd+Gj16dF4drzRtLnpIjRo1ajY+EwAAAICmrdkGUKuvvnpeCS/6PJXE7Z9++ilXNk3LXXfdlSuh1llnnXw7ej3VrKT64Ycf0vzzz1/w6AEAAACaj2YbQO222265mikakT/99NN52twZZ5yRNttss7TYYovV+ZgImm6++eZaK9+ttdZaeXW8wYMH59svvvhinrIHAAAAQAtfBS+89tpr6fzzz0/vvPNOnl4X4dNxxx1XqwdUTbfffnt64IEH0qBBg2ptf+ihh9INN9yQf1500UXzCnoxLQ8AAACAFh5AAQAAAFB+zXYKHgAAAACNgwAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoAAAAAAolAAKAAAAgEIJoKAZGTRoUNpoo43KPQygDN5999101FFHpc022yz16dMnrbPOOumEE05IX331VbmHBsxGX3zxRVpmmWXqvFx55ZXlHh5Qxr8HHnjggbTFFlukFVZYIW288cbp5ptvnu3jo2VrU+4BALPuu+++y398xj8sW7VqVe7hAGXwwgsvpPfffz8NGDAgLbLIImno0KHpj3/8Y3rrrbfSI4884rsBWphDDjkkrbrqqrW29ezZs2zjAcr798BTTz2VTjzxxLTnnnumNddcM7399tvp4osvTu3bt0+77bZbWcZMyyOAgmZg++23z39shu7du5d7OEAZbLvttmmfffZJFRX/r7i5Y8eO6fjjj08ff/xxWmKJJco6PmD2WnrppdNaa61V7mEAjeTvgRtuuCH1798/nXTSSfn2hhtumMaNG5euv/56ARSzjSl40AxcddVV6Z577klbbrlluYcClMkCCyxQK3wqiW3zzDNPWcYEAJT/74EJEyakN998M22wwQa1tkcI9eWXX+b/UQWzgwAKmoFevXqlvn37pvnnn7/cQwHKrLKyMpfh/+Mf/0iXX355OuCAA9K8885b7mEBs1lVVVWaPHlyuYcBNIK/Bz7//PP874MFF1yw1vYePXrk688++2y2jZOWzRQ8AGhG/v3vf+f+DiFK6g8//PByDwkogyOOOCJfzznnnGmVVVZJhx56aG48DLQ8MdWuNDW/ptLtsWPHlmVctDwCKABoRpZffvk0cODAvBLWjTfemPtCxSo3rVu3LvfQgNlgrrnmSuecc05aaKGFUps2bXJlw6233pp233339PDDD2tEDi2YfwtQbgIoAGhGOnfunFe+ikuU42+zzTbp6aefzo1HgeavS5cuaaeddqq+3a9fv9znZd11101//etf00EHHVTW8QHl+bdB+OGHH2ptHz9+fPX3BswOekABQDNVWgVn+PDh5R4KUEbREyam4o0ZM6bcQwHKIHo9xaIkn3zySa3tpebjKiOZXQRQANAM1BUy/etf/8rXSy65ZBlGBJRDXb1c3nnnnfTtt9/mqkig5enUqVPuAffcc8/V2v7CCy/kxuSLL7542cZGy2IKHjQDH374YV7pZvTo0WnSpElp8ODBefsSSyyR2rVrV+7hAbNBTKuJni+bbLJJXvUu/uD805/+lNZbb7205pprlnt4wGwS/Z9GjBiRNttss/yH5ZAhQ3I/uD59+tS5PDvQMv4e2H///dNhhx2Wzj///Dw1N+6PnpEnnHBCatWqVbmHTwvRqirWaAWatI022igNHTp0qu3R96W0vCrQvA0aNCg3GI5y+lGjRuUpN5tvvnn+x+aUq94AzdczzzyTbrvttvTRRx/lP0TnmWeetNVWW+VV8Ep9YICW+ffA/fffn2644Ya8UEnXrl3TgAED0n777VeG0dJSCaAAAAAAKJQeUAAAAAAUSgAFAAAAQKEEUAAAAAAUSgAFAAAAQKEEUAAAAAAUSgAFAAAAQKEEUAAAAAAUSgAFAAAAQKEEUAAAzdgee+yRtt5663IPAwBo4dqUewAAAKQ0aNCgdOKJJ1bf7tChQ5p33nnTCiuskLbbbru08cYbN8h5vvvuu3TrrbemtddeO6288soNckwAgOkRQAEANCIHHnhg6tatW5o4cWL64osv0rPPPpv+9re/pa222iqdd955qV27drMcQF111VWpY8eOAigAYLYRQAEANCKbbrpp6t27d/XtqIq67rrr0uWXX54rok455ZSyjg8AoD70gAIAaMRat26dDj744LTjjjumgQMHpk8++aT6vjfffDPtt99+uZKpb9++ac8998zbpiUqqkpT+S644IK0zDLL5MsJJ5yQt33wwQf5GOuvv36e+hfH3XvvvdPLL788G54pANCcCaAAAJqACIIqKyvTY489lm+/8soracCAAWnUqFFp//33z5cRI0akvfbaK1/XZe65505HHHFE/nmzzTZLZ5xxRr5sv/32eduYMWPy1LwddtghHX/88emggw5K48aNS/vuu2965513ZuOzBQCaG1PwAACagKhUat++ffrwww9TVVVVOu2003LV0y233JKrpEJUL/Xv3z/deOON6aSTTprqGJ07d07bbLNNuuyyy9KKK66Yfv3rX9e6f9VVV82Xkp9++imvoLfJJpvk4KtXr16z4ZkCAM2RAAoAoImYc84507fffpvefffdNGTIkDz97uuvv661T4REgwcPrvc5nnrqqXTXXXel//3vf/lcJSNHjpylsQMALZsACgCgiRg7dmyaZ555cvgUptWQvGfPnvU6/s0335zOP//81L1797TTTjulxRZbLE/bO/roo3PVFQBAfQmgAACagJh69/3336dll122Ogw69thj0xJLLDHVvjFVb2bFdLtrrrkmV1DdeeedqUOHDtX3lab4AQDUlwAKAKAJuO2223IQtOWWW1Y3GZ9rrrnShhtuOFPHKYVJ0dC8ptGjR6fvvvsu93uqGT4BADQEq+ABADRiUe10ww03pHvuuSfts88+6Re/+EVaYYUV0kILLZT++Mc/pm+++abW/hEs/dyKdfPNN19q1apV+uSTT2ptj6l9bdu2TUOHDq21/bnnnksTJ05s4GcFALQ0KqAAABqRJ598MjcAj9Dnq6++Ss8//3z66KOP8up1RxxxRN6nTZs26fe//3065JBD0hZbbJG23Xbb3Lfpyy+/zE3Ee/funS699NI6j9+uXbu08sorpwcffDBXUHXp0iWHWTvssEM+x1/+8pc0xxxzpEUWWSS9/vrreTxTVksBAMwsARQAQCNy3XXXVQdFUa203HLLpaOOOipPjatpgw02yL2aYv8IjSZMmJCro/r165d+/etf/+w5zjnnnHT66afn1e7iPAceeGDefvLJJ+frRx55JF+vssoq6e6770577rlnQc8WAGgpWlVZ0gQAAACAAukBBQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABQAAAEChBFAAAAAAFEoABfx/7dgxAQAAAMIg+6c2xT6IAQAAAKQEFAAAAAApAQUAAABASkABAAAAkBJQAAAAAKQEFAAAAAApAQUAAADASgecOlafpRHb3wAAAABJRU5ErkJggg==",
      "text/plain": [
       "<Figure size 1200x800 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import os\n",
    "from glob import glob\n",
    "import numpy as np\n",
    "\n",
    "# Directory containing the files\n",
    "directory = \"/Users/hobbang/Desktop/bias/final_result/\"\n",
    "\n",
    "# Find all files ending with _weight_mc.csv\n",
    "files = glob(os.path.join(directory, \"*_weight_mc.csv\"))\n",
    "\n",
    "# List to hold data from all models\n",
    "all_data = []\n",
    "\n",
    "# Process each file\n",
    "for file_path in files:\n",
    "    model_name = os.path.basename(file_path)[:-13]  # Assuming '_weight_mc.csv' is 13 characters\n",
    "\n",
    "    # Read the CSV\n",
    "    testing = pd.read_csv(file_path)\n",
    "\n",
    "    # Compute llm_decision\n",
    "    testing['llm_decision'] = testing.apply(\n",
    "        lambda row: row['buy'] if row['llm_answer'] == 'buy' else (\n",
    "            row['sell'] if row['llm_answer'] == 'sell' else None\n",
    "        ),\n",
    "        axis=1\n",
    "    )\n",
    "\n",
    "    # Compute is_change\n",
    "    testing['is_change'] = testing['before_decision'] != testing['llm_decision']\n",
    "\n",
    "    # Compute change rate by delta\n",
    "    change_rate_by_delta = testing.groupby('delta')['is_change'].mean().reset_index()\n",
    "    \n",
    "    # Add model column\n",
    "    change_rate_by_delta['model'] = model_name\n",
    "    \n",
    "    # Append to all_data\n",
    "    all_data.append(change_rate_by_delta)\n",
    "\n",
    "# Concatenate all data\n",
    "if all_data:\n",
    "    df_all = pd.concat(all_data)\n",
    "\n",
    "    # Get unique deltas and models\n",
    "    deltas = sorted(df_all['delta'].unique())\n",
    "    models = sorted(df_all['model'].unique())\n",
    "\n",
    "    # Plot setup\n",
    "    fig, ax = plt.subplots(figsize=(12, 8))  # Adjust size as needed\n",
    "    \n",
    "    bar_width = 0.8 / len(models)  # Width of the bars\n",
    "    \n",
    "    positions = np.arange(len(deltas))\n",
    "    \n",
    "    for i, model in enumerate(models):\n",
    "        model_data = df_all[df_all['model'] == model].sort_values('delta')\n",
    "        # Assuming all models have the same deltas\n",
    "        change_rates = model_data['is_change'].values  # Get the change rates\n",
    "        \n",
    "        ax.bar(positions + i * bar_width, change_rates, bar_width, label=model)\n",
    "\n",
    "    # Set x-ticks to center of groups\n",
    "    ax.set_xticks(positions + (len(models) - 1) / 2 * bar_width)\n",
    "    ax.set_xticklabels(deltas)\n",
    "    \n",
    "    ax.set_xlabel('Delta')\n",
    "    ax.set_ylabel('Change Rate')\n",
    "    ax.set_title('Change Rate by Delta for All Models')\n",
    "    ax.set_ylim(0, 1)\n",
    "    ax.yaxis.set_major_formatter(plt.FuncFormatter(lambda y, _: '{:.0%}'.format(y)))\n",
    "    ax.legend(title='Models')\n",
    "    \n",
    "    plt.tight_layout()\n",
    "    plt.show()\n",
    "else:\n",
    "    print(\"No files found.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 320,
   "id": "878d9e65",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "ticker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "opinion",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "evidence1",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "evidence2",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "34233786-33a6-4619-869c-5c182b0d4b04",
       "rows": [
        [
         "0",
         "AES",
         "buy",
         "Analysis of AES's recently secured contracts for 2.5 gigawatts (GW) of new solar and energy storage projects is projected to increase the 5-year compound annual growth rate (CAGR) for Free Cash Flow per Share from a previously modeled 6.0% to 7.8%. A discounted cash flow (DCF) model re-run with this higher growth rate, while holding the weighted average cost of capital (WACC) constant at 8.0%, supports a valuation that is 5% above the current stock price.",
         "In the most recent quarter, the company's consolidated Adjusted EBITDA margin improved by 120 basis points to 31.5%, driven by a 4% reduction in operating expenses in its US & Utilities strategic business unit. Sustaining this level of operational efficiency over the next four quarters would add an incremental $0.08 to forward earnings per share (EPS) estimates, which, when multiplied by the sector's average forward P/E ratio of 14x, implies a potential price increase of 5%."
        ],
        [
         "1",
         "AES",
         "sell",
         "A sensitivity analysis of AES's debt structure, of which 45% is at a variable rate, shows that the 50 basis point increase in benchmark rates over the last quarter will raise annualized interest expenses by approximately $45 million. This is projected to erode the company's net profit margin by 70 basis points in the upcoming fiscal year, leading to a downward revision of forward EPS estimates that justifies a 5% decrease in the stock's valuation.",
         "An internal review of AES's capital project pipeline reveals that its large-scale \"Meridian Energy Storage\" initiative is experiencing a 12% cost overrun, translating to an unforeseen capital expenditure of $220 million. This budget revision is expected to lower the company's consolidated Return on Invested Capital (ROIC) by 35 basis points over the next two years, and our discounted cash flow (DCF) model indicates this directly supports a 5% reduction in our price target."
        ],
        [
         "2",
         "SJM",
         "buy",
         "Analysis of recent supply chain optimizations shows a 130 basis point expansion in gross margin to 35.5% in the most recent quarter, contributing to an earnings per share (EPS) of $2.40, which beat consensus estimates by 5.3%. Applying a revised forward P/E multiple of 12.6x, up from 12.0x, to account for these sustained efficiency gains, indicates a potential 5% increase in the stock's valuation.",
         "The company's market share in the high-growth frozen handheld snacks category has increased by 200 basis points, from 14% to 16%, over the last six months following successful product launches. This incremental share is projected to boost divisional revenue by $95 million annually, leading to a revised discounted cash flow (DCF) analysis that raises our price target by 5%."
        ],
        [
         "3",
         "SJM",
         "sell",
         "Internal forecasts indicate a 120 basis point compression in consolidated operating margin over the next six months, from 17.5% to 16.3%, driven by a 10% rise in key commodity input costs and increased promotional spending in the coffee segment. This margin erosion, when applied to consensus revenue estimates, lowers our forward EPS forecast from $9.80 to $9.31. A valuation model applying a constant forward P/E multiple of 12x to this reduced EPS implies a potential 5% decrease in the stock price.",
         "Recent syndicated retail data reveals a 90 basis point decline in market share for the U.S. Retail Pet Foods segment over the last quarter, reducing its share to 16.5%. This segment contributes 38% of the company's operating income. Our discounted cash flow (DCF) model, updated to reflect a lower long-term growth rate for this segment from 2.0% to 1.0%, results in a reduction of our intrinsic value calculation and supports a 5% decrease in our target price for the stock."
        ],
        [
         "4",
         "HON",
         "buy",
         "Honeywell's Aerospace Technologies segment operating margin is projected to expand by 80 basis points over the next four quarters due to supply chain efficiencies and a more favorable sales mix. This margin improvement, applied to consensus revenue forecasts, increases projected segment net income by $350 million. A discounted cash flow (DCF) model updated with this higher profitability indicates the company's intrinsic value is understated, supporting a 5% increase in the stock price.",
         "The Performance Materials and Technologies (PMT) division captured an additional 2.2% market share in the sustainable technology solutions market in the last half-year, growing its backlog by $1.5 billion. This high-growth segment now trades at a 15% P/E discount to its direct peers. A valuation re-rating of just the incremental earnings from this new backlog, bringing it in line with the peer average, would justify a 5% appreciation in Honeywell's overall stock price."
        ],
        [
         "5",
         "HON",
         "sell",
         "Analysis of Honeywell's Aerospace segment reveals that the order backlog for high-margin aftermarket services has declined by 12% over the last two quarters, while key competitors have seen an average backlog growth of 3%. A regression model indicates this decline in future recurring revenue will likely lead to a 2.8% reduction in next fiscal year's consensus earnings per share (EPS). This earnings revision, combined with an anticipated P/E multiple compression of 2.2% due to perceived market share loss, points to a potential 5% decrease in the stock's price.",
         "In the most recent quarter, the Performance Materials and Technologies (PMT) segment experienced a 300 basis point contraction in operating margin, falling to 18.5% from 21.5% a year prior, due to increased input costs for specialty polymers. This margin pressure is projected to reduce the company's total net income by $410 million over the next twelve months. This figure translates to a $0.58 reduction in forward EPS, representing a 5% negative impact on the current consensus estimate and justifying a corresponding 5% downward revision of the stock's target price."
        ],
        [
         "6",
         "ED",
         "buy",
         "A revised discounted cash flow (DCF) model incorporating the positive outcome of the recent regulatory rate case supports a higher valuation. The commission's approval for a $2.1 billion investment in grid modernization increases the company's allowed Return on Equity (ROE) to 9.4% from 9.0% previously. This enhanced, stable cash flow profile justifies a 5% increase in our price target.",
         "The \"Smart Grid Efficiency\" initiative is projected to reduce annual operating and maintenance (O&M) expenses by $95 million over the next fiscal year, exceeding internal targets by 15%. This cost savings is expected to expand the company's operating margin by 65 basis points, leading to a revised forward EPS estimate of $5.05. Applying the utility sector's average forward P/E multiple of 20x suggests a valuation 5% higher than the current stock price."
        ],
        [
         "7",
         "ED",
         "sell",
         "A recent preliminary ruling from a key state regulatory body indicates a potential reduction in the allowed Return on Equity (ROE) from 9.0% to 8.4% in the upcoming rate case. This 60 basis point compression is forecast to reduce forward earnings per share (EPS) by 7%, which, when applied to the stock's 5-year average price-to-earnings ratio of 18.5x, justifies a 5% decrease in the stock price.",
         "An internal analysis of non-fuel Operating and Maintenance (O&M) expenses reveals a sustained increase of 4% quarter-over-quarter for the last three quarters, outpacing revenue growth of 1.5%. This trend is projected to compress the company's EBITDA margin by 120 basis points over the next fiscal year. A DCF model sensitivity analysis shows that this level of margin erosion directly corresponds to a 5% decrease in the stock's intrinsic value."
        ],
        [
         "8",
         "JKHY",
         "buy",
         "Analysis of recent contract wins shows that Jack Henry's private cloud adoption rate among mid-tier credit unions has accelerated, with platform migration increasing by 18% in the last quarter compared to a 14% historical average. This accelerated migration is projected to increase the company's full-year recurring revenue forecast by 2.5%, which, when factored into a discounted cash flow (DCF) model with a stable weighted average cost of capital (WACC) of 7.8%, results in a 5% increase in the stock's intrinsic value.",
         "The company's operating margin expanded by 120 basis points to 23.1% in the most recent quarter, driven by a 3% reduction in software development lifecycle costs from improved automation. Extrapolating this margin improvement for the full fiscal year leads to an upward revision of our earnings per share (EPS) estimate by 4.5%. Applying the company's 5-year average forward P/E multiple of 29x to this higher EPS figure supports a price target that is 5% above the current market price."
        ],
        [
         "9",
         "JKHY",
         "sell",
         "Analysis of competitive pressures on pricing shows Jack Henry's operating margin contracted by 140 basis points year-over-year to 21.6% in the most recent quarter. Our revised Discounted Cash Flow (DCF) model, which adjusts the terminal operating margin assumption downward from 23.0% to 21.9% to reflect this new trend, yields a fair value estimate that is 5% below the current share price.",
         "The company's Net Revenue Retention (NRR) rate, a key metric for its recurring revenue base, has declined to 99% over the last twelve months, down from a consistent historical average of 105%. This sub-100% rate indicates net customer churn. A valuation model applying a lower revenue growth multiplier, consistent with a contracting client base, supports a price target 5% lower than the current market price."
        ],
        [
         "10",
         "INTC",
         "buy",
         "Analysis of Intel's Foundry Services (IFS) pipeline reveals new client contracts projected to contribute $3.2 billion in additional revenue over the next fiscal year. This high-margin revenue is forecast to increase forward earnings per share (EPS) by $0.14, which, when capitalized at the stock's current forward P/E multiple of 15x, supports a 5% increase in the share price.",
         "The accelerated ramp-up of the Intel 4 process node has resulted in manufacturing yields 12% above initial targets, projected to reduce cost of goods sold (COGS) by $1.1 billion over the next twelve months. This operational efficiency gain expands the company's gross margin by 180 basis points, and a revised discounted cash flow (DCF) model incorporating this sustained improvement indicates a 5% increase in the stock's fair value."
        ],
        [
         "11",
         "INTC",
         "sell",
         "Internal analysis indicates that a combination of higher-than-anticipated 18A process node ramp-up costs and increased pricing pressure in the Client Computing Group will compress the company's forward 12-month gross margin by 200 basis points, from a consensus estimate of 43.5% to a revised forecast of 41.5%. A sensitivity analysis of our discounted cash flow (DCF) model shows that a 200 basis point reduction in the long-term gross margin assumption results in a 5% decrease in the derived stock price.",
         "Our forecast for Intel's Return on Invested Capital (ROIC) for the upcoming fiscal year is 3.0%, driven by a $3 billion upward revision in our CapEx forecast to fund the foundry buildout without a commensurate increase in near-term operating income. This projected ROIC of 3.0% is now 500 basis points below the company's estimated Weighted Average Cost of Capital (WACC) of 8.0%. Our valuation model, which applies a discount for negative economic profit, calculates that this 500 basis point negative ROIC-WACC spread justifies a 5% reduction in the stock's fair value."
        ],
        [
         "12",
         "O",
         "buy",
         "Analysis of the company's recent $1.8 billion acquisition pipeline in the European consumer-centric retail market shows an average initial cash yield of 7.1%, which is 60 basis points higher than the firm's most recently reported weighted average cost of capital (WACC) of 6.5%. This positive investment spread is projected to add $0.22 to the forward twelve-month Adjusted Funds From Operations (AFFO) per share. Applying the stock's historical median Price/AFFO multiple of 14.0x to this incremental AFFO growth implies a valuation increase of $3.08 per share, representing a potential 5% increase from the current price.",
         "A review of the current lease portfolio indicates that contractual annual rent escalators, primarily tied to inflation indices, are now tracking at an average of 2.1%, up from 1.4% in the previous year. This 70-basis-point acceleration in organic growth, combined with a record-high portfolio occupancy rate of 99.4%, is projected to increase Same-Store Net Operating Income by an additional $95 million over the next fiscal year. Capitalizing this incremental income at the stock's implied cap rate of 6.7% justifies an increase to Net Asset Value (NAV) per share that supports a 5% appreciation in the stock price."
        ],
        [
         "13",
         "O",
         "sell",
         "Internal analysis of the company's same-store portfolio reveals a 70 basis point decline in occupancy rates over the last two quarters, from 98.9% to 98.2%. This trend has prompted a downward revision of our full-year Adjusted Funds From Operations (AFFO) forecast from $4.15 per share to $3.94 per share. Applying the historical Price/AFFO multiple of 13.5x to this revised estimate implies a valuation correction and a potential 5% decrease in the stock price.",
         "The company's weighted average interest rate on its total debt is projected to increase by 55 basis points over the next 18 months as $4.2 billion of debt with an average coupon of 3.4% matures and is refinanced at current market rates near 5.8%. This increase in borrowing costs is expected to compress the net investment spread on new acquisitions by 80 basis points, directly impacting future growth. Our dividend discount model, adjusted for this lower long-term growth rate, now indicates the stock is overvalued and suggests a 5% downside to its intrinsic value."
        ],
        [
         "14",
         "AKAM",
         "buy",
         "Our analysis indicates that Akamai's cybersecurity division revenue grew 22% year-over-year in the last quarter, surpassing consensus estimates of 18%. This segment, which now accounts for 45% of total revenue, also saw its operating margin expand by 200 basis points to 28%. Recalibrating our sum-of-the-parts valuation model to reflect the increased contribution from this higher-margin, faster-growing segment results in a 5% increase to our 12-month price target.",
         "A recent channel check reveals that Akamai's Connected Cloud platform has captured an additional 0.5% of the developer-focused cloud market share since its launch six months ago. The accelerated integration of this business has also improved overall operational efficiency, boosting the company-wide operating margin by 50 basis points to 20.5% last quarter. Adjusting our discounted cash flow model for this improved margin profile and higher-than-expected cloud adoption rate increases our fair value estimate by 5%."
        ],
        [
         "15",
         "AKAM",
         "sell",
         "Analysis of the most recent quarterly report shows Akamai's operating margin for its Content Delivery Network (CDN) segment compressed from 21.5% to 19.8% year-over-year due to increased bandwidth costs and competitive pricing pressures. This margin erosion has led to a downward revision of the company's full-year non-GAAP EPS guidance from $6.20 to $5.95. A valuation model applying the new guidance to the stock's historical forward P/E ratio of 18x suggests a 5% decrease in the target share price.",
         "Internal channel checks reveal a deceleration in new customer acquisitions for Akamai's security solutions portfolio, with the sales cycle lengthening from an average of 4.5 months to 6.0 months over the past two quarters. This slowdown is projected to reduce the security segment's previously expected year-over-year revenue growth rate from 14% to 10%. The resulting 4 percentage point drop in this high-margin segment's growth rate is expected to lower the company's overall intrinsic value, leading to a 5% price decline."
        ],
        [
         "16",
         "AMT",
         "buy",
         "Analysis of recent carrier capital expenditure plans indicates an acceleration in 5G network densification, projecting a 3.2% increase in new lease amendments for American Tower over the next fiscal year. This incremental leasing activity is expected to boost annual property revenue by $250 million, which, based on the company's historical enterprise value to revenue multiple of 14.5x, supports a valuation increase of 5%.",
         "A comparative analysis shows American Tower's forward Price-to-Adjusted Funds From Operations (P/AFFO) ratio is currently 19.5x, a 9.5% discount to its primary peer group average of 21.5x. A reversion to just half of this peer group discount, to a multiple of 20.5x, driven by superior international portfolio growth of 8% versus the peer average of 6%, would imply a 5% upside to the current stock price."
        ],
        [
         "17",
         "AMT",
         "sell",
         "Our analysis of AMT's debt structure indicates that upcoming refinancing of $4.5 billion in corporate bonds will increase the company's weighted average cost of debt from 3.4% to 4.1%. This 70-basis-point increase will elevate annual interest expense by approximately $315 million, causing the interest coverage ratio to deteriorate from 3.2x to 2.8x. We project this will lead to a contraction in the stock's P/E multiple, resulting in a 5% decrease in our target price.",
         "Channel checks with major wireless carriers reveal a deceleration in 5G network capital expenditures, leading us to revise our forecast for AMT's full-year organic tenant billings growth from 5.8% down to 4.6%. This 120-basis-point slowdown is expected to reduce our Adjusted Funds From Operations (AFFO) per share estimate from a consensus of $10.10 to our revised figure of $9.60, directly supporting a 5% reduction in the stock's valuation."
        ],
        [
         "18",
         "IBM",
         "buy",
         "IBM's Hybrid Cloud & AI division reported revenue growth of 12% year-over-year in the last quarter, surpassing consensus estimates of 8%. As this high-margin segment now accounts for 42% of total revenue, a forward P/E multiple expansion from 15.0x to 15.75x is justified, implying a 5% increase in the target stock price.",
         "The company's free cash flow (FCF) for the trailing twelve months reached $13.1 billion, a 4.8% beat over the high-end of management's guidance. Incorporating this sustained higher FCF generation rate into a discounted cash flow model, holding the weighted average cost of capital (WACC) constant at 8.5%, increases the intrinsic value per share by 5%."
        ],
        [
         "19",
         "IBM",
         "sell",
         "Internal analysis of the most recent quarter's performance in the Software segment indicates that the renewal rate for multi-year platform agreements has declined from 92% to 87%. This five-point drop is projected to reduce forward-looking recurring revenue by $450 million, impacting full-year earnings per share (EPS) by an estimated $0.60. Applying the company's historical forward P/E multiple of 14.5x translates this EPS reduction into a price decline of $8.70, representing a 5% downside from the current price.",
         "The company's free cash flow (FCF) to sales margin has decreased by 150 basis points, from 14.5% to 13.0%, over the last six months due to increased capital expenditures and weaker working capital management. A sensitivity analysis of our discounted cash flow (DCF) model shows that this sustained reduction in FCF generation efficiency directly lowers the calculated intrinsic value of the stock by $8.90 per share, indicating a potential 5% price correction."
        ],
        [
         "20",
         "BSX",
         "buy",
         "Analysis of early adoption rates for the recently FDA-approved Farapulse™ PFA System in key U.S. markets indicates sales are tracking 18% above initial consensus estimates. This outperformance is projected to add an incremental $400 million in revenue over the next four quarters. At the product line's estimated 24% operating margin, this will contribute an additional $0.07 to annual EPS, supporting a 5% increase in the stock's valuation based on its current forward P/E ratio.",
         "The company's ongoing supply chain optimization program is projected to improve gross margins by 60 basis points over the next fiscal year, exceeding initial targets of 40 basis points. This enhanced efficiency is expected to reduce Cost of Goods Sold by approximately $240 million. This operational saving boosts our free cash flow forecast by $185 million, which, when incorporated into our discounted cash flow (DCF) model, results in a 5% increase to the stock's intrinsic value."
        ],
        [
         "21",
         "BSX",
         "sell",
         "Internal analysis projects a 250 basis point contraction in gross margins for the next fiscal year, from 70.5% to 68.0%, due to a 15% rise in key component costs. This margin pressure is expected to reduce our forward EPS estimate by $0.11. Holding the forward P/E multiple constant, this earnings revision directly implies a 5% downside to our price target.",
         "Our channel checks indicate that new competitive product launches are set to erode market share in BSX's Drug-Eluting Stent portfolio. We are revising our growth forecast for the Cardiovascular segment, which represents 40% of sales, down from 9% to 6% for the upcoming fiscal year. This revision lowers the company's overall weighted-average revenue growth rate by 1.2 percentage points, which, when factored into our DCF model, results in a 5% reduction in our calculated fair value for the stock."
        ],
        [
         "22",
         "BIIB",
         "buy",
         "An internal valuation of Biogen's Phase II drug candidate for multiple sclerosis, BII-214, now projects a risk-adjusted Net Present Value (rNPV) of $2.1 billion, up from a previous estimate of $950 million. This increase is driven by recent trial data showing a 40% improvement in relapse rate reduction over the current standard of care. This updated rNPV adds approximately $12.50 in value per share, justifying a 5% increase from the current price level.",
         "The company's recently completed operational efficiency initiative is projected to increase the non-GAAP operating margin by 200 basis points in the next fiscal year. This margin expansion is expected to boost annual free cash flow (FCF) by $350 million. Applying a discounted cash flow (DCF) model with this incremental FCF, holding all other assumptions constant, results in a revised intrinsic value that is 5% higher than the current market price."
        ],
        [
         "23",
         "BIIB",
         "sell",
         "Our channel checks indicate that Biogen's primary multiple sclerosis drug is facing accelerated market share erosion, losing 120 basis points of U.S. market share last quarter, double the consensus expectation of a 60 basis point decline. We project this will lead to a $490 million revenue shortfall over the next twelve months compared to current street estimates. After applying the company's 21% net profit margin, this lowers our forward EPS estimate by $0.72, which, based on the stock's 15.5x forward P/E ratio, warrants a 5% downward revision of our price target.",
         "A review of the clinical development path for BIIB-098, a key pipeline asset for neuromuscular disorders, now suggests a delay in the Biologics License Application (BLA) filing by at least three quarters due to new FDA data requests. Our discounted cash flow (DCF) model adjustment, which increases the discount rate for the asset by 2% to reflect higher risk and pushes peak sales out to FY2031 from FY2029, results in a reduction of $11.50 in our per-share valuation, representing a 5% decrease from the current price."
        ],
        [
         "24",
         "WM",
         "buy",
         "Analysis of recent operational efficiency programs, specifically route optimization AI and automated sorting upgrades, indicates a 60 basis point improvement in EBITDA margins over the last two quarters. This efficiency is projected to boost forward earnings per share (EPS) by 7% more than current analyst consensus. Applying the stock's 5-year average forward P/E ratio of 27x to this revised EPS estimate suggests a valuation that is 5% higher than the current trading price.",
         "The company's expansion of its Renewable Natural Gas (RNG) facilities is projected to increase annual free cash flow (FCF) by $220 million, a 5.5% lift from the trailing twelve months, once fully operational in the next fiscal year. Incorporating this incremental, high-margin cash flow into a discounted cash flow (DCF) model, while maintaining a conservative weighted average cost of capital (WACC) of 7.0%, results in a revised price target that is 5% above the current stock price."
        ],
        [
         "25",
         "WM",
         "sell",
         "Analysis of recent regional pricing data and input cost trends indicates that price escalators in municipal contracts are lagging behind a 14% year-over-year increase in fleet maintenance and labor costs. This is projected to compress EBITDA margins by 75 basis points over the next two quarters, leading to a revised earnings forecast that supports a valuation 5% lower than the current stock price.",
         "The company’s planned increase in capital expenditures for recycling infrastructure is now projected to have a Return on Invested Capital (ROIC) of 6.2%, which is below the company's updated Weighted Average Cost of Capital (WACC) of 6.8%. This value-destructive capital allocation reduces our discounted cash flow (DCF) valuation for the company, indicating a potential downside of 5% from its current price level."
        ],
        [
         "26",
         "UPS",
         "buy",
         "Analysis of recent operational efficiency initiatives shows a 60 basis point improvement in operating margin over the last two quarters, primarily from network optimization and automation. This margin expansion is projected to increase forward full-year EPS by $0.70. Applying the sector's average forward P/E ratio of 18.5x suggests this earnings boost alone justifies a 5% increase from the current stock price.",
         "The company's International Package segment revenue grew 9.5% year-over-year, beating consensus estimates by 200 basis points, driven by a successful expansion into high-growth emerging markets. A discounted cash flow (DCF) model adjustment, which raises the long-term growth assumption for this segment by a conservative 0.5%, increases the derived intrinsic value per share by 5%."
        ],
        [
         "27",
         "UPS",
         "sell",
         "Internal analysis projects a 70-basis-point contraction in forward operating margins for the next two quarters, from 12.5% to 11.8%, driven by a 15% surge in jet fuel costs that is only partially offset by surcharges. This margin compression, when applied to our discounted cash flow model, reduces the fair value estimate and suggests a potential 5% decrease in the stock price.",
         "Consensus estimates project a 2.0% year-over-year growth in U.S. Domestic average daily volume for the coming quarter. Our proprietary channel checks reveal a deceleration in shipments from a top-three enterprise customer, leading to a revised volume growth forecast of just 0.5%. This 150-basis-point shortfall in the company's largest segment is projected to lower full-year EPS guidance by approximately $0.45, supporting a 5% downside revision to our price target."
        ],
        [
         "28",
         "MCK",
         "buy",
         "Our proprietary channel checks indicate that McKesson's U.S. Pharmaceutical segment is achieving a 25 basis point improvement in operating margin due to increased efficiency from its new automated distribution centers. This margin expansion is not yet reflected in consensus estimates and is projected to increase forward full-year EPS by 3.2%, which our valuation model suggests will drive a 5% increase in the stock price as earnings are revised upward.",
         "An analysis of the company's capital allocation strategy reveals an acceleration in its share repurchase program, fueled by stronger-than-expected free cash flow from its medical-surgical supply business. The company is on track to reduce its total share count by an additional 2.5% beyond initial guidance for the fiscal year. This incremental buyback activity is calculated to be accretive to EPS and directly supports a 5% price appreciation from current levels."
        ],
        [
         "29",
         "MCK",
         "sell",
         "Analysis of generic drug pricing models and recent supply contract renegotiations indicates a projected 15 basis point compression in the U.S. Pharmaceutical segment's operating margin, from an anticipated 1.25% down to 1.10% over the next two quarters. This margin erosion is expected to lower full-year EPS forecasts by approximately 6.5%, which, when applying the sector's average forward P/E multiple, implies a valuation adjustment leading to a 5% decrease in the stock price.",
         "Due to the loss of an exclusive distribution contract with a mid-sized regional hospital network, consolidated revenue growth for the next fiscal year is now forecast at 3.0%, a downgrade from the prior consensus of 4.2%. A discounted cash flow (DCF) analysis recalibrated with this lower long-term growth assumption and a corresponding 50 basis point increase in the weighted average cost of capital (WACC) to reflect increased business risk yields a price target that is 5% below the current share price."
        ],
        [
         "30",
         "ITW",
         "buy",
         "The company's new operational efficiency program is projected to increase operating margins by 120 basis points over the next four quarters. Applying the current forward Price-to-Earnings (P/E) multiple of 24x to the resulting 5.1% projected increase in Earnings Per Share (EPS) suggests a potential 5% appreciation in the stock price.",
         "Based on last quarter's reported figures, ITW's trailing twelve-month free cash flow of $3.2 billion results in a Free Cash Flow (FCF) yield of 4.41%. A reversion to the company's 5-year historical average FCF yield of 4.20% implies the stock is currently undervalued and supports a price increase of 5% to align with its historical valuation norm."
        ],
        [
         "31",
         "ITW",
         "sell",
         "Internal modeling shows that a persistent 15% increase in key raw material costs over the last two quarters is expected to compress the company's forward operating margin by 120 basis points, from 24.5% to 23.3%. This revision is projected to lower consensus full-year EPS estimates by 4.8%, leading to a re-rating of the stock and a potential 5% decrease in its price.",
         "Analysis of the company's backlog and order rates indicates a deceleration in organic revenue growth to 1.5% for the upcoming fiscal year, underperforming the sector average of 3.0%. Consequently, the stock's current forward P/E ratio of 22x is no longer justified against the peer average of 20.9x, suggesting a valuation multiple compression that implies a 5% decrease in the stock price to align with its peer group."
        ],
        [
         "32",
         "JNJ",
         "buy",
         "The MedTech segment's operating margin expanded by 120 basis points year-over-year in the last quarter due to supply chain optimization and a more favorable product mix. This margin improvement is projected to add an additional $0.45 to the full-year earnings per share (EPS) forecast. Applying the stock's current forward P/E ratio of 18x to this incremental EPS suggests an added value of $8.10 per share, justifying a 5% increase in the stock price.",
         "Following positive Phase III trial results for its next-generation immunology drug, \"ImmuShield,\" the company has raised its peak annual sales forecast for the drug from $2.5 billion to $4.0 billion. The incremental $1.5 billion in projected peak sales adds approximately $13 billion to the company's risk-adjusted net present value (rNPV), which translates to an increase of $8.25 per share and supports a 5% price appreciation."
        ],
        [
         "33",
         "JNJ",
         "sell",
         "Internal analysis of the MedTech division reveals a sustained operating margin compression of 120 basis points over the last two quarters, from 26.8% to 25.6%, due to increased supply chain costs. Applying the company's historical price-to-operating-income multiple of 9.5x to this lower profitability level suggests a valuation that is 5% below the current share price.",
         "Sales forecasts for a key oncology drug, representing 10% of pharmaceutical segment revenue, have been revised downwards. The projected 5-year compound annual growth rate (CAGR) has been cut from 7.0% to 3.5% due to new competitor data. A discounted cash flow (DCF) model updated with this revised growth trajectory results in a fair value estimate that is 5% lower than the current market price."
        ],
        [
         "34",
         "VTR",
         "buy",
         "The latest operational update reveals that Same-Store Net Operating Income (NOI) in the Senior Housing Operating Portfolio (SHOP) is tracking 4% ahead of internal forecasts for the current fiscal year, driven by a 250 basis point outperformance in occupancy rates. This stronger-than-expected performance is projected to lift full-year Normalized FFO per share to $3.15, which is $0.15 above consensus estimates. Capitalizing this incremental FFO at the sector average multiple of 15x implies an unrealized value of $2.25 per share, representing a 5% upside from the current price.",
         "The company recently completed the strategic disposition of a non-core asset portfolio for $500 million, realizing a 15% gain over book value. Proceeds were used to retire a tranche of senior notes with a 5.5% coupon, leading to a projected reduction in the Net Debt to Adjusted EBITDA ratio from 6.1x to 5.7x by year-end. This deleveraging event is expected to lower the company's weighted average cost of capital by 40 basis points, justifying an expansion of the forward Price/FFO multiple from 14.0x to 14.7x, which directly implies a 5% increase in the stock's target price."
        ],
        [
         "35",
         "VTR",
         "sell",
         "The company's updated guidance for the next fiscal year projects normalized Funds From Operations (FFO) per share at a midpoint of $3.00, which is 4.8% below the prior consensus analyst estimate of $3.15. Our valuation model, applying the sector's average price-to-FFO multiple of 15.5x to this revised guidance, indicates a necessary valuation reset, resulting in a 5% decrease in the stock price.",
         "An analysis of Ventas's Senior Housing Operating Portfolio (SHOP) reveals that same-store occupancy rates have declined by 120 basis points over the last six months to 84.0%. This trend is forecasted to cause a 2.5% reduction in the portfolio's Net Operating Income (NOI) for the upcoming quarter. Recalibrating our discounted cash flow model with this lower NOI run-rate results in a 5% decrease in our target price for the stock."
        ],
        [
         "36",
         "HPE",
         "buy",
         "Analysis of the High-Performance Computing & AI (HPC & AI) segment reveals a 150 basis point expansion in operating profit margin to 11.5% over the last two quarters, driven by supply chain optimization and a more favorable product mix. Projecting this improved margin profile forward in a discounted cash flow (DCF) model, while holding other assumptions constant, yields a revised price target that is 5% higher than the current market price.",
         "HPE's forward Price-to-Earnings (P/E) ratio stands at 8.2x, representing a significant discount to the peer group average of 9.5x. As the company's Edge-to-Cloud platform's Annualized Revenue Run-rate (ARR) grew 31% year-over-year in the most recent quarter, we anticipate a partial re-rating of its valuation multiple. A modest P/E multiple expansion to 8.6x, which still represents a discount to peers, would justify a 5% increase in the stock's valuation."
        ],
        [
         "37",
         "HPE",
         "sell",
         "Analysis of the most recent quarterly report reveals the operating margin for the High-Performance Computing & AI (HPC & AI) segment compressed by 300 basis points year-over-year, from 11.5% to 8.5%, due to increased R&D spending and competitive pricing pressures. This margin erosion in a key growth segment is projected to lower the company's forward non-GAAP EPS by $0.09, which adjusts our valuation model to reflect a 5% decrease in the stock's fair value.",
         "According to recent industry reports, HPE's share of the global server market has declined by 90 basis points over the last six months, from 15.8% to 14.9%. Compounding this, the Intelligent Edge segment's revenue growth decelerated to 1.2% last quarter, missing consensus expectations of 4.5%. Lowering our long-term growth rate assumption in our DCF model to reflect these trends reduces our intrinsic value estimate, warranting a 5% decrease in our price target."
        ],
        [
         "38",
         "EFX",
         "buy",
         "Analysis of the Workforce Solutions segment shows revenue from new verification services for the small-to-medium business (SMB) market reached $85 million last quarter, 20% ahead of internal forecasts. This higher-margin revenue, previously unincorporated in our models, is projected to increase the company's forward-looking free cash flow per share by 4.8%. Applying our standard discounted cash flow (DCF) methodology to this enhanced cash flow results in a 5% increase to our target stock price.",
         "The company's ongoing cloud infrastructure migration has reduced technology-related operating expenses by 4% quarter-over-quarter, leading to a 60 basis point expansion in consolidated operating margins. If this efficiency level is maintained, it will translate to an additional $0.42 in earnings per share (EPS) over the next fiscal year. Applying the sector's average forward P/E multiple of 23x to this incremental EPS justifies a 5% increase in the stock's valuation."
        ],
        [
         "39",
         "EFX",
         "sell",
         "Internal analysis of forward guidance reveals a projected contraction in operating margins for the next fiscal year from 24.2% to 22.9%, a 130-basis-point decline. This is attributed to a 15% year-over-year increase in required cybersecurity infrastructure spending and higher data acquisition costs. Applying this lower margin to consensus revenue forecasts results in a revised earnings per share (EPS) estimate that is 7% below street expectations, supporting a valuation model that indicates a potential 5% decrease in the stock price.",
         "A competitive analysis report shows Equifax's market share in the U.S. Workforce Solutions verification services segment has eroded from 47% to 44.5% over the last two quarters. This 2.5 percentage point loss to emerging fintech competitors is expected to reduce the segment's year-over-year revenue growth from a previously anticipated 11% to 7%. As this segment contributes over 40% of total company profit, a revised discounted cash flow (DCF) analysis factoring in the lower long-term growth rate for this key engine suggests a 5% downside to the current share price."
        ],
        [
         "40",
         "AMD",
         "buy",
         "Internal analysis projects Data Center segment revenue for the upcoming quarter will grow 24% year-over-year, surpassing consensus estimates of 20%. This, combined with an anticipated 200 basis point expansion in segment operating margin to 32% due to a richer product mix, supports a revised forward earnings model that implies a 5% increase in the current stock price.",
         "Recent supply chain audits reveal that channel inventory for the Gaming segment has decreased by 15% over the past 60 days, significantly outpacing the 10% reduction anticipated by the market. This faster inventory normalization, coupled with an 8% sequential increase in forward orders from console partners, suggests a recovery that could add $0.10 to full-year EPS, warranting a 5% price increase based on the current forward P/E multiple."
        ],
        [
         "41",
         "AMD",
         "sell",
         "Competitive analysis of the Client Computing segment indicates that aggressive pricing from a primary rival will result in a 200 basis point operating margin contraction for AMD in the second half of the year. Our model forecasts this will reduce the consensus full-year earnings per share (EPS) estimate from $3.80 to $3.61, a reduction that directly supports a 5% decrease in the stock's valuation.",
         "Our supply chain analysis reveals that wafer costs from AMD's main foundry partner are set to increase by an unforecasted 8% over the next two quarters. Incorporating this higher input cost into our Discounted Cash Flow (DCF) model reduces our forward gross margin assumption by 125 basis points, leading to a 5% reduction in the calculated intrinsic value per share."
        ],
        [
         "42",
         "CBOE",
         "buy",
         "Analysis of Cboe's European derivatives platform shows a 12% quarter-over-quarter increase in average daily volume, surpassing peer growth of 7%. This volume outperformance is projected to add $0.18 to the next fiscal year's EPS. Applying a conservative forward P/E multiple of 23x to this incremental earnings boost implies an additional $4.14 in share value, justifying a 5% price increase from current levels.",
         "A review of the company's data and access solutions segment reveals a 98.5% subscription renewal rate over the last two quarters, coupled with a 6% increase in average revenue per user (ARPU). This combination of high retention and price realization improves the segment's discounted cash flow (DCF) valuation by $920 million, which supports a 5% increase in the company's total equity valuation."
        ],
        [
         "43",
         "CBOE",
         "sell",
         "Internal analysis projects that a recent 3.2% quarter-over-quarter decline in U.S. options average daily volume (ADV), driven by a loss of 1.5 percentage points of market share in high-margin index options, will lower forward full-year revenue guidance by $55 million. This revised guidance translates to a projected EPS of $7.41, a 5.2% reduction from the prior consensus estimate of $7.82, suggesting a corresponding 5% decrease in the stock's valuation based on a stable P/E multiple.",
         "The company's updated forward guidance indicates a 250 basis point contraction in its adjusted operating margin, from 58.5% to 56.0%, due to a 15% increase in technology infrastructure costs necessary to defend against competitive pressures. This margin erosion is expected to reduce free cash flow per share by 6.1%, leading our discounted cash flow (DCF) model to revise the intrinsic value estimate downwards by exactly 5%."
        ],
        [
         "44",
         "HRL",
         "buy",
         "Proprietary channel checks indicate that Hormel's ongoing supply chain optimization initiative is running ahead of schedule, projecting a 40-basis-point improvement in consolidated operating margin for the next fiscal year. This efficiency gain is expected to add $0.09 to forward earnings per share (EPS). Applying the stock's 5-year average forward P/E ratio of 19.5x to this incremental earnings suggests a potential 5% increase in the share price.",
         "Internal modeling of Hormel's recent foodservice product line expansion shows it is on track to contribute an incremental $180 million in revenue over the next twelve months, with a net margin of 7%. This accretive growth, which is currently under-appreciated by the market, increases the present value of future free cash flows in our discounted cash flow (DCF) model by $1.80 per share, indicating a 5% potential appreciation from the current valuation."
        ],
        [
         "45",
         "HRL",
         "sell",
         "Analysis of recent quarterly performance indicates a significant contraction in profitability. The company's operating margin declined by 150 basis points to 9.0% from 10.5% in the prior-year period, primarily due to a 4% increase in feed costs that was not fully passed on to consumers. Our revised earnings model, which projects this lower margin profile persisting for the next four quarters, results in a reduced EPS forecast and supports a 5% decrease in our valuation of the stock.",
         "Channel checks and proprietary data show a weakening in brand strength within the key Refrigerated Foods segment. Sales volume in this category decreased by 2.5% year-over-year, underperforming the broader market which saw flat volume. This trend, coupled with a market share loss of 120 basis points in the branded bacon category, reduces our forward revenue growth assumption by 1% annually, leading to a conclusion of a 5% potential downside to the current stock price."
        ],
        [
         "46",
         "AOS",
         "buy",
         "In the most recent quarter, the company's North American segment reported a 150 basis point year-over-year improvement in gross margin to 41.5%, driven by supply chain efficiencies and favorable raw material pricing. This margin expansion contributed to an earnings per share (EPS) of $1.02, beating consensus estimates of $0.97. A historical analysis indicates that a 5% EPS surprise of this nature has typically led to a positive re-rating, suggesting a potential 5% increase in the stock price.",
         "The company’s international segment, particularly in India, has seen accelerated adoption of its new line of commercial water heaters, capturing a 4% market share within the first six months, doubling internal projections. This high-growth sub-segment is now projected to grow at 20% annually, versus 12% for the rest of the international business. Factoring this accelerated, high-margin revenue stream into a sum-of-the-parts valuation model results in a 5% increase in the total price target."
        ],
        [
         "47",
         "AOS",
         "sell",
         "An internal analysis of rising commodity costs, specifically a 12% increase in steel prices over the last six months, is projected to compress gross margins by 150 basis points in the upcoming fiscal year. This margin pressure is expected to reduce full-year Earnings Per Share (EPS) from a consensus estimate of $3.60 to a revised forecast of $3.42, a reduction that models a corresponding 5% decrease in the stock price.",
         "Recent channel checks in the North American wholesale market indicate a slowdown in commercial boiler demand, leading to a revised sales forecast for that product line of a 4% year-over-year decline, compared to previous guidance of 3% growth. As this segment carries a higher-than-average operating margin of 18%, the negative revision is expected to lower the company's forward Price-to-Earnings (P/E) multiple from 22x to 20.9x, resulting in a 5% decrease in the stock's target price."
        ],
        [
         "48",
         "AAPL",
         "buy",
         "Analysis of Apple's Services division indicates a gross margin expansion of 180 basis points over the last two quarters, from 71.0% to 72.8%, driven by a more favorable mix of high-margin advertising and App Store revenue. Projecting this new margin structure onto next year's consensus Services revenue forecast of $102 billion adds an incremental $1.84 billion in gross profit. Applying the company's historical price-to-gross-profit multiple of 8.5x suggests this margin surprise alone supports a valuation increase of approximately $15.6 billion, justifying a 5% increase in the stock price.",
         "A proprietary channel check model monitoring supply chain orders for the upcoming iPhone product cycle projects a 4% year-over-year increase in initial production builds, to 92 million units, ahead of the market's expectation of 88.5 million units. This suggests stronger-than-anticipated initial demand, particularly for Pro models. This 3.5 million unit beat, at an assumed blended net profit of $310 per device, would contribute an additional $1.085 billion to net income in the launch quarter. Our valuation model indicates this incremental earnings power warrants a 5% upward revision to the stock's fair value."
        ],
        [
         "49",
         "AAPL",
         "sell",
         "Analysis of the premium smartphone market (>$800) in key emerging economies reveals Apple's market share has eroded from 42% to 38% over the last two quarters. This 4-point decline is forecast to lower next year's earnings per share (EPS) by $0.25. Applying the stock's forward P/E ratio of 28x, this adjustment directly translates to a potential 5% decrease in the target stock price.",
         "The gross margin for the high-growth Services segment contracted by 150 basis points last quarter to 71.3%, due to rising content and royalty costs. A revised discounted cash flow (DCF) model, which adjusts the long-term Services margin assumption downward by this 150 basis-point figure, results in a reduction of the calculated intrinsic stock value by 5%."
        ]
       ],
       "shape": {
        "columns": 4,
        "rows": 854
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ticker</th>\n",
       "      <th>opinion</th>\n",
       "      <th>evidence1</th>\n",
       "      <th>evidence2</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>AES</td>\n",
       "      <td>buy</td>\n",
       "      <td>Analysis of AES's recently secured contracts f...</td>\n",
       "      <td>In the most recent quarter, the company's cons...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>AES</td>\n",
       "      <td>sell</td>\n",
       "      <td>A sensitivity analysis of AES's debt structure...</td>\n",
       "      <td>An internal review of AES's capital project pi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>SJM</td>\n",
       "      <td>buy</td>\n",
       "      <td>Analysis of recent supply chain optimizations ...</td>\n",
       "      <td>The company's market share in the high-growth ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>SJM</td>\n",
       "      <td>sell</td>\n",
       "      <td>Internal forecasts indicate a 120 basis point ...</td>\n",
       "      <td>Recent syndicated retail data reveals a 90 bas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>HON</td>\n",
       "      <td>buy</td>\n",
       "      <td>Honeywell's Aerospace Technologies segment ope...</td>\n",
       "      <td>The Performance Materials and Technologies (PM...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>849</th>\n",
       "      <td>COR</td>\n",
       "      <td>sell</td>\n",
       "      <td>Analysis of recent contract renewals indicates...</td>\n",
       "      <td>Our proprietary channel checks reveal a slowdo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>850</th>\n",
       "      <td>DOC</td>\n",
       "      <td>buy</td>\n",
       "      <td>Analysis of leasing agreements signed in the l...</td>\n",
       "      <td>The company's recently announced disposition o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>851</th>\n",
       "      <td>DOC</td>\n",
       "      <td>sell</td>\n",
       "      <td>Internal analysis of the Life Science portfoli...</td>\n",
       "      <td>The company's Net Debt to Adjusted EBITDA rati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>852</th>\n",
       "      <td>CPAY</td>\n",
       "      <td>buy</td>\n",
       "      <td>Corpay's adjusted EBITDA margin expanded by 12...</td>\n",
       "      <td>Internal projections for Corpay's new corporat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>853</th>\n",
       "      <td>CPAY</td>\n",
       "      <td>sell</td>\n",
       "      <td>Analysis of Corpay's latest quarterly report r...</td>\n",
       "      <td>Competitive intelligence data shows that in th...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>854 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    ticker opinion                                          evidence1  \\\n",
       "0      AES     buy  Analysis of AES's recently secured contracts f...   \n",
       "1      AES    sell  A sensitivity analysis of AES's debt structure...   \n",
       "2      SJM     buy  Analysis of recent supply chain optimizations ...   \n",
       "3      SJM    sell  Internal forecasts indicate a 120 basis point ...   \n",
       "4      HON     buy  Honeywell's Aerospace Technologies segment ope...   \n",
       "..     ...     ...                                                ...   \n",
       "849    COR    sell  Analysis of recent contract renewals indicates...   \n",
       "850    DOC     buy  Analysis of leasing agreements signed in the l...   \n",
       "851    DOC    sell  Internal analysis of the Life Science portfoli...   \n",
       "852   CPAY     buy  Corpay's adjusted EBITDA margin expanded by 12...   \n",
       "853   CPAY    sell  Analysis of Corpay's latest quarterly report r...   \n",
       "\n",
       "                                             evidence2  \n",
       "0    In the most recent quarter, the company's cons...  \n",
       "1    An internal review of AES's capital project pi...  \n",
       "2    The company's market share in the high-growth ...  \n",
       "3    Recent syndicated retail data reveals a 90 bas...  \n",
       "4    The Performance Materials and Technologies (PM...  \n",
       "..                                                 ...  \n",
       "849  Our proprietary channel checks reveal a slowdo...  \n",
       "850  The company's recently announced disposition o...  \n",
       "851  The company's Net Debt to Adjusted EBITDA rati...  \n",
       "852  Internal projections for Corpay's new corporat...  \n",
       "853  Competitive intelligence data shows that in th...  \n",
       "\n",
       "[854 rows x 4 columns]"
      ]
     },
     "execution_count": 320,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "qual = pd.read_csv(\"/Users/hobbang/Desktop/bias/evi/gemini_quant_ver3.csv\")\n",
    "qual"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "hy",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
